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AIDS and HIV infection
In 1981, the acquired immunodeficiency syndrome (AIDS) was described for the 
first time in previously healthy homosexual men [1]. Two years later, the human 
immunodeficiency virus (HIV) was discovered as the cause of AIDS [2]. HIV belongs 
to the class of retroviruses, using the enzyme reverse transcriptase to convert viral 
RNA into DNA [3]. For the process of replication, the virus needs the CD4 cells of 
the human immune system, leading to destruction of the human immune response 
[4]. HIV can be transmitted through unprotected sexual intercourse, mother-to-child 
transmission, transfusion of contaminated blood or the use of contaminated 
injection needles.
Antiretroviral drugs
Survival of HIV-infected subjects can be prolonged by treatment with antiretroviral 
drugs [5]. To achieve highly active antiretroviral therapy (HAART), at least three 
antiretroviral drugs from at least 2 different classes should be combined. The five 
classes of antiretroviral drugs are shown in Table 1. Each of the classes has a 
unique target in the life cycle of the virus (Figure 1).
Nucleoside reverse transcriptase inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs) inhibit the replication of HIV by 
inhibition of the enzyme reverse transcriptase. NRTIs are prodrugs that require 
intracellular phosphorylation to the active tri-phosphate metabolites [6]. Tenofovir 
is the only nucleotide analogue that must be di-phosphorylated as it already 
contains one phosphate group [7]. The first drug to treat HIV, zidovudine, was 
introduced in 1987 and belongs to the NRTI class [8] .
Non-nucleoside reverse transcriptase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit the replication 
of HIV by induction of allosteric changes to the enzyme reverse transcriptase. 
In contrast to NRTIs, NNRTIs do not require phosphorylation to become active [9]. 
Nevirapine was the first NNRTI to be approved in 1996 [10].
Protease inhibitors
Protease inhibitors inhibit the reproduction of HIV by inhibition of the enzyme 
protease. Saquinavir, indinavir and ritonavir were the first protease inhibitors to be 
approved in 1996 [11].
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Table 1  Overview of antiretroviral drug classes.
NRTIs NNRTIs Protease Entry Integrase
  inhibitors inhibitors inhibitors
Abacavir Delavirdine Atazanavir Enfuvirtide Raltegravir
Didanosine Efavirenz Darunavir Maraviroc
Emtricitabine Nevirapine Fosamprenavir
Lamivudine  Indinavir
Tenofovir  Lopinavir
Stavudine  Nelfinavir
Zalcitabine  Ritonavir
Zidovudine  Saquinavir
  Tipranavir
NRTIs: nucleoside reverse transcriptase inhibitors
NNRTIs: non-nucleoside reverse transcriptase inhibitors
Figure 1  Targets of antiretroviral drug classes.
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Integrase inhibitors
A new class of integrase inhibitors can inhibit the reproduction of HIV by inhibition of the 
enzyme integrase. Raltegravir is the first integrase inhibitor that was recently approved [14].
Epidemiology of HIV infection
Global estimates from the Joint United Nations Programme on HIV/AIDS (UNAIDS) and 
the World Health Organization (WHO) show that 33.2 million people, of whom 2.5 million 
children, were living with HIV at the end of 2007 [15]. The numbers of infected adults and 
children per region are shown in Figure 2. The region most affected by the AIDS epidemic 
remains Sub-Saharan Africa, where 68% of the adults and nearly 90% of the children 
infected with HIV live. Of all AIDS deaths in 2007, 76% occurred in Sub-Saharan Africa, 
illustrating the unmet need for HIV treatment in resource-limited countries.
Clinical pharmacological research of HIV treatment
Although challenging, clinical pharmacological research of HIV treatment in 
resource-limited countries can be facilitated by sponsorships and North-South 
collaboration between partners from the developed and developing world. Most of 
the research in this thesis was funded by the European and Developing Countries 
Clinical Trials Partnership (EDCTP) and by the Poverty Related Infection Oriented 
Research (PRIOR) network that was established by a grant from the Netherlands 
Foundation for the Advancement of Tropical Research (NWO-WOTRO) and the 
Netherlands Foundation for Health Research and Development (ZonMw). The 
North-South collaboration consisted of two European institutes (Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands and the Medical Research 
Council, Clinical Trials Unit, London, United Kingdom) and two African institutes 
(University Teaching Hospital, Lusaka, Zambia and Kilimanjaro Christian Medical 
Centre, Moshi, Tanzania). This thesis focuses on clinical pharmacology in HIV-infected 
children (Part I), HIV-infected adults (Part II) and HIV-TB co-infection (Part III).
I. Clinical pharmacology in HIV-infected children 
A major barrier to scaling up HIV treatment for children in resource-limited areas of 
the world has been the lack of affordable, accessible and appropriate paediatric 
Entry inhibitors
Entry inhibitors inhibit the reproduction of HIV by inhibition of HIV entry into the cell. 
A subclass of fusion inhibitors is active through inhibition of fusion between HIV and 
cellular membranes [12]. The first and only fusion inhibitor, enfuvirtide, was 
approved in 2003 [13]. Maraviroc is the first entry inhibitor of a new subclass of 
CCR5 antagonists that was recently approved [14]. CCR5 antagonists inhibit the 
entry of HIV into the cell by inhibition of binding to the co-receptor CCR5. 
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Figure 2  Adults and children estimated to be living with HIV in 2007.
UNAIDS/WHO. AIDS epidemic update, 2007 [15].
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layer chromatography method for semi-quantitative detection of nevirapine in saliva 
of HIV-infected adults.
Complexity and costs of several effective strategies to prevent mother-to-child 
transmission (MTCT) of HIV have limited large-scale introduction in low-income 
countries. Administration of a single dose nevirapine to the mother shortly before 
delivery and to the newborn after birth was found to be a simple and cost-effective 
strategy to reduce the risk of MTCT in low-income countries by 50% [23]. A major 
disadvantage is the development of resistance in up to 70% of women [24], which 
may diminish the effectiveness of nevirapine when a mother becomes pregnant 
again or acquires an indication for nevirapine-based HAART in the future [25]. It is 
likely that nevirapine resistance develops due to the combination of a low genetic 
barrier to resistance [19] and a long half-life [26]. The risk for the development of 
resistance is increased when subtherapeutic nevirapine concentrations remain in 
the blood for a long period of time. A short-course of an enzyme inducer may 
reduce resistance development by increasing metabolism and decreasing half-life 
of nevirapine. In Chapter 6, a pilot study investigating the effect of enzyme inducers 
on the elimination half-life of nevirapine is presented. The study was conducted in 
the Netherlands as prelude to a study in Tanzania to test a suitable intervention for 
its ability to reduce the development of nevirapine resistance. 
III. Clinical pharmacology in HIV-TB co-infection 
Tuberculosis (TB) is a common opportunistic infection in HIV-infected subjects, 
particularly in developing countries [27]. Co-administration of HIV and TB treatment 
is frequently indicated. Standard of care treatment regimens for TB include 
rifampicin, which is a strong inducer of cytochrome P450 enzymes, resulting in 
drug-drug interactions with antiretroviral therapy [28]. Patients on rifampicin are 
preferably treated with efavirenz-based HAART [27], which does not lead to a 
clinically relevant interaction [29, 30]. Although rifampicin reduces nevirapine 
exposure by 20-55% [31], nevirapine is an alternative to efavirenz among 
non-Caucasian patients [32, 33].
Second-line treatment for patients who have failed NNRTI-based regimens does 
often include protease inhibitors [27]. Rifampicin, however, causes large decreases 
antiretroviral drug formulations [16]. This has led to the pragmatic approach of 
prescribing generic adult fixed dose combination (FDC) tablets of nevirapine, 
stavudine and lamivudine to children. In addition to difficulties with accurate cutting 
and possible unequal distribution of drugs within tablets, a major problem is that 
the drug ratios are designed for adult dosing. Pharmacologically speaking, 
HIV-infected children cannot simply be regarded as small adults. Pharmacokinetics 
of antiretroviral drugs are highly variable in the paediatric population as children 
mature and grow rapidly and individually until they are adults [17]. For example, 
(young) children metabolize the NNRTI nevirapine more rapidly than adults. 
Chapter 1 focuses on general characteristics related to pharmacokinetic processes 
in HIV-infected children. Chapter 2 describes the exposure to nevirapine in 
HIV-infected Malawian and Zambian children treated with divided adult FDC 
tablets. 
Recently, paediatric-friendly generic FDC tablets were developed for HIV-infected 
children with higher nevirapine to stavudine and lamivudine ratios than adult tablets 
in accordance with paediatric dose recommendations. We performed an independent 
pilot bioequivalence study of these paediatric FDC tablets in comparison to the 
branded products (Chapter 3). Subsequently, we investigated whether the 
antiretroviral drug ratio in the paediatric FDC tablets results in optimal exposure of 
nevirapine, stavudine and lamivudine in a target population of Zambian HIV-infected 
children (Chapter 4).
II. Clinical pharmacology in HIV-infected adults
The access to HIV treatment for adults in resource-poor countries has improved in 
the past few years, mainly due to global efforts such as the “3 by 5” initiative of 
WHO [18]. Most of the generic regimens that have become available are nevirapine-
based. A disadvantage of NNRTI drugs such as nevirapine is the low genetic barrier 
for the development of resistance [19]. Patients at risk for virological failure are 
those with subtherapeutic plasma concentrations of nevirapine [20-22]. Therapeutic 
Drug Monitoring (TDM) is a well-known tool for the optimization of nevirapine 
dosing in the developed world [22], but is not often performed in resource-limited 
settings due to the lack of simple and affordable assays to determine the exposure 
to nevirapine. Chapter 5 describes the validation of a simple and economical thin 
In
tr
o
d
u
c
ti
o
n
16 17
References
1.   Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal
  candidiasis in previously healthy homosexual men: evidence of a new acquired cellular 
  immunodeficiency. N Engl J Med 1981; 305(24):1425-31.
2.    Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. 
  N Engl J Med 2003; 349(24):2283-5.
3.    Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic 
  retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. 
  Science 1984; 224(4648):500-3.
4.    Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. 
  Science 1988; 239(4840):617-22.
5.    Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among
  patients with advanced human immunodeficiency virus infection. 
  New England Journal of Medicine 1998; 338(13):853-60.
6.    Stein DS, Moore KH. Phosphorylation of nucleoside analog antiretrovirals: a review for 
  clinicians. Pharmacotherapy 2001; 21(1):11-34.
7.    Antoniou T, Park-Wyllie LY, Tseng AL. Tenofovir: a nucleotide analog for the management 
  of human immunodeficiency virus infection. Pharmacotherapy 2003; 23(1):29-43.
8.    Ezzell C. AZT given the green light for clinical treatment of AIDS. Nature 1987; 326(6112):430.
9.    Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse 
  transcriptase inhibitors. Clin Pharmacokinet 2001; 40(12):893-905.
10.   Bowersox J. Nevirapine approved by FDA. Food and Drug Administration. NIAID AIDS 
Agenda 1996:10.
11.    Folkers G. Two new protease inhibitors approved by FDA. Food and Drug Administration. 
  NIAID AIDS Agenda 1996:4-5.
12.  Dando TM, Perry CM. Enfuvirtide. Drugs 2003; 63(24):2755-66.
13.  EMEA. Fuzeon; Summary of Product Characteristics. 2007.
14.  Two new drugs for HIV infection. Med Lett Drugs Ther 2008; 50(1277):2-4.
15.   UNAIDS/WHO. AIDS epidemic update. 2007. Available at: http://data.unaids.org/pub/
EPISlides/2007/2007_epiupdate_en.pdf.
16.   Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. 
Pediatrics 2007; 119(4):838-45.
 
in the exposure to protease inhibitors [34-37]. We previously demonstrated that 
increased doses of lopinavir/ritonavir soft gel capsules (SGCs) compensate for the 
interaction with rifampicin [34]. Recently, the SGC formulation was replaced by a 
new heat-stable tablet formulation that exhibits slightly higher bioavailability 
irrespective of food intake. This has been a major improvement, especially for 
resource-limited settings where there may be a lack of options for refrigeration or 
food. Data from the interaction study with rifampicin and the SGC formulation of 
lopinavir/ritonavir cannot simply be extrapolated to the new tablet formulation. 
Chapter 7 describes the subsequent study in healthy volunteers evaluating the 
pharmacokinetics of two adjusted dose regimens of lopinavir/ritonavir tablets in 
combination with rifampicin. Clinical experience with the combined use of lopinavir/
ritonavir and rifampicin in the Netherlands is described in Chapter 8.
Objectives of this thesis
This thesis presents the first output of a North-South collaboration in clinical 
pharmacological research of HIV treatment. Part I deals with the optimization of 
paediatric regimens for the scale-up of HIV treatment in resource-limited countries. 
Part II focuses on TDM in HIV-infected adults and the optimization of a cost-effective 
strategy for the reduction of MTCT in low-income countries. In Part III, the 
challenges of combined treatment with lopinavir/ritonavir and rifampicin for HIV-TB 
co-infection are described. Finally, a General discussion is presented. 
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Clinical pharmacology 
in HIV-infected children 
Part I
Children with HIV are not 
small adults: what is different 
in pharmacology? 
Chapter 1
Rafaëlla L’homme1,2, Adilia Warris2,3, Diana Gibb4, David Burger1,2
1 Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands; 2 Nijmegen University Centre for Infectious diseases (NUCI), Nijmegen, 
The Netherlands; 3 Department of Pediatrics, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands; 4 Medical Research Council, Clinical Trials Unit, London, UK
Current Opinion in HIV and AIDS 2007; 2:405-9
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Purpose of review
Pharmacokinetics of antiretroviral drugs are highly variable among HIV-infected 
children. This review describes pharmacokinetic processes in children and recent 
pharmacokinetic data in children with HIV. The general lack of pharmacokinetic 
data and the potential role of therapeutic drug monitoring (TDM) is being 
discussed.
Recent findings
It was unexpectedly found that exposure to lopinavir is decreased in the first 6 
months of life. Recent findings of subtherapeutic efavirenz concentrations in 
children suggest that pediatric dose recommendations should be re-evaluated. In 
addition, recommended dosing of lamivudine leads to lower exposure in children 
younger than 6 years of age. Preliminary results of pediatric fixed-dose combination 
(FDC) tablets for HIV-infected children with a higher nevirapine to stavudine and 
lamivudine ratio than adult FDCs suggest adequate drug exposure. As an alternative 
to plasma sampling, concentrations of nevirapine can be determined in saliva.
Summary
There is a shortage of pharmacokinetic data in the highly variable population of 
HIV-infected children. Selected pharmacology studies should be undertaken to 
improve pediatric dose guidance of existing antiretroviral drugs. TDM is a useful tool 
to optimize treatment in HIV-infected children. However, more data are needed to 
establish child-specific reference values.
Keywords
children, HIV, pharmacokinetics
Introduction
HIV-infected children cannot simply be regarded as small adults, pharmacologically 
speaking. Pharmacokinetics of antiretroviral drugs are highly variable in the 
pediatric population as children mature and grow rapidly and individually until they 
are adults. This brief review focuses on general characteristics relating to the 
processes in pharmacokinetics (absorption, distribution, metabolism, excretion) in 
the pediatric population, followed by recent examples of antiretroviral drug 
pharmacokinetics in HIV-infected children. In addition, practical dosing issues of 
antiretroviral drugs in children are taken into account. Finally, the role of therapeutic 
drug monitoring for HIV-infected children is being discussed. 
Absorption
The gastrointestinal absorption of oral drugs in children is different from that in 
adults, because of developmental changes of the gastrointestinal tract. During the 
first 2 years of life, the pH in the stomach of children is high compared with the pH 
in adults [1**]. Gastric emptying time is delayed in neonates, whereas in infants and 
older children gastric emptying time is more rapid than in adults [2]. Similarly, 
intestinal motility is reduced in neonates and increased in older infants [1**]. 
Furthermore, intestinal drug absorption in neonates may be influenced by increased 
permeability of the mucosa, immature biliary function, reduced first-pass metabolism, 
maturation of carrier mechanisms and variable microbial colonisation [1**]. 
Food restrictions to optimize absorption of some antiretroviral drugs can be 
problematic in young HIV-infected children who need regular feeding and may not 
tolerate high-fat meals [2]. The authors of one study supposed that the much higher 
apparent nelfinavir plasma clearance and volume of distribution found in children 
below the age of 2 years was due to a decrease in bioavailability [3*]. These results 
were in agreement with our previous finding that children below 2 years tend to be 
at higher risk for low plasma concentrations of nelfinavir [4]. The reduced 
bioavailability in infants can be explained by differences in diet between young 
infants and older children, as the bioavailability of nelfinavir is influenced by the 
quantity and type of food with which it is administered [3*, 5]. Moreover, 
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children. Doses of drugs with a large Vd can be based on body weight, because 
tissue binding capacity and Vd in children are similar to those in adults [1**]. The 
fact that protein binding tends to be reduced in neonates may be relevant for drugs 
with high protein binding capacity in combination with a small Vd. An increase in the 
unbound drug fraction may result in a larger Vd and increased efficacy and toxicity 
on short-term. However, stabilization of the unbound drug concentration may be 
expected due to enhanced clearance of the drug and therefore dose adjustments 
do not necessarily seem to be indicated [1**]. 
Enfuvirtide, the first fusion inhibitor for the treatment of HIV-infection, is administered 
subcutaneously and exhibits a small Vd, low systemic clearance and high plasma 
protein binding [10]. Body weight adjusted dosing (2.0 mg/kg bid) in 25 HIV-infected 
children between 5 and 16 years of age resulted in enfuvirtide exposure similar to 
that obtained in HIV-infected adults receiving a dosage of 90 mg bid [11]. Recently, 
it was confirmed that pediatric enfuvirtide dosing per body weight is appropriate in 
children from 6 years of age as enfuvirtide exposure was not affected by age [12*]. 
No data are available regarding the use of enfuvirtide in neonates. Another example 
of a drug with high protein binding capacity in combination with a small Vd is the 
relatively new antiretroviral tipranavir. The pharmacokinetic profile of tipranavir in 
pediatric patients is currently under investigation [13].
Metabolism
The rate of drug metabolism in children is influenced by changes in hepatic enzyme 
activity. Drugs can be metabolized by hepatic enzymes involved in phase 1 
(oxidation, reduction and hydrolysis) and phase 2 (conjugation) reactions. 
Cytochrome (CYP) P450 is an important mixed-function oxidase system with 
reduced activity in neonates. This explains the fact that most drugs have a 
prolonged elimination half-life in neonates. The elimination half-life of most 
substrates approaches adult levels at the age of 2 to 6 months, when a significant 
amount and activity of enzymes is present [1**]. Activity of liver enzymes exceeds 
adult levels at 1 to 4 years and declines to adult levels at the end of puberty [2]. 
Below the age of 2 months it seems wise to start with a very low dose and modify 
subsequent doses based on response, adverse events and if possible drug 
bioavailability of weakly acidic compounds like nelfinavir may be reduced in the first 
2 years of life due to a higher pH in the stomach [3*]. Atazanavir and indinavir are 
2 other examples of antiretroviral drugs that require an acidic gastric medium for 
adequate absorption [6]. Therefore, absorption of atazanavir and indinavir may also 
be reduced in the first 2 years of life, when gastric pH is slowly declining towards 
adult levels. This effect theoretically could abate with concurrent ritonavir use [6]. 
While there are insufficient data to recommend atazanavir with or without ritonavir 
or indinavir plus ritonavir in young children [7**], studies have been presented on 
the use of these antiretroviral drugs in older children. Recently, first data were 
reported on the pediatric use of ritonavir-boosted atazanavir by 23 children and 
adolescents with a median age of 16 years (range, 10-19 years) [8*]. The adult dose 
of 300 mg atazanavir and 100 mg ritonavir in children weighing more than 50 kg and 
the reduced dose of 200 mg atazanavir and 100 mg ritonavir in children weighing 
less than 50 kg, grossly gave a satisfactory plasma concentration at random timing 
in children with good adherence. Nevertheless, virological failure was observed in 
one third of the children identified as good compliers; the authors claim that this 
may have been caused by the insufficient antiviral potency of the nucleoside 
reverse transcriptase inhibitors (NRTIs) that were used as backbone [8*]. Reduced 
dosages of indinavir (220-300 mg/m2), when boosting with either 100 mg or with full 
ritonavir dosages appeared to provide adequate indinavir concentrations in most 
out of 19 Thai children with median ages of 9.7 and 11.3 years, respectively [9]. It is 
important to keep in mind that the available pharmacokinetic data for atazanavir 
and indinavir mentioned above are mainly from older children, in whom the level of 
gastric pH is not expected to influence absorption.
Distribution
The distribution of drugs in the body changes during childhood, because of 
age-specific differences in water content and plasma protein concentrations. The 
volume of total body water and extracellular fluid is high in young infants [1**]. 
Drugs with a small volume of distribution (Vd <0.4 L/kg in adults) distribute over the 
extracellular fluid, while drugs with a large Vd (>0.6 L/kg in adults) are extensively 
tissue bound [1**]. Since body surface area (BSA) correlates with extracellular fluid 
volume, BSA may be used to predict the dose of drugs with a small Vd in young 
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African children aged 8 months to 18 years, subtherapeutic nevirapine concentrations 
were only observed in 3% of those prescribed ≥ 300 mg/m2/day compared to 23% 
of those prescribed < 300 mg/m2/day [18**]. Preliminary results in Zambian 
children of at least 6 months that were dosed according to this 300 mg/m2/day 
cut-off were promising as few subtherapeutic concentrations were observed [19]. 
With this knowledge, it is inappropriate to support dosing of nevirapine below 300 
mg/m2/day in HIV-infected children at this stage. Ren et al have recently presented 
data on efavirenz concentrations in children with and without the anti-tuberculous 
enzyme inducer rifampin [20]. Standard recommended doses were used. Rifampin 
did not significantly reduce efavirenz concentrations. However, the fact that 50% of 
the children had a subtherapeutic efavirenz concentration, suggests that 
recommendations for efavirenz doses should be re-evaluated. An example of 
reduced first-pass metabolism of the NRTI zidovudine in neonates was published 
longer ago. After an oral dose of zidovudine, bioavailability was 89% in the first 2 
weeks of life and 61% in children that were older than 2 weeks [21].
Excretion
Drug excretion in children is influenced by maturation of the kidney function. 
Glomerular filtration (GFR) and active tubular secretion (AS) are reduced in neonates 
and rise to adult values at about 3 and 7 months of age, respectively [22]. In older 
children, GFR and AS may actually exceed adult values [22]. Peak renal functions 
occur between the ages of 3 and 5 years [2]. Logically, drug dosing in children 
should be based on GFR if excretion by GFR is most significant and should be 
based on AS if excretion by AS is most significant [1**]. In the first week of life GFR 
may be based on an inert marker or gestational age, while after the first week of life 
plasma creatinine may be used as a marker for GFR [1**]. In children above 2 years 
without renal insufficiency drug doses can be based on BSA, since there is a good 
correlation with GFR [1**]. 
The NRTI lamivudine is preliminary eliminated by renal excretion of non-metabolized 
drug. The renal clearance of lamivudine was found to be greater than the glomerular 
filtration rate, which implies that lamivudine is also actively secreted into the renal 
tube [23]. A higher dose of lamivudine is recommended in children (4 mg/kg bid) 
concentrations. Between 2 and 6 months of age careful dosing of drugs based on 
body weight appears to be appropriate [1**]. After maturation of liver enzymes at 
the age of 6 months, metabolism is mainly dependent on liver growth, except for 
metabolism by the enzymes glucuronosyltransferase (UGT) and CYP2D6. As liver 
volume correlates well with BSA, it seems reasonable to base drug doses in 
children from the age of half a year on BSA as long as UGT and CYP2D6 are not 
involved in the pathway of metabolism [1**].  
Metabolism of antiretroviral drugs from the protease inhibitor (PI) and non 
nucleoside reverse transcriptase inhibitor (NNRTI) classes in particular varies 
markedly with age in children and is also more variable between children of the 
same age and size compared to adults. In this paragraph, the focus will be on the 
PI-combination lopinavir/ritonavir and the NNRTIs nevirapine and efavirenz as these 
are the preferred options to be given in combination with 2 NRTIs as initial therapy 
for HIV-infected children. Metabolism of lopinavir is predominantly mediated by 
hepatic CYP3A4. Ritonavir inhibits the activity of CYP3A4 resulting in boosted 
plasma lopinavir concentrations [14]. Jullien et al have recently shown that lopinavir 
pharmacokinetics vary greatly during childhood and that children below the age of 
6 months and boys above the age of 12 years may have decreased levels of 
exposure to lopinavir [15**]. The increased ability to eliminate lopinavir in neonates 
was surprising when looking at the pharmacokinetic process of metabolism alone, 
as the activity of CYP3A4 is known to be markedly reduced in the first weeks of life 
[15**]. However, when taking into account the pharmacokinetic processes of 
absorption and distribution, a decrease in the pharmacokinetic enhancement 
provided by ritonavir was found to be the most likely explanation [15**]. This 
example shows us the importance of looking at all aspects of the pharmacokinetic 
process and the actual testing of our hypotheses in the target population of 
HIV-infected children. Once daily dosing of lopinavir/ritonavir (460/115 mg/m2) in 19 
HIV-infected children between 1.4 and 12.9 years resulted in mean pharmacokinetic 
parameters comparable to once daily dosing (800/200 mg) in adults, although the 
variability in trough levels was much higher in children [16**]. Subtherapeutic 
trough levels were more often experienced in younger children [16**]. In 2003, 
virologic responses in 74 HIV-infected children (1.6 months to 14.5 years) supported 
the use of nevirapine doses greater than 300 mg/m2/day, which was higher than 
recommended by the manufacturers at the time of publication [17]. Recently, in 127 
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concentrations of PIs and NNRTIs are better predictors of antiretroviral response or 
toxicity than drug dose is [26]. This is expected to be even more evident in 
HIV-infected children where guidelines may advise inconsistent categories or wide 
ranges of drug doses due to the lack of sufficient pharmacokinetic data. For 
example, the US Food and Drug Administration (FDA) approved lopinavir/ritonavir 
for HIV-infected children from the age of 6 months even though the dose validation 
in the lowest weight group was limited to a small number of children, while the 
European Medicines Agency (EMEA) approved the combination only for children of 
at least 2 years of age [16**]. It would be helpful to have some guidance on the 
minimum number of children per weight group that should be used in pharmacokinetic 
studies to register antiretroviral drugs for the use in children. Since little or no target 
drug levels are available for children, antiretroviral drug concentrations in children 
are targeted to adult reference values [25]. Adult references may be insufficient for 
children because of the unique features of HIV-infection in children such as 
immature immune systems and high viral loads or may be too high in case of 
increased sensitivity of children for side effects [2]. In addition to optimization of 
antiretroviral therapy dosage for children, TDM may be used as a direct and 
objective instrument to measure non-adherence, which is a substantial problem in 
pediatric HIV-infected children [2]. A new interest of research is the development of 
noninvasive, reliable and cost-effective methods for application of TDM in HIV- infected 
children. As an alternative to plasma sampling, concentrations may be determined 
in saliva for antiretroviral drugs with low protein binding like nevirapine [27*].  
Conclusion 
Due to the shortage of pharmacokinetic data in the highly variable population of 
HIV-infected children, antiretroviral drug dosing remains complicated. Selected 
pharmacology studies should be undertaken to improve pediatric dose guidance of 
existing antiretroviral drugs. Furthermore, the new European regulation for pediatric 
drugs will lead to an obligation for pediatric research for every new drug developed 
for adults and having a potential use for children, in exchange for a six month 
extension of the supplementary protection certificate. TDM can be used to optimize 
treatment for the individual HIV-infected child. However, more data are needed to 
establish child-specific reference values.
compared to adults (150 mg: ± 2 mg/kg bid). We have recently demonstrated that 
recommended dosing of lamivudine in a group of 51 children between 1.7 and 18 
years leads to lower plasma exposure and maximum concentration of lamivudine in 
children younger than 6 years of age when compared with older children or adults 
[24**]. Part of the explanation could be the use of oral solution in younger children 
and tablets in older children, as the bioavailability of the solution may be less in 
children. Another reasonable explanation could be enhanced renal clearance in 
children between 1.7 and 6 years of age compared to older children. 
Practical dosing issues
Adult antiretroviral formulations do not allow doses to be easily adjusted in small 
increments as the child grows. The development of pediatric friendly liquid 
formulations of individual antiretroviral drugs has been a good solution for the 
treatment of HIV-infected children in the developed world. In contrast, liquid 
formulations are generally no option for children in resource limited settings, where 
liquids are too expensive and too difficult to transport and store due to large volumes 
and short shelf-lives. The mainstay of first-line therapy for HIV-infected adults in 
resource-limited settings is a fixed-dose combination (FDC) of stavudine, lamivudine 
and nevirapine. Recent findings demonstrate that it is difficult to achieve adequate 
nevirapine levels with divided adult FDC tablets in young children without the risk of 
overdosing with stavudine [18**]. However, newly developed small, crushable, 
dispersible and scored FDC tablets for HIV-infected children with a higher proportion 
of nevirapine are currently undergoing clinical investigation and preliminary results 
suggest adequate exposure of all three antiretrovirals over the entire range of ages 
[19]. Development of solid pediatric formulations containing a PI may be problematic 
as minimum tablet sizes are expected to be too big for pediatric use.
Role of Therapeutic Drug Monitoring
Treatment of HIV-infected children may be considered as an indication for 
therapeutic drug monitoring (TDM), because of high inter- and intrapatient variability 
of antiretroviral drug concentrations [25]. In HIV-infected adults, plasma drug 
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Abstract
Objective: To investigate nevirapine concentrations in African HIV-infected children 
receiving divided Triomune® tablets (stavudine+lamivudine+nevirapine).
Design: Cross-sectional study.
Methods: Steady-state plasma nevirapine concentrations were determined in 
Malawian and Zambian children aged 8 months–18 years receiving Triomune® in 
routine outpatient settings. Predictors from height-for-age, BMI-for-age, age, sex, 
post-dose sampling time and dose/m2/day were investigated using centre-stratified 
regression with backwards elimination (p<0.1).
Results: Of the 71 Malawian and 56 Zambian children (median age 8.4 versus 8.5 
years, height-for-age -3.15 versus -1.84 respectively), only 1 (3%) of those prescribed 
≥ 300 mg/m2/day nevirapine had subtherapeutic concentrations (<3.0mg/L)
compared with 22 (23%) of those prescribed <300 mg/m2/day; most children with 
subtherapeutic nevirapine concentrations were taking half or quarter Triomune® 
tablets. Lower nevirapine concentrations were independently associated with lower 
height-for-age (indicating stunting) (+0.37mg/L per unit higher [95% CI -0.003,+0.74], 
p=0.05), lower prescribed dose/m2 (+0.89mg/L per 50mg/m2 higher [+0.32,+1.46], 
p=0.002) and higher BMI-for-age (indicating lack of wasting) (-0.42mg/L per unit 
higher [-0.80,-0.04], p=0.03).
Conclusions: Currently available adult fixed dose combination tablets are not well 
suited for children, particularly at younger ages: Triomune® 30 is preferable to 
Triomune® 40 because of the higher dose of nevirapine relative to stavudine. Further 
research is required to confirm that concentrations may be reduced in stunted but 
increased in wasted children. Development of appropriate paediatric fixed dose 
combination tablets is essential if antiretroviral therapy is to be made widely 
available to children in resource-limited settings.
Introduction
There are 2.2 million HIV-infected children in sub-Saharan Africa of whom 370,000 
are in urgent need of antiretroviral therapy (ART) [1, 2]. Operational challenges to 
scaling up ART for children include a lack of HIV diagnostic and monitoring tests for 
infants and limited expertise of health personnel in caring for HIV-infected children 
receiving ART. However a major obstacle in resource-limited settings is lack of 
affordable, accessible and appropriate paediatric antiretroviral drug formulations [3].
In order to provide ART to HIV-infected children, several countries have taken the 
pragmatic approach of prescribing divided adult fixed dose combination (FDC) 
antiretroviral tablets of Triomune® 30 or 40 (30 or 40 mg stavudine, 150 mg 
lamivudine, 200 mg nevirapine) to children. In addition to difficulties with accurate 
cutting and possible unequal distribution of drugs within tablets, a major problem 
with such an approach is that the ratios of drugs are designed for adult dosing. 
Since the rate at which children metabolise drugs is different to that of adults, and 
this may also vary with age, the ratios required will be different, particularly where 
dosing recommendations for children are based on surface area, as for nevirapine [4].
There are limited pharmacokinetic and dosing data on nevirapine as part of a FDC 
in children [5, 6] and how these may vary with ethnicity and degree of malnutrition. 
Here we aimed to determine steady state plasma concentrations of nevirapine in 
HIV-infected Malawian and Zambian children receiving divided adult fixed dose 
combination tablets of Triomune® 30 or 40, many of whom were malnourished.
Methods
Study population
This cross-sectional study took place in the paediatric ART clinics of Queen 
Elizabeth Central Hospital (QECH), Blantyre, Malawi and the University Teaching 
Hospital (UTH), Lusaka, Zambia between December 2004 and June 2005. 
HIV-infected children aged 8 months to 18 years who had received Triomune® 30 or 
40 for at least a month were enrolled. Ethical approval was obtained and written 
informed consent was sought from parents or guardians, and assent from children 
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not scored; the pills were split at home at both centres, though QECH provided pill 
cutters for this purpose. Nevirapine was dose escalated in both centres, with all 
children receiving half nevirapine dose for 2 weeks before proceeding to full 
nevirapine dose. During this dose escalation phase, the children at QECH received 
Triomune® 40 once daily with Lamivir-S® (40 mg stavudine, 150 mg lamivudine) 
once daily. At UTH, the children received Triomune® 30 once daily only. Once on full 
dose, the majority of children received Triomune® twice daily.
Single steady state blood samples were collected at routine clinic visits, at variable 
times post-dose, and plasma was separated and stored at -70ºC prior to 
transportation to the Netherlands. Nevirapine concentrations were assayed at 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, using 
validated HPLC [10]. Data were collected on demographics, growth parameters, 
last drug dose, timing of sample compared to last intake and co-medication.
Statistical methods
We used height-for-age to capture stunting and BMI-for-age as a pseudo weight-
for-height score to capture wasting, calculated using the 1990 British Growth Charts 
[11] in Stata 9 [12]. CDC weight-for-height [13] could not be used as 50% of the 
children were outside the height range.
We estimated the effects of height-for-age, BMI-for-age, age, sex, time between last 
dose and sampling and dose/m2/day using linear regression of nevirapine 
concentration and logistic regression of therapeutic nevirapine concentration 
(≥ 3.0 mg/L or not, chosen as a consensus to be that best reflective of clinical 
practice [14-16]), stratifying for centre using meta-analysis methods with fixed 
effects, as centre was strongly confounded with many of the potential predictors. 
We used backwards elimination (p<0.1) to identify the most important predictors, 
investigating non-linearity using fractional polynomials [17].
Results
Baseline and pharmacokinetic data were available for 71 children from QECH and 
56 children from UTH (Table 1). Although median ages were similar (8.4 versus 8.5 
where appropriate. At QECH, HIV-infected children were prescribed Triomune® 40 
tablets (the only product available in Malawi) according to body weight as per 
national guidelines [7], either whole (containing 200 mg nevirapine) or divided into 
quarter (50 mg nevirapine), half (100 mg nevirapine) or three-quarter (150 mg 
nevirapine) parts. At UTH, children >10kg only, in long term follow-up of a previous 
trial of cotrimoxazole prophylaxis [8], were prescribed half or whole Triomune® 30 
tablets according to surface area as per WHO guidelines [9]; children weighing 
<10kg received liquids and were excluded from this study. Triomune® tablets are 
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Table 1  Baseline characteristics by centre.
  QECH (n=71) UTH (n=56) p
Age, years 8.4 (4.5,11.9) 8.5 (7.0,12.6) 0.22
 Age 0.5-3 years old 17 (24%) 0 (0%) <0.001
Sex, female 31 (44%) 30 (54%) 0.27
Weight, kg 19.1 (12.4,24.9) 21.5 (18.3,32.0) 0.01
Height, cm 111 (95,129) 121 (109,135) 0.01
BMI, kg/m2 15.4 (14.5,16.5) 15.7 (14.5,17.2) 0.65
Weight-for-age z-score -2.76 (-3.74,-1.79) -1.77 (-2.40,-0.99) 0.0001
Height-for-age z-score -3.15 (-3.82,-2.42) -1.84 (-2.98,-1.17) 0.0001
BMI-for-age z-score -0.89 (-1.64,0.07) -0.50 (-1.63,0.27) 0.55
Total daily prescribed nevirapine dose    
 mg/kg 9.8 (9.1,10.5) 11.1 (9.6,12.3) <0.0001
 mg/m2 243 (217,270) 288 (250,344) <0.0001
Total daily prescribed lamivudine dose    
 mg/kg 7.3 (6.9,7.9) 8.3 (7.2,9.2) <0.0001
Total daily prescribed stavudine dose *    
 mg/kg 2.0 (1.8,2.1) 1.4 (1.7,1.8) <0.0001
Time between starting ART and 
sampling (months) † 5.9 (3.2,8.1) 8.7 (5.5,17) 0.0004
Time between last dose and 
sampling, hours ‡ 8.9 (8.3,9.6) 3.5 (2.5,4.2) <0.0001
Values given are median (IQR) and ranksum p-values comparing centres for continuous variables and number (%) 
and p-value comparing centres using chi-squared test for categorical variables.
* Triomune® 40 at QECH, Triomune® 30 at UTH.
† Date of starting ART missing for one UTH child.
‡ Sampling time missing for 7 UTH children.
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lamivudine and nevirapine to stavudine for the lightest children than the ratio of these 
drugs in adult Triomune® 30 or Triomune® 40 tablets. This is illustrated in figure 1, and 
the weights of children in the study are shown at the top of this figure. All but four of the 
27 children weighing <15kg were from QECH; for a fixed dose of lamivudine, children 
under 15kg have recommended nevirapine doses over 25% greater than that in 
Triomune®. Uneven dosing and provision of one-quarter and three-quarter tablets 
occurred at QECH, but not at UTH, where only half or whole Triomune® tablets taken 
twice daily were used. The median nevirapine dose received was lower at QECH than 
at UTH (median (IQR) dose/m2/day 243 (217, 270) mg/m2/day at QECH versus 288 (250, 
344) mg/m2/day at UTH). Of note, age and nevirapine dose/m2/day were strongly 
years at QECH and UTH respectively), more young children were enrolled from 
QECH, with 24% aged 0.5-3 years compared to none from UTH. Children from 
QECH were on average more malnourished by all anthropometric measures 
(median (IQR) height-for-age -3.15 (-3.82, -2.42) versus -1.84 (-2.98, -1.17) at UTH; 
BMI-for-age -0.89 (-1.64, 0.07) versus -0.50 (-1.63, 0.27) respectively). Children at 
UTH had been on ART for on average 3 months longer (median 8.7 (IQR 5.5, 17) 
[range 1.4, 46] months) compared to those at QECH (5.9 (3.2, 8.1) [2.2, 38] months).
The recommended daily nevirapine dose in children is 300-400 mg/m2 [9, 18]. Of note, 
achieving a daily dose of 300 mg/m2 requires a much higher ratio of nevirapine to 
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Figure 1  Comparison of nevirapine (NVP) to lamivudine (3TC) and  nevirapine 
to stavudine (d4T) ratios in Triomune® 30 and Triomune® 40 tablets 
versus ratios of the drugs as recommended for children.
Figure 2  Nevirapine (NVP) dose/m2 and concentration by weight.
 (a) Total daily prescribed nevirapine dose/m2 (mg/m2).
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respectively) and were excluded from subsequent analyses, since these high 
concentrations did not seem to be explained by the stated prescribed dose. Other 
characteristics of these two children were comparable to the cohort (age 3 and 7 
years, BMI-for-age +1.00 and +0.61, height-for-age -3.70 and -2.53, daily dose/m2 
285 and 253 mg/m2/day respectively). Neither child was taking fluconazole 
prophylaxis or therapy, which is known to increase nevirapine exposure [19].
Of the remaining 125 children, the median (IQR) nevirapine concentrations were 4.8 
(2.8, 6.5) and 7.0 (5.4, 10.5) mg/L at QECH and UTH respectively. Nineteen (27%) 
confounded, as the youngest children receiving the lowest doses of quarter and half 
tablets also had the lowest doses in mg/m2/day (Figure 2a). Lamivudine and stavudine 
were closer to the recommended 8 mg/kg/day and 2 mg/kg/day respectively (Table 1), 
although children at QECH, who were on average younger and received Triomune® 40, 
tended to have lower lamivudine doses and higher stavudine doses.
Samples were taken later post-dose at QECH (median (IQR) 8.9 (8.3, 9.6) hours 
versus 3.5 (2.5, 4.2) hours at UTH; Table 1). Two children (one at QECH and one at 
UTH) had nevirapine concentrations estimated at over 20 mg/L (22 and 31 mg/L 
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Figure 2  (b) Nevirapine concentration (mg/L). Table 2  Nevirapine dose and concentration by age group.
  Age group (years)
  0.5-3 (n=17) 4-6 (n=26) 7-10 (n=41) 11+ (n=43)
Number of Triomune® tablets prescribed   
Quarter once daily (50 mg) 6 (35%) 0 0 0
Quarter twice daily (100 mg) 8 (47%) 0 1 (2%) 0
Quarter once daily 
+ half once daily (150 mg) 
3 (18%) 8 (31%) 6 (15%) 1 (2%)
Half twice daily (200 mg) 0 18 (69%) 26 (63%) 8 (19%)
Half once daily + three-quarters
once daily (250 mg) 
0 0 5 (12%) 7 (16%)
Three-quarters twice daily (300 mg) 0 0 0 2 (5%)
Three-quarters once daily 
+ whole once daily (350 mg) 
0 0 1 (2%) 4 (9%)
Whole twice daily (400 mg) 0 0 2 (5%) 21 (49%)
Total daily prescribed nevirapine dose    
mg  100 (50,100) 200 (150,200) 200 (200,200) 350 (250,400)
mg/kg 9.3 (7.9,11.4) 11.1 (10.3,12.5) 9.9 (9.3,10.5) 10.2 (9.4,11.8)
mg/m2 204 (147,232) 271 (242,297) 247 (234,263) 298 (258,347)
Nevirapine concentration, mg/L ‡ 3.9 (1.5,5.1) 6.4 (4.2,8.1) 5.7 (3.2,7.1) 6.8 (4.7,9.8)
Subtherapeutic nevirapine 
concentration < 3.0 mg/L 
6 (38%) ‡ 3 (12%) 10 (25%) ‡ 4 (9%)
Values given are median (IQR) for continuous variables and number (%) for categorical variables.
‡ Excluding two patients with nevirapine concentrations >20 mg/L. 
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of the QECH children and 4 (7%) of the UTH children had subtherapeutic nevirapine 
concentrations (defined as <3.0 mg/L; median age 8.1 years). Five of these had 
concentrations below 0.2 mg/L and 11 below 1 mg/L. Thirty-two (26%) children had 
concentrations over 8 mg/L and 20 (16%) had concentrations over 10 mg/L.
The majority (100 (87%) of the 125) of children were either on no other medications 
or cotrimoxazole alone. None of the concomitant medications used are known to 
interact with nevirapine, except isoniazid, which could inhibit the liver enzyme 
CYP3A4 [20] and potentially increase nevirapine concentrations. However, the three 
children on isoniazid (all at QECH) all had nevirapine concentrations below the 75th 
centile (2.3, 5.6 and 8.1 mg/L).
Only 2 (7%) of the 28 children prescribed ≥ 350 mg/day nevirapine (three-quarter/
whole Triomune® tablets; median dose/m2 337 (range 274, 454) mg/m2) had 
subtherapeutic nevirapine concentrations compared with 10 (15%) of the 65 children 
prescribed 200-<350 mg/day nevirapine (half/three-quarter tablets; dose/m2 260 
(170, 353) mg/m2) and 11 (34%) of the 32 children prescribed 50-<200 mg/day 
(quarter/half tablets; dose/m2 214 (120, 297) mg/m2) (Figure 2b). Only 1 (3%) of the 
30 children prescribed a nevirapine dose adjusted for body surface area of ≥ 300 
mg/m2/day had a subtherapeutic concentration compared with 22 (23%) of the 95 
children prescribed <300 mg/m2/day.
Age and nevirapine dose received were strongly confounded, as expected (Table 2). 
However, because younger children have a higher surface area relative to weight, 
this also led to strong confounding with dose adjusted for surface area: the 
youngest children received the lowest doses and also received the lowest doses 
adjusted for surface area compared with the recommended 300-400 mg/m2/day 
[9]. Reflecting underlying variation in surface area adjusted dosing, 38% (6 of 16) in 
the youngest age group (0.5-3 years old) had subtherapeutic concentrations 
compared with 12% (3 of 26), 25% (10 of 40) and 9% (4 of 43) in the age groups 4-6, 
7-10 and 11+ years respectively.
Children with higher dose/m2, higher height-for-age but lower BMI-for-age had 
higher nevirapine concentrations in univariable and multivariable models (Table 3a). 
A 50 mg/m2 higher daily dose of nevirapine was independently associated with a 
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centres) where staff training and facilities would be extremely limited. Provision of 
individual syrups and dosing by surface area were considered impossible on a 
national basis. Triomune® 40 (but not 30) was already in use and about to be 
recommended for adults in the national programme, but it was clearly not possible 
to dose all 3 components according to individual recommendations using Triomune® 
40 for children. Given a choice between separate paediatric formulations, underdosing 
nevirapine (particularly in younger children) or overdosing lamivudine and stavudine, 
a pragmatic decision was made to base Triomune® 40 recommendations on doses 
for lamivudine and stavudine, i.e. on a mg/kg basis, with a linear relationship 
between weight and dose, and accepting that nevirapine was likely to be underdosed 
in the youngest children.
Our results indicate that using divided Triomune® tablets in this way can lead to 
subtherapeutic nevirapine concentrations at any age and body weight when these 
are associated with low nevirapine doses/m2/day. Younger, smaller children who are 
more likely to receive quarter tablets and have higher surface area for weight are at 
particular risk, with nearly half of those receiving quarter tablets either once or twice 
daily having subtherapeutic concentrations. Because of the higher viral loads and 
faster metabolism in young children, the potential for development of drug resistant 
virus is significant [21, 22]. Therefore quarter Triomune® tablets should be avoided 
where appropriate alternative ART formulations exist. We did not measure lamivudine 
or stavudine levels in plasma; although this is not the active moiety of these drugs, 
which act intracellularly, the doses prescribed suggest that subtherapeutic levels of 
these drugs could also have occurred in some children. This is of particular concern 
for lamivudine given the low genetic barrier to development of the M184V mutation, 
and recent findings that 8 mg/kg/day dosing may also be too low in children under 
6 years of age [23].
We found that the strongest predictor of nevirapine level was the dose prescribed 
in mg/m2/day and subtherapeutic concentrations were infrequently observed in 
those children receiving a nevirapine dose of ≥ 300 mg/m2/day. Body surface area 
measurements are difficult to calculate and errors have been reported [24]. A recent 
paper describing underdosing of many antiretrovirals in children points out 
non-concordance of dosing when calculated using mg/kg versus mg/m2 
recommendations for nevirapine in particular [4]. In collaboration with leading HIV 
0.89 [0.32, 1.46] mg/L higher nevirapine concentration (p=0.002). A one unit higher 
height-for-age was independently associated with a 0.37 (95% CI [-0.003, 0.74]) 
mg/L higher nevirapine concentration (p=0.05), but a one unit lower BMI-for-age 
was independently associated with a 0.42 [0.04, 0.80] mg/L higher nevirapine 
concentration (p=0.03). There was no evidence that the effect of any of these 
variables was non-linear. Of note, whilst age and dose/m2 were both significant 
univariable predictors, age was a confounder of dose/m2, and only dose/m2 had an 
independent effect on nevirapine concentration. There was no evidence of an effect 
of sex on nevirapine concentration (full multivariable model, p=1.0).
We examined the above variables with respect to the likelihood of achieving 
nevirapine concentrations above the therapeutic threshold. A one unit increase in 
height-for-age was independently associated with a 48 [7, 106] % increase in the 
odds of achieving a therapeutic nevirapine concentration (p=0.02, Table 3b). There 
was no evidence of an association between achieving a therapeutic nevirapine 
concentration and BMI-for-age, nor dose/m2 (univariable OR=0.90 [0.64, 1.27], 
p=0.6; 1.14 [0.71, 1.82], p=0.6 respectively), but power was low and height-for-age 
and dose/m2 were confounded, with 70% of those with height-for-age z-score<-4 
prescribed <250 mg/m2 daily, compared to just 35% of those with height-for-age 
z-score≥ -4.
Discussion
In the absence of appropriate paediatric antiretroviral drug formulations in resource-
limited settings, divided adult fixed dose combination (FDC) antiretroviral tablets 
are often prescribed for use in children. In addition to limited information on the 
uniformity of distribution of the component drugs in the tablet and difficulties in 
cutting the unscored tablets accurately, the drugs are in a fixed dose ratio that is not 
appropriate for children. For example, national guidelines drawn up in 2003 for the 
delivery of ART to HIV-infected children in Malawi needed to reconcile dosing 
recommendations for three drugs: two with dosing recommendations based on 
weight, the third on either surface area or on weight with a step down in dose at age 
8 years, reflecting the fact that nevirapine is metabolised more rapidly in younger 
children. The guidelines needed to be applied in District units (or smaller health 
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which could affect absorption are unlikely. An alternative explanation is a possible 
pharmacogenomic or -genetic effect, as the CYP2B6 T/T genotype at position 516 
is more common in African-Americans than in European-Americans and is 
associated with greater efavirenz exposure [26] and, to a lesser extent, with greater 
nevirapine exposure [27]. Misunderstanding instructions about how many pieces of 
tablet or tablets to give could also have occurred. A limitation of our study is that we 
did not measure adherence, nor were any drugs taken under direct observation; 
nevirapine concentrations may therefore reflect adherence as well as prescribed 
dose. Those children with very low nevirapine concentrations are unlikely to have 
taken ART for several days, emphasising the difficulties of administering drugs to 
young children. In addition, we did not have viral loads to be able to relate nevirapine 
levels to treatment success or failure.
Nevirapine pharmacokinetics have been studied recently in 34 Thai children 
(median age 8.4 years) who similarly received divided tablets (GPO-VIR S30®, 
equivalent to Triomune® 30) [5]. In this study 33 of the 34 children achieved 
therapeutic concentrations (defined as ≥ 3.4 mg/L). However none were receiving 
quarter tablets and the mean daily nevirapine dose was considerably higher at 328 
mg/m2, compared to 265 mg/m2 in our study. A recent comparison of the 
pharmacokinetics of liquid formulations versus split Triomune® 40 in 18 Malawian 
children (median age 7 years) concluded that although quartered multiples of FDC 
tablets are reasonable for use in larger children, liquid formulations are better for 
smaller children [6].
Our findings demonstrate that it is difficult to achieve adequate nevirapine levels 
[28] in young children with divided Triomune® tablets without a risk of overdosing 
with stavudine, especially when using Triomune® 40. Therefore, for young children, 
paediatricians currently face a difficult decision, as increasing the Triomune® dose 
to ensure adequate nevirapine will consequently increase the dose of lamivudine 
and stavudine. Higher doses of stavudine in particular may lead to toxicity; its main 
side effect, peripheral neuropathy, can be difficult to identify in children and may be 
irreversible. Use of Triomune® 30 rather than Triomune® 40 would enable higher 
doses of nevirapine and lamivudine to be given and, as higher doses of lamivudine 
may anyway be beneficial in younger children, this would be preferable [23]. An 
alternative strategy would be to supplement quarter Triomune® tablets with 
paediatric pharmacologists, WHO has recently developed standardised weight-band 
based dosing tables for all antiretrovirals used in children, using surface area dose 
calculations as the basis for conversion into weight bands. This should simplify 
dosing of antiretrovirals in resource-limited settings [9]. Of note, over a quarter of 
the children in our study had plasma nevirapine concentrations over 8 mg/L and 
16% had concentrations over 10 mg/L, although overt toxicity was not observed.
Our results suggest that nevirapine concentrations may be reduced in stunted but 
increased in wasted children, with lower height-for-age (a pseudo-measure for 
stunting) independently associated with lower nevirapine concentrations and lower 
BMI-for-age (a pseudo-measure for wasting) independently associated with higher 
nevirapine concentrations. One possible explanation is that wasted children will be 
older than well-nourished children of the same weight, and so will metabolise the 
same dose of nevirapine more slowly. As malnutrition is common in HIV-infected 
children in sub-Saharan Africa and is often used as a clinical criteria of eligibility to 
access ART, these results carry important implications for clinical practice. Further 
pharmacokinetic studies in a larger number of children taking a range of antiretroviral 
drugs is required to confirm these findings. It is possible that different recommendations 
for dosing malnourished children may be required, although in general if food is 
available, weight gain and growth after starting ART is rapid. Doses also need to be 
monitored carefully with any rapid changes in height and/or weight. However, children 
in this study remained stunted and wasted 3 or more months after starting ART.
Although samples were on average taken later post-dose at QECH compared to 
UTH (median 8.9 vs 3.5 hours), the long half-life of nevirapine (median 25.5, range 
[12.1,  105.2] hours in children [5], similar to median 24.3 hours observed in adults 
[25]) leads to only a minimal difference between nevirapine peak and trough 
concentrations at steady state. Indeed we observed no effect of dose timing in the 
multivariable analysis. In addition, the lower limit of the therapeutic range for 
nevirapine (3.0 mg/L) is based on a study in which samples were taken at random 
times [14]. Two children (one from each centre) had nevirapine concentrations 
estimated at over 20 mg/L and were excluded from the main analysis. These high 
concentrations did not seem to be explained by the stated prescribed dose, which 
was comparable to the other children, or by concomitant medications. Further, 
children had been on nevirapine for median 6.5 months, so gastrointestinal problems 
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additional nevirapine syrup, although this may not always be available and would 
be more difficult for caregivers. Of note, despite the low nevirapine levels achieved 
and the potential for development of resistance, the children in this cohort continue 
to go to school, put on weight and come to clinic, in contrast to the high mortality 
observed in the cohort when ART was not available [8]. As a result of these data 
and also because Triomune 30 is now available in Malawi, national paediatric ART 
dosing guidelines have been amended: the Triomune® dose has been increased in 
younger children such that few children now receive less than 300 mg/m2 nevirapine, 
while accepting a modest increase in the doses of lamivudine and stavudine.
Cipla Pharmaceuticals are developing FDC antiretroviral tablets in two formulations 
suitable for infants and children with a higher proportion of nevirapine, Pedimune® 
Baby (6 mg stavudine, 30 mg lamivudine, 50 mg nevirapine) and Pedimune® Junior 
(twice Baby dose). Tablets are scored to enable dividing for accurate dosing and 
are dispersible. They are currently undergoing clinical investigation but are not yet 
pre-qualified by WHO and therefore so far not accessible to national ART 
programmes. The availability of these and other paediatric generic FDC tablets for 
resource-limited settings is eagerly awaited and long overdue. It is a high priority for 
successful scaling up ART for children.
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Abstract
Objectives: Cipla Pharmaceuticals have developed generic fixed-dose combinations 
of stavudine, lamivudine and nevirapine for HIV-infected children (Pedimune Baby 
and Junior). We determined the pharmacokinetic profiles of stavudine, lamivudine 
and nevirapine in Pedimune and compared these with the branded products.
Methods: This phase-I, comparative, single-center, open-label, three-period, 
single- dose study was designed as a pilot study to exclude large differences in 
pharmacokinetics. Six healthy males were randomized to the following regimen 
sequences: ABC; ACB; BCA; BAC; CAB; CBA (A = reference, B = Pedimune Baby, 
C = Pedimune Junior). Single doses of medication were administered at 3 time 
points 4 weeks apart. An 8h pharmacokinetic curve was recorded at day 1 of every 
cycle after medication intake. In addition, blood samples were taken on day 2, 3, 4, 
8 and 15. 
Results: Nonparametric statistical tests revealed no statistically significant 
differences in Cmax (0.173≤ P≤ 0.753) and Tmax (0.317≤ P≤ 1.000) of stavudine, 
lamivudine and nevirapine between the 2 Pedimune formulations and the branded 
drugs. Also, there were no significant differences in AUC0-∞  of stavudine, lamivudine 
and nevirapine between Pedimune Junior and the branded drugs (0.345≤ P≤ 0.600) 
and between Pedimune Baby and the branded drug for nevirapine (P=0.463). In 
contrast, the AUC0-∞ of stavudine (mean change: +21%; P=0.046) and lamivudine 
(mean change: +14%; P=0.028) differed significantly between Pedimune Baby and 
the branded dugs, but these changes were considered not clinically significant.
Conclusions: The pharmacokinetic profiles of stavudine, lamivudine and nevirapine 
in Pedimune Baby and Junior are comparable to the branded products. Based on 
these results, it is acceptable to test the pharmacokinetics and dosing requirements 
of Pedimune in HIV-infected children. 
Introduction
In well resourced countries, Anti-Retroviral Therapy (ART) with three or more potent 
drugs has resulted in major reductions in morbidity and mortality of HIV-infected 
adults and children [1, 2].
There are now intensive efforts by governments and non-governmental organizations 
to increase the number of people being treated with ART in resource-limited parts 
of the world where 90% of infected individuals live. For HIV-infected adults in these 
settings, pharmaceutical companies have reduced drug costs through separate 
pricing, and generic manufacturers have been allowed to produce ART combinations 
at lower costs without facing patent claims. 
Cipla Pharmaceuticals is an India-based generic manufacturer that has produced a 
fixed-dose combination (FDC) tablet for HIV-infected adults, (Triomune - 30 or 
40mg stavudine, 150mg lamivudine, 200mg nevirapine), to be taken twice-daily 
without food restriction. Bioequivalence and clinical efficacy have been demonstrated 
[3-5]. At a price of less than 1 euro/day, Triomune is now a reasonable option for 
many adult patients, and is frequently used in access-to-care programs. 
In 2005, it was estimated that at least 660,000 children were in need of ART [6], of 
whom 90% live in sub-Saharan Africa. However, fewer than 4% of individuals 
receiving ART in 2005 were children. There are several reasons for this including 
difficulties in making an early diagnosis of HIV in HIV-exposed infants and lack of 
personnel trained in paediatric ART management. However, arguably the biggest 
barrier is lack of appropriate formulations of ART, including FDC tablets, and simple 
dosing tables. Paediatric brand liquid formulations are expensive, may require water 
for reconstitution, which is not always available in good quality, and may require 
refrigeration, which is a particular problem in rural areas. Further, until recently, 
there were no FDC tablets for children. Triomune is sometimes prescribed dosed as 
half or quarter tablets. However, lack of scoring can result in inaccurate breaking 
and hence inaccurate dosing. Of more concern are preliminary data from a study in 
Malawian and Zambian children which showed that nevirapine underdosing was 
common, particularly in the youngest children receiving quarter tablets of Triomune [7]. 
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Regimen B (test 1): 4 combined-formulation tablets consisting of 6mg stavudine, 
 30mg lamivudine, and 50mg nevirapine (Pedimune Baby, Cipla Pharmaceuticals).
Regimen C (test 2): 2 combined-formulation tablets consisting of 12mg stavudine, 60mg
 lamivudine, and 100mg nevirapine (Pedimune Junior, Cipla Pharmaceuticals).
Single doses of medication, normalized to 200mg of nevirapine, were administered 
at 3 time points 4 weeks apart. Medication was taken orally after a minimum fast of 
3 hours. One of the investigators directly observed medication ingestion. Breakfast 
and lunch were standardised on the day of medication ingestion and were 
administered 2 and 5 hours after intake, respectively. 
Blood was collected just before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 24, 48, 72, 168 
and 336 hours after intake. Blood samples were stored at 2-8°C for maximum 8 
hours until being centrifuged. Immediately after centrifugation, plasma was 
separated and stored at –40°C until analysis. Plasma concentrations of stavudine 
and lamivudine were determined in all samples up to 24 hours after intake by a 
validated HPLC assay with ultraviolet (UV) detection [8]. Plasma concentrations of 
nevirapine were determined in all samples by a validated HPLC assay with UV 
detection, modified from a method published by Hollanders et al [9]. The lower and 
upper limits of quantification for the modified assay were 0.03 and 15 mg/L, 
respectively. The intraday precision ranged from 0.4% to 11.4%, while additional 
variation as a result of performing the assay on different days ranged from 0.0% to 
2.1%. The accuracy of the assay ranged from 100.1% to 104.8%. 
The pharmacokinetic (PK) parameters Cmax and Tmax were calculated directly from 
observations of plasma concentrations. Non compartmental pharmacokinetic 
analysis was performed by using WinNonlin software package (version 4.1; 
Pharsight Corporation, Mountain View, Calif.) to determine the PK parameter 
AUC0-∞. 
Wilcoxon’s signed rank test was used to compare Cmax, AUC0-∞ and Tmax between 
the generic and branded formulations. Descriptive statistics were carried out by 
using SPSS‚ software version 12.0 [SPSS Inc., 1989-2003]. 
To address this issue, Cipla Pharmaceuticals have recently developed two generic 
fixed-dose combinations for HIV-infected children (Pedimune Baby and Pedimune 
Junior) including the same agents as in Triomune, but in a different dose ratio, with 
higher dose of nevirapine. Pedimune Baby contains 6mg stavudine, 30mg 
lamivudine and 50mg nevirapine, while Pedimune Junior contains double the dose. 
Pedimune tablets are small, dispersible or crushable, and scored.
The primary objective of this pilot study was to determine the pharmacokinetic 
profile of stavudine, lamivudine and nevirapine in Pedimune Baby and Pedimune 
Junior after single-dose in healthy males, and to compare this to the individual 
branded products. The study was conducted in the Netherlands as a prelude to a 
pharmacokinetic study of Pedimune in HIV-infected children in Zambia which has 
recently started.
Materials and methods
This phase-I, comparative, single-center, open-label, three-period, single-dose 
study was not designed as a bioequivalence study but as a pilot study to exclude 
large differences in pharmacokinetic profiles. Healthy male subjects aged 18 to 65 
years were eligible for enrollment after pre-entry and laboratory evaluation. Subjects 
who tested positive for HIV and/or hepatitis B or C and subjects with abnormal 
clinical laboratory test results were excluded. Subjects were not allowed to take any 
concomitant drug (for two weeks preceding dosing), except for paracetamol and 
loperamide. The study protocol was reviewed and approved by the Ethics 
Committee of the Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands. Informed consent was obtained from all subjects before enrollment. 
Subjects were randomized to one of the following regimen sequences: ABC; ACB; 
BCA; BAC; CAB; CBA:
Regimen A (reference): 24mg stavudine (24mL Zerit powder for suspension 1 mg/ 
 mL, Bristol-Myers Squibb), 120mg lamivudine (12mL Epivir solution 10mg/mL, 
 GlaxoSmithKline) and 200mg nevirapine (one Viramune tablet of 200mg, 
 Boehringer Ingelheim). 
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Nonparametric statistical tests revealed no statistically significant differences in the 
Cmax (0.173 ≤  P ≤  0.753) and Tmax (0.317 ≤  P ≤  1.000) of stavudine, lamivudine 
and nevirapine between the two Pedimune formulations and the branded drugs. 
Furthermore, no statistically significant differences in the AUC0-∞ of stavudine, 
lamivudine and nevirapine were found between Pedimune Junior and the branded 
drugs (0.345 ≤  P ≤  0.600). The AUC0-∞ of stavudine (P = 0.046) and lamivudine 
(P = 0.028) differed significantly between Pedimune Baby and the branded 
formulations, while there was no significant difference in the AUC0-∞ of nevirapine 
(P = 0.463). For Pedimune Baby the mean AUC0-∞ of stavudine and lamivudine was 
21% and 14% higher compared to the branded dugs, respectively.
Treatments were generally well tolerated. No adverse events were reported after 
intake of Pedimune Junior. Reported mild adverse events, possibly related to 
treatment, were diarrhoea (1 out of 6 subjects on branded products and 1 out of 6 
Results
Six healthy white male subjects were enrolled in the protocol. The median age, 
height, and body weight (range) were 43 (21-63) years, 1.84 (1.74-1.98) m, and 86.5 
(69.0-100.0) kg, respectively. All 6 males completed the study.
Plasma concentrations of stavudine, lamivudine and nevirapine after single doses 
of the branded drugs (A), Pedimune Baby (B) and Pedimune Junior (C) are 
illustrated in Figures 1, 2 and 3, respectively. There are no large differences between 
the different plasma concentration-time curves.
Primary pharmacokinetic (PK) parameters of stavudine, lamivudine and nevirapine 
after single doses of the branded drugs (A), Pedimune Baby (B) and Pedimune 
Junior (C) are shown in Table 1. 
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Figure 1  Mean stavudine concentrations (mg/L) in 6 healthy males  
after intake of a single dose of Zerit, Pedimune Baby and  
Pedimune Junior.
Figure 2  Mean lamivudine concentrations (mg/L) in 6 healthy males 
 after intake of a single dose of Epivir, Pedimune Baby and   
 Pedimune Junior.
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Although the formulations are designed for HIV-infected children, it is generally not 
accepted to study pharmacokinetics of new agents or new formulations in healthy 
children. Therefore, healthy adults were included. Due to a possible effect of 
endogenous or exogenous estrogenic hormones on the pharmacokinetics of nevirapine, 
the effect of nevirapine on oral contraceptives, more toxicity of nevirapine in healthy 
females, and the small sample size, we only included male subjects.
Nonparametric statistical tests revealed no statistically significant differences in the 
Cmax and Tmax of stavudine, lamivudine and nevirapine between the two Pedimune 
formulations and the branded drugs. Moreover, no statistically significant differences 
were found for the AUC0-∞ of stavudine, lamivudine and nevirapine between 
Pedimune Junior and the branded drugs. While there was no significant difference 
in the AUC0-∞ of nevirapine between Pedimune Baby and Viramune, the AUC0-∞ of 
stavudine and lamivudine was significantly higher (21 and 14%, respectively) after 
subjects on Pedimune Baby) and nausea (2 out of 6 subjects on branded products). 
All adverse events resolved spontaneously.
Discussion 
The present pilot study shows that the pharmacokinetic profiles of stavudine, 
lamivudine and nevirapine in Pedimune Baby and Junior are comparable to the 
individual branded products after intake of single doses. 
A bioequivalence study is typically conducted as a single-dose, crossover trial. With 
three different formulations a minimum number of 6 subjects was needed for this pilot 
study to test all possible sequences. The study was not powered to prove bioequivalence, 
but to exclude large differences (> 50%) in pharmacokinetic parameters. 
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Figure 3  Mean nevirapine concentrations (mg/L) in 6 healthy males 
 after intake of a single dose of Viramune, Pedimune Baby and 
 Pedimune Junior.
Table 1  Pharmacokinetic parameters of stavudine, lamivudine and 
 nevirapine in 6 healthy males after intake of a single dose 
 of branded drugs (Zerit, Epivir, Viramune), Pedimune Baby 
 and Pedimune Junior.
PK parameters Branded drugs (A) Pedimune Baby (B) Pedimune Junior (C)
Stavudine
Cmax (mg/L) 0.43 (0.19-0.54) 0.49 (0.26-0.77) 0.38 (0.29-0.52)
AUC0-∞ (mg·h/L) 1.05 (0.73-1.54) 1.27 (0.85-1.71) 1.08 (0.67-1.51)
Tmax (h) 1.08 (0.50-4.00) 0.58 (0.50-1.00) 0.83 (0.50-1.50)
Lamivudine
Cmax (mg/L) 1.20 (0.55-1.56) 1.33 (0.70-1.92) 1.04 (0.83-1.24)
AUC0-∞ (mg·h/L) 4.48 (3.48-5.59) 5.09 (3.57-6.50) 4.41 (3.66-5.75)
Tmax (h) 1.25 (0.50-5.00) 1.00 (0.50-2.50) 1.67 (0.50-4.00)
Nevirapine
Cmax (mg/L) 1.96 (1.64-2.29) 1.71 (0.96-2.91) 1.93 (1.48-2.48)
AUC0-∞ (mg·h/L) 136.05 (85.04-203.58) 127.92 (88.15-199.39) 127.53 (77.38-246.85)
Tmax (h) 2.33 (1.00-5.00) 6.25 (1.00-24.00) 2.42 (1.00-5.00)
Values given are mean (range).
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intake of Pedimune Baby when compared to the individual branded formulations. 
However, we do not consider these differences in AUC0-∞ (far below 50%) to be 
large and find the pharmacokinetic profiles of stavudine, lamivudine and nevirapine 
in Pedimune Baby and Junior comparable to the individual branded products. In 
addition, it would be more worrisome when AUC0-∞ of stavudine and/or lamivudine 
were lower instead of higher, as observed here. In general, virological failure is 
much more difficult to manage than toxicity.
Cipla Pharmaceuticals is currently conducting a formal bioequivalence study on 
Pedimune prior to applications for registration, and to meet prequalification criteria 
set by the WHO. Prior to results being available from this, we believe that the 
information from this independent pilot study showing comparable pharmacokinetic 
profiles of the three agents (stavudine, lamivudine and nevirapine) between the 
newly-developed Pedimune tablets and the branded products, is sufficient for us to 
start a larger pharmacokinetic study in African HIV-infected children in Zambia who 
are a key target population for use of Pedimune. The children in our trial are closely 
monitored for potential toxicity and virological failure, because bioequivalence of 
the Pedimune tablets still needs to be proven. Given that large numbers of children 
are either receiving no Anti-Retroviral Therapy (ART), or inappropriate ART doses 
from part Triomune tablets, it is imperative that fixed-dose combinations of 
appropriate formulations and doses are tested urgently and then become available 
and licensed for children as soon as possible.  
In conclusion, the pharmacokinetic profiles of stavudine, lamivudine and nevirapine 
in Pedimune Baby and Junior are comparable to the individual branded products. 
Based on the results of this pilot study, it is acceptable to start testing the 
pharmacokinetics and dosing requirements of Pedimune Baby and Junior in HIV- 
infected children, while monitoring closely for potential toxicity and virological failure. 
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Abstract
Objective: Triomune Baby and Junior have been developed in response to the 
urgent need for appropriate paediatric fixed-dose combination antiretroviral tablets, 
with higher nevirapine to stavudine and lamivudine ratios than adult tablets in 
accordance with paediatric recommendations. We determined whether this ratio 
results in optimal exposure in the target population.
Methods: Seventy-one Zambian children were treated with Triomune Baby or Junior 
dosed according to weight-bands. After 4 weeks or more, a 12-hour pharmacokinetic 
curve was recorded. Antiretroviral plasma concentrations were assayed by high-
performance liquid chromatography.
Results: Six children were excluded because of poor adherence. Of the remaining 
65, 24 (37%) were female, 24 (37%) weighed less than 15kg and most were 
malnourished. Mean (range) nevirapine C12h, Cmax and AUC12h of 6.0 (1.4,16.9) 
mg/L, 10.0 (3.8,22.5) mg/L and 94.4 (32.1,232) h.mg/L were higher than those 
reported in adults. Nevirapine C12h was subtherapeutic (<3.0 mg/L) in four (6%) 
children. Mean stavudine and lamivudine C12h, Cmax, AUC12h (<0.015 mg/L, 0.45 
mg/L, 1.05 h.mg/L and 0.09 mg/L, 1.33 mg/L, 5.42 h.mg/L) were comparable to 
adults. There was no evidence of a difference in nevirapine AUC12h across weight-
bands (p=0.2), while the difference in stavudine (p=0.0003) and lamivudine 
AUC12h (p=0.01) was driven by the single weight-band with unequal dosing.
Conclusions: Nevirapine concentrations were higher but more variable than those 
in adults; pharmacokinetic parameters of stavudine and lamivudine were comparable 
to adults. As nevirapine underdosing is of greater concern than overdosing, the 
Triomune Baby and Junior ratio appears to be appropriate for children weighing 6kg 
and over. Further research is required for children under 6kg.
 
Introduction
Of 2.3 million children living with HIV in 2006, almost 90% in sub-Saharan Africa, an 
estimated 780,000 urgently require antiretroviral (ARV) therapy [1]. Where liquids 
are available, they are costly, have short shelf-lives, and are difficult to transport and 
store [2]. Due to lack of availability of affordable and appropriate paediatric ARV 
drug formulations, divided adult fixed-dose combination tablets (FDCs) are 
frequently provided for children. However, adult FDCs do not allow easy dose 
adjustment as a child grows. Further, and more importantly, drug ratios in these 
adult FDCs are not correct for children. Our previous study in 127 HIV-infected 
Malawian and Zambian children receiving divided adult FDCs (Triomune; Cipla 
Pharmaceuticals, India; 200mg nevirapine, 30 or 40mg stavudine, 150mg lamivudine) 
demonstrated a risk of nevirapine underdosing [3], due to children, particularly the 
youngest, metabolizing nevirapine more rapidly than adults. Underdosing is a major 
threat to long-term success of ARV therapy, as lack of potency in suppressing viral 
replication will result in development of mutations, particularly against drugs with a 
low genetic barrier to resistance such as nevirapine and lamivudine, and limit 
subsequent treatment options [4, 5]. This is of particular concern for children facing 
a life-time requirement of ARV therapy.
To address this problem, Cipla Pharmaceuticals have developed small, dispersible, 
crushable, scored FDCs for HIV-infected children in two sizes (Triomune Baby and 
Junior) with relatively higher nevirapine versus stavudine and lamivudine dose ratios 
compared to the adult FDC, in accordance with paediatric dosing recommendations 
[6]. In our independent pilot bioequivalence study, the pharmacokinetics (PK) of 
Triomune Baby and Junior were similar to branded products in six healthy males [7]. 
Formal bioequivalence was demonstrated by Cipla Pharmaceuticals (data on file). 
Here we studied the PK of nevirapine, stavudine and lamivudine in Zambian 
HIV-infected children prescribed Triomune Baby or Junior twice daily according to 
surface-area derived weight-bands, to determine whether the dose ratio results in 
optimal ARV exposure in the target population.
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Blood collection and drug concentration assays
At least four weeks after starting Triomune Baby or Junior, a 12-hour PK curve was 
undertaken, following directly observed medication ingestion. Non-breast-fed 
children fasted for ≥ 3 hours before intake, and standardized meals were given 1-2, 
4-6 and 8-12 hours after intake. Two mL of blood was collected just before and 1, 2, 
4, 6, 8 and 12 hours after intake. Plasma was separated and stored at -80ºC until 
transportation to the Netherlands on dry-ice. 
Plasma concentrations of nevirapine, stavudine and lamivudine were assayed at the 
Department of Clinical Pharmacy of the Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands, using two validated HPLC assays with 
ultraviolet detection [9, 10]. The plasma drug concentration 12 hours post-dose 
(C12h) and maximum concentration (Cmax) were determined directly from 
concentration-time data. The area under the concentration-time curve 0-12 hours 
post dose (AUC12h) was evaluated using the linear-log trapezoidal rule. 
Children were excluded if there was evidence of non-adherence, i.e. if the ratio 
between nevirapine C12h and predose concentration was more than 2 and 
Methods
Study population and design
CHAPAS1 is an open, randomised, controlled, phase I/II trial designed to assess 
the appropriate dosing of, and adherence to, Triomune Baby (50mg nevirapine, 
6mg stavudine, 30mg lamivudine) and Junior (double Baby dose). Two hundred 
HIV-infected children aged 3 months to 14 years weighing <30kg who fulfill WHO 
criteria for initiating ARV therapy have been enrolled at the University Teaching 
Hospital, Lusaka, Zambia. Children were randomised in a 1:1 ratio to take Triomune 
Baby or Junior either immediately at full dose in a twice-daily schedule, or in a 
once-daily dose escalation schedule with an additional stavudine/lamivudine tablet 
(Lamivir-S, Cipla Pharmaceuticals) for the first 14 days, followed by full dose. 
Children previously treated with ARVs, including for prevention of mother-to-child 
HIV transmission, were excluded. Further exclusion criteria were severe laboratory 
abnormalities, active opportunistic infection, and treatment with any medication 
known to be contra-indicated in combination with nevirapine, stavudine and/or 
lamivudine.
The first 64 children enrolled in CHAPAS1 were to participate in the PK substudy, 
with 16 per age-group <3, 3-6, 7-10 and 11-14 years. These children had to fulfill all 
enrolment criteria for CHAPAS1 and also not suffer from illnesses that could 
influence the PK of the ARVs such as diarrhea, vomiting, renal or liver disease, and 
not be taking concomitant medication with interactions to the ARVs.
Full nevirapine dosing was chosen to aim for daily doses of 300-400 mg/m2 [6] 
using estimated body surface area (BSA) for weight converted into weight-bands 
(3-<6, 6-<10, 10-<15, 15-<20, 20-<25, 25-<30kg) [8]. Daily stavudine and 
lamivudine doses were targeted to 2 and 8 mg/kg respectively. Nevirapine dose 
ranges in mg/m2 and stavudine and lamivudine dose ranges in mg/kg (Table 1) are 
the result of the same dose in mg being given over weight (and BSA) ranges. 
Of note, one weight-band (15-<20kg) has unequal morning and evening doses.
The protocol was reviewed and approved by the Ethics Committees of the University 
of Zambia, Lusaka and University College London. Written informed consent was 
obtained from parents or guardians, and children where appropriate.
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Table 1  Dosing schedule by weight-band and associated nevirapine 
(NVP), stavudine (d4T) and lamivudine (3TC) doses.
Weight- Type of Number of  Daily dose, Daily dose, Daily dose,
band, kg tablets tablets daily mg mg/m2 * & ** mg/kg *
  a.m. p.m. NVP d4T 3TC NVP d4T 3TC
3-<6 Triomune Baby 1 1 100 12 60 294-476 2.0-4.0 10.0-20.0
 (NVP 50mg,
6-<10 d4T 6mg, 1½ 1½ 150 18 90 306-441 1.8-3.0 9.0-15.0
 3TC 30mg)***
10-<15 Triomune Junior 1 1 200 24 120 308-408 1.6-2.4 8.0-12.0
15-<20 (NVP 100mg, 1 1½ 250 30 150 316-385 1.5-2.0 7.5-10.0
20-<25 d4T 12mg, 1½ 1½ 300 36 180 326-380 1.4-1.8 7.2-9.0
25-<30 3TC 60mg)*** 2 2 400 48 240 364-435 1.6-1.9 8.0-9.6
*  Most recent WHO daily dose recommendations are 300-400 mg/m2 nevirapine, 2 mg/kg stavudine and 8 mg/kg 
lamivudine [6].
 ** Based on estimated equivalent body surface area for weight [8]. 
 *** Adult Triomune 30 or 40 tablets contain 200mg nevirapine, 30 or 40mg stavudine, 150mg lamivudine. 
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non-adherence was independently suspected by the study team, or if this ratio was 
more than 4 without suspected non-adherence. 
Statistical methods
Weight-for-age, height-for-age and body mass index (BMI)-for-age z-scores were 
calculated using the 1990 British Growth Charts [11] in Stata 9 [12] and CD4-for-age 
using published age-related reference ranges [13]. Nevirapine, stavudine and 
lamivudine AUC12h were compared across weight-bands and age groups using 
analysis of variance adjusted for randomisation. 
Results
Of the 71 children enrolled in the PK substudy, six were excluded due to evidence of 
non-adherence. These six, aged 10 months to 12 years, had similar weights and CD4% 
to the rest of the cohort, and daily prescribed nevirapine doses of 363-424 mg/m2. 
Of the remaining 65 children, 16, 18, 16 and 15 were aged <3, 3-6, 7-10 and 11-14 
years respectively. The majority were malnourished and moderately to severely 
immunodeficient (Table 2). The mean (range) daily prescribed nevirapine dose at 
enrolment was 370 (317, 486) mg/m2. Of note, two children who were dosed at 
enrolment according to screening weight (10 and 11kg) had experienced weight 
loss (both to 9.8kg) by the time of enrolment, and therefore received doses equating 
to 427 and 416 mg/m2 respectively at enrolment. Thirty-one (48%) and 34 (52%) 
were randomised to the full dose and dose escalation arms of CHAPAS1 respectively.
The median (range) time from ARV therapy initiation to PK day was 27 (26, 56) days. 
Seven children gained and one lost weight after enrolment such that they were in 
the next higher (three 6-<10kg, one 10-<15kg, two 15-<20kg and one 20-<25kg at 
enrolment) or next lower (one 15-<20kg) weight-band on PK day. Doses were 
adjusted after the end of the PK day.
Nevirapine concentrations were higher than those previously reported in adults 
(Table 3), though C12h was subtherapeutic (<3.0 mg/L) [4, 14] in four (6%) children: 
one in each of the weight-bands 3-<6kg (1 of 2 children), 10-<15kg (1 of 9), 
20-<25kg (1 of 12) and 25-<30kg (1 of 10); aged 9 months, 6, 10 and 10 years; and 
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(mg/L) by weight-band.
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weeks were detected in a small number of children (grade 3 anaemia (n=3), bilirubin 
(n=1); grade 4 bilirubin (n=1), creatinine (n=1), thrombocytopenia (n=1); all single 
measurements). One further child had grade 4 bilirubin at week four which was not 
known to have resolved by death from pneumonia (HIV-related) at nine weeks. 
Discussion
In Zambian HIV-infected children receiving the recently developed paediatric FDCs 
Triomune Baby or Junior, nevirapine plasma concentrations were higher and more 
variable than historical data in adults, while overall PK parameters of stavudine and 
lamivudine were comparable. 
Triomune Baby and Junior are small, dispersible, crushable, scored tablets with 
ARV ratios designed to best fit recommended paediatric doses of individual drugs 
according to WHO guidelines [6]. Importantly, the nevirapine dose in these FDCs 
has been increased relative to the dose in the adult FDCs (Triomune) to compensate 
for higher metabolism of nevirapine in children. We developed weight-band-based 
dosing tables for Triomune Baby and Junior to simplify dosing in resource-limited 
settings. We aimed to achieve daily nevirapine doses ≥ 300 mg/m2, converted into 
weight-bands, to minimise the risk of subtherapeutic plasma concentrations [3, 14] 
and virological failure [5].
Since no paediatric reference drug concentrations are available for these ARV 
doses and ratios, we compared our results with adult reference values. In these 65 
children, nevirapine plasma concentrations were higher than in adults. However, 
nevirapine C12h was subtherapeutic (<3.0 mg/L) [4, 14] in 6% of children and the 
inter-patient variability was greater than in adults [15]. Therefore we would not 
recommend a lower nevirapine dose in children, who are at greater risk of 
underdosing for several reasons [17]. Further, in spite of higher average exposure, 
nevirapine-related adverse reactions were transient with only temporary treatment 
interruptions, and nevirapine Cmax and AUC12h were comparable between children 
with and without nevirapine-related toxicities. This reflects the lack of a well-defined 
upper limit of the therapeutic range. The higher average nevirapine exposure 
minimised the percentage of children with subtherapeutic concentrations and 
receiving daily prescribed nevirapine doses of 326-409 mg/m2. Further, variability in 
nevirapine C12h (interquartile range 4.1, 7.0 mg/L) was greater than previously 
reported in adults (3.2, 5.1 mg/L) [15, 16]. PK parameters of stavudine and 
lamivudine were comparable to those previously reported in adults (Table 3). 
Mean plasma concentrations are shown in Figure 1 by weight-band. As there were 
only two children in the lowest weight-band 3-<6kg, and one (5.2kg) had low 
plasma concentrations of nevirapine but high concentrations of stavudine and 
lamivudine, compared to the other (3.4kg), they were excluded from the statistical 
analyses. There was no evidence of a difference in nevirapine AUC12h across the 
five remaining weight-bands (p=0.2) or the four age groups (p=0.1). There was a 
difference in stavudine and lamivudine AUC12h by weight-band (p=0.0003 and 0.01 
respectively) which appeared to be driven by lower concentrations in the single 
weight-band with a lower dose in the morning than the evening (15-<20kg, 19 
children) (Table 3). There was no significant difference in stavudine or lamivudine 
AUC12h by age group (p=0.6 and 0.4 respectively).
All but three of the children were on co-trimoxazole prophylaxis. Eleven (17%) 
children took one, one took two and one took three additional medications on 
the PK day (five amoxicillin, seven ferrous sulphate, three paracetamol, one 
pyrimethamine/sulfadoxine).
Considering adverse events likely related to nevirapine by ≤ 8 weeks after initiating 
ARV therapy, three of the 65 children in the substudy had grade 2 nevirapine rashes 
within one month, which all resolved after 9-11 days following temporary 
discontinuation of nevirapine (subsequently continued). One further child had a 
grade 1 nevirapine rash at two weeks, which resolved after seven days, followed by 
transient grade 3 raised liver enzymes on PK day (single values, then returned to 
normal); no changes were made to nevirapine. Four other children had transient 
single measurement grade 3 raised liver enzymes on PK day which returned to 
normal without nevirapine interruption. Nevirapine PK parameters in the eight 
children with nevirapine-related toxicities were comparable to those in the 57 
without (mean (range) Cmax 10.6 (4.1, 18.9) vs. 9.9 (3.8, 22.5) mg/L, p=0.7; AUC12h 
102 (40.4, 200) vs. 93.3 (32.1, 232) h.mg/L, p=0.6). In addition, transient 
asymptomatic laboratory abnormalities not judged related to any ARV drug by ≤ 8 
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important not to overdose stavudine in young children who will have long-term 
exposure to ARVs by virtue of therapy initiation early in life. However, when using 
stavudine as part of a FDC, it is also crucial not to underdose nevirapine and 
lamivudine, which have low genetic barriers to resistance. Our previous study in 127 
HIV-infected Malawian and Zambian children receiving divided adult Triomune 30 or 
40 (30 or 40mg stavudine respectively) demonstrated that it is impossible to achieve 
adequate nevirapine concentrations in young children without risking overdosing with 
stavudine, especially when using Triomune 40, but even when using Triomune 30 [3]. 
In that study, 18% of children had a subtherapeutic random nevirapine plasma 
concentration (<3.0 mg/L), compared to only 6% with a subtherapeutic trough 
nevirapine plasma concentration in this current study. Further, the difference in the 
proportion of subtherapeutic nevirapine concentrations may have been larger if we 
had evaluated nevirapine C12h in our previous study, though smaller if we had directly 
observed medication intake in that study. In a Thai study, only 3% (1 of 34) of children 
who received divided adult FDCs (GPO-VIR S30, GPO, Thailand; equivalent to 
Triomune 30) had subtherapeutic nevirapine concentrations (defined as <3.4 mg/L) 
[20] and the average nevirapine dose was considerably higher at 328 mg/m2 [20] 
compared to 265 mg/m2 in our previous study [3]. However, the average age was 
higher and none were <3 years (compared with 13% in our previous study), nor did 
any receive quarter or three-quarter tablets (compared with 42%) [3].
To avoid overdosing with stavudine while aiming to achieve therapeutic nevirapine 
concentrations in children taking adult FDCs, liquid formulations allow for more 
accurate dosing of the smallest children where there are no alternatives [21]. 
However, liquid formulations are costly, difficult to transport and store, and are 
complicated for carers to administer (for example, three syrups each of different 
volume rather than low numbers of whole or divided FDCs). Further, frequent 
changes in volumes of separate liquid ARVs as a child grows presents considerable 
challenges for both carers and medical providers. Paediatric FDCs in an appropriate 
ratio for children, such as Triomune Baby and Junior, are attractive alternatives, 
especially in resource-limited settings. It is hoped that in the future alternative 
FDCs, such as Atripla, Truvada and Kivexa, which do not contain stavudine, will 
become available for children. One disadvantage of FDCs is less flexibility of 
dosing, exemplified by the common practice of dose escalation of the auto-inducing 
drug nevirapine during the first two weeks of treatment to avoid high plasma 
therefore the related risk for the development of resistance, without any evidence of 
increased toxicity. There was no evidence of a difference in nevirapine AUC12h by 
weight-band ≥ 6kg or age group.
We determined stavudine and lamivudine plasma concentrations as surrogates of 
intracellular concentrations of the pharmacologically active triphosphate metabolites, 
because obtaining adequate blood volumes for determination of intracellular 
concentrations of nucleoside reverse transcriptase inhibitor triphosphates is 
ethically, logistically and technically difficult in children [18]. Our assumption was 
that comparable plasma concentrations between children and adults would reflect 
comparable intracellular concentrations. Unlike nevirapine, the plasma concentration 
parameters of stavudine and lamivudine were comparable to those reported in 
adults, with no differences across pre-specified age groups. A previous study 
reported that recommended daily lamivudine dosing (8 mg/kg) [6] leads to lower 
AUC12h and Cmax in younger compared to older children [19]. However, of note, in 
our study younger children received relatively higher lamivudine doses per kg 
compared to older children, as a consequence of optimising dosing of three ARVs 
across six weight-bands, resulting in adequate plasma exposures across all ages.
There was a difference in stavudine and lamivudine AUC12h by weight-band, which 
appeared to be driven by the single weight-band with unequal dosing. However, the 
reduced plasma exposure to stavudine and lamivudine after the lower morning 
dose would not be representative of the average 24-hour exposure; in addition the 
long intracellular half-life of lamivudine may not be reflected in plasma concentrations. 
Nevirapine exposure appears to be less affected by unequal dosing, most likely 
because of its long elimination half-life. Although unequal dosing should be avoided 
where possible for drugs with a short elimination half-life, this may be preferable to 
increasing complexity and hence risking lower adherence by administering larger 
numbers of lower dose tablets equally per dosing interval. We plan to investigate 
adherence, in particular between equal and unequal dosed weight-bands, using 
detailed adherence data collected in CHAPAS1.
WHO recently recommended Triomune 30 for all adults irrespective of body size 
because of increasing concerns about stavudine-associated lipodystrophy and 
data suggesting that the lower dose may be adequate in adults. It is particularly 
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additional PK sampling is needed in children <6kg. Following successful review of 
this study in African HIV-infected children, who are a key target population, WHO 
now recommend the Triomune Baby and Junior ratios and these FDCs have been 
approved by the United States Food and Drug Administration. It is hoped they will 
now be made accessible to national ARV therapy programs at low cost, and that 
future efforts will be made to develop other solid paediatric FDCs which do not 
contain stavudine. 
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concentrations and possible toxicity. In the case of Triomune Baby and Junior, this 
means provision of an additional stavudine/lamivudine tablet during the first two 
weeks to allow full dosing of these ARVs. CHAPAS1 is currently investigating 
whether increased complexity of dose escalation outweighs the possible reduction 
of adverse events. Of note, nevirapine dose escalation in 52% of children in this PK 
substudy would not have influenced our results as sampling was carried out at 
steady state [22] and this was confirmed by sensitivity analyses unadjusted for 
randomisation (results not shown). Our PK data suggest no effect of drug 
concentrations on the rate of adverse events. Co-medications used in our study 
would not be expected to influence outcomes.
We assessed the PK of the antiretroviral drugs based on observed intake. Six (of 71, 
8%) children did not meet our strict adherence criteria; this raises potential cause for 
concern regarding adherence, which we will investigate further in our planned adherence 
analyses. Exclusion of these children allowed reliable estimation of the PK parameters.
Since there were only two children in the lowest weight-band (3-<6kg), there are 
insufficient data to draw conclusions about dosing for children weighing <6kg at 
this stage. In light of critical interim results from the CHER trial [23] suggesting the 
importance of early treatment of infants, this extension to children <6kg is crucial. 
We are currently enrolling into a further substudy to estimate 4-sample PK curves of 
the three ARVs in children aged ≥ 1 month weighing 3-<6kg at enrollment who are 
receiving Triomune Baby.
The children in our PK substudy will continue to be followed in CHAPAS1. Further 
analyses are planned to evaluate possible predictors of ARV plasma concentrations, 
in particular the impact of malnutrition; we previously demonstrated lower nevirapine 
concentrations in stunted African children and higher concentrations in wasted 
children for the same dose per BSA [3]. In addition, analyses are planned to 
investigate the impact of predictors on subsequent changes in CD4%, viral load and 
resistance, in particular with respect to the lower plasma exposure of stavudine and 
lamivudine observed in the weight-band with unequal dosing.
We conclude that the ARV ratio of nevirapine, stavudine and lamivudine in the 
paediatric FDCs Triomune Baby and Junior is appropriate for children ≥ 6kg; 
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Abstract
Background: We developed a simple and inexpensive thin layer chromatography 
(TLC) assay for semi-quantitative detection of nevirapine saliva concentrations in 
resource-limited settings. The method was validated in an African target 
population.
Methods: Paired plasma and saliva nevirapine concentrations were assayed by 
high-performance liquid chromatography (HPLC); saliva concentrations were also 
assayed by TLC. The false positive rate was the proportion of subtherapeutic 
nevirapine saliva and plasma concentrations by HPLC reported as being therapeutic 
in saliva by TLC. The false negative rate was the proportion of therapeutic nevirapine 
saliva and plasma concentrations by HPLC reported as subtherapeutic in saliva by 
TLC. The extent of agreement in TLC readings between 5 technicians and 2 batches 
of TLC sheets was evaluated.
Results: Twenty-five (9%) of 286 African adults had a subtherapeutic plasma 
nevirapine concentration. The median saliva/plasma nevirapine concentration ratio 
was 0.51. The false positive rate by TLC was 0.00 (none out of 23) compared to 
HPLC saliva result and 0.08 (2 out of 25) compared to HPLC plasma result. 
The false negative rate by TLC was 0.01 (3 out of 263) compared to HPLC saliva 
result and 0.01 (3 out of 261) compared to HPLC plasma result. The extent of 
agreement in TLC result was substantial between 5 technicians (Fleiss’ kappa 0.77) 
and 2 batches of sheets (Cohen’s kappa 0.80).
Conclusions: The TLC assay was found to be sensitive, specific and robust in 
detection of subtherapeutic nevirapine concentrations in saliva of African HIV-
infected adults. It is an attractive alternative to HPLC for therapeutic drug monitoring 
of nevirapine in resource-limited settings.
 
Introduction
Nevirapine is widely prescribed in combination with nucleoside reverse transcriptase 
inhibitors for the treatment of HIV-infection in resource-limited countries. Adequate 
plasma concentrations of nevirapine are required to achieve a successful response, 
whereas subtherapeutic concentrations (defined as <3.0mg/L) are related to 
development of mutations and virological failure [1-3]. Even in the case of perfect 
adherence to standard doses, some patients will remain at risk for underdosing 
because of interpatient variability in nevirapine exposure or drug-drug interactions.
In the developed world, Therapeutic Drug Monitoring (TDM) [3] is a well-known tool 
for the optimization of nevirapine dosing in HIV-infected patients. Due to the lack of 
simple and affordable methods to determine the exposure to nevirapine, TDM is 
hardly ever performed in resource-limited settings. Previous studies suggest that 
saliva may be used as an alternative body fluid for TDM of nevirapine [4, 5]. Saliva 
nevirapine concentrations in HIV-infected [4] and healthy [5] Caucasians are 
approximately half of the values observed in plasma. We recently developed a thin 
layer chromatography (TLC) method to provide a simple and economical tool for 
semi-quantitative measurement of nevirapine in saliva.
The primary objective of this study was to validate our newly developed TLC 
method for TDM of nevirapine in saliva of HIV-infected Africans. Secondary 
objectives were to determine the relation between saliva and plasma nevirapine 
concentrations and the proportion of subtherapeutic nevirapine concentrations in 
an African population.
Methods
Study population
Three hundred HIV-infected adults on a nevirapine (Viramune® or a generic formulation) 
containing regimen for at least 4 weeks were eligible for enrolment at a routine visit 
to the adult HIV clinic of the Kilimanjaro Christian Medical Centre (KCMC), Moshi, 
Tanzania. Patients suffering from oral lesions or ulcers and those who were unable 
to self-report date and time of last nevirapine ingestion were excluded. The protocol 
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saliva. The intraday precision of the assays ranged from 0.4% to 3.2% for plasma 
and from 1.3% to 4.1% for saliva. Additional variation as a result of performing the 
assays on different days ranged from 0.0% to 0.4% for plasma and from 0.8% to 
2.2% for saliva. The accuracy of the assays ranged from 102% to 105% for plasma 
and from 99% to 102% for saliva. Saliva/plasma ratios of nevirapine concentrations 
and the proportion of subjects with a subtherapeutic nevirapine plasma concentration 
below 3.0 mg/L [3] were determined. In addition, saliva concentrations of nevirapine 
were semi-quantitatively analysed at the Biotechnology Laboratory of KCMC, 
Moshi, Tanzania, using a newly developed TLC method.
Experimental TLC method
A reference solution of 1.75 mg/L nevirapine (Boehringer Ingelheim) was obtained 
by dilution of a stock solution (0.875 mg/mL nevirapine in dimethylsulfoxide, DMSO, 
Merck 102931) in blank saliva; both were kept at -80°C.
The reference solution and saliva samples were thawed at room temperature, mixed 
(1 minute) and centrifuged (9000 g, 1 minute). Of the reference and samples, 1.0 mL 
was transferred into a 10 mL glass test tube. After addition of 0.5 mL 0.2 M ammonia 
(diluted from 25% ammonia, Labopharma) and 5 mL tert-butylmethylether (Riedel 
- de Haën), tubes were closed, mixed (1 minute), centrifuged (1150 g, 5 minutes) 
and kept at -80 ºC until the lower layer was frozen completely (20 minutes). 
The organic layer was poured into a 10 mL glass test tube and was dried in two days. 
An eluent (or mobile phase) was prepared (toluene:ethyl acetate = 1:1, ACME 
Chemicals and Unilab, respectively) and poured into a TLC container. The container 
was closed and left for 1 hour. After addition of 50 µL methanol to the dried test 
tubes, they were closed and mixed (1 minute). One µL of the reference and samples 
was slowly pipetted in small dense dots at least 1.5 cm from the side and 2.0 cm 
from the bottom of a silica gel TLC sheet (height 10.0 cm; width 20.0 cm, Merck), as 
shown in Figure 1. After drying, spots were checked for similarity of size and shape 
under UV light (254 nm, CAMAG 022.9120). The TLC sheet was placed in the 
container with eluent for approximately 12 minutes (Figure 2). It was marked for the 
distance the eluent had moved and was dried in the air. The intensity of the spots 
was determined under UV light and compared to the reference spot (Figure 3). 
A spot that was less intense than the reference was considered subtherapeutic (see 
was reviewed and approved by the Ethics Committee of Tumaini University, Moshi, 
Tanzania. Written informed consent was obtained from all subjects before enrolment.
Sample collection and drug concentration assays
At a routine visit to the clinic, unannounced paired blood and saliva samples were 
collected within 5 minutes. Stimulated saliva was obtained by a salivette (Sartstedt, 
Etten-Leur, the Netherlands) using a dental cotton roll impregnated with citric acid 
(20 mg), which stimulates the salivary flow. Study subjects were asked to chew on 
the roll for approximately 1 minute. Blood and saliva samples were stored at 2-8ºC 
for a maximum of 8 hours. Plasma was separated and stored at -80ºC until 
transportation to the Netherlands on dry-ice. Saliva was obtained by centrifugation 
of the cotton roll at 800 g for 10 minutes. Two aliquots were stored at -80°C: one for 
analysis by TLC in Tanzania and one for transportation to the Netherlands and 
analysis by high-performance liquid chromatography (HPLC).  
Plasma and saliva concentrations of nevirapine were assayed at the Department of 
Clinical Pharmacy of the Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands, using validated HPLC assays with ultraviolet (UV) detection, 
modified from a method published by Hollanders et al [6]. Pre-treatment of plasma 
samples remained the same [6] and did not differ from the preparation of saliva 
samples. Briefly, 150 µL of saliva or plasma was mixed with 150 µL of perchloric 
acid, vortexed for 20 seconds and centrifuged for 5 minutes at 11,000 rpm. 
Subsequently, 200 µL of the clear supernatant was transferred to insert vials and 
placed in the autosampler. The lower and upper limits of quantification of the 
modified assays were 0.167 and 16.7 mg/L for plasma and 0.158 and 15.8 mg/L for 
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Figure 1  Preparation of thin layer 
chromatography sheet with 
saliva samples.
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HPLC [6] (<1.5 mg/L) that was reported as therapeutic in saliva by TLC. The false 
negative rate was defined as the proportion of therapeutic nevirapine saliva 
concentrations by HPLC [6] (≥1.5 mg/L) that was reported as subtherapeutic in 
saliva by TLC. 
Twenty-five saliva samples with nevirapine concentrations by HPLC [6] closest to 
the TLC reference were selected to test the robustness of the TLC method. The extent 
of agreement in TLC result between 5 different technicians (Fleiss’ kappa [7]) and 
2 different batches of TLC sheets (Cohen’s kappa [8]) was evaluated in these 25 
saliva samples. 
The stability of the stock solution (nevirapine in DMSO) was tested after storage at 
-40 °C for 50 months. The stability of the reference solution (nevirapine in blank 
saliva) was tested after storage at room temperature for 17 hours, after storage at 
-40 °C for 2 months, and after freezing and thawing twice. Interference of possible 
co-medications was evaluated by comparison of the retention factor (Rf: distance 
travelled by compound divided by distance travelled by eluent front) of extractable 
and detectable (UV light, 254 nm) compounds with the Rf value of nevirapine. 
In addition, blank saliva samples from at least 6 subjects not taking nevirapine were 
tested for interference by endogenous substances.
Biological validation of TLC method
All plasma and saliva samples were used to determine the biological sensitivity and 
specificity of the TLC method. The false positive rate was defined as the proportion 
of subtherapeutic nevirapine plasma concentrations by HPLC [6] (<3.0 mg/L [3]) 
that was reported as therapeutic in saliva by TLC. The false negative rate was 
defined as the proportion of therapeutic nevirapine plasma concentrations by HPLC 
[6] (≥3.0 mg/L [3]) that was reported as subtherapeutic in saliva by TLC.
Results
Of the 300 subjects enrolled in the study, 14 were excluded because of problems 
with labelling, too little volume of saliva or lost saliva. The mean (range) age of the 
remaining 286 African subjects (200 women) was 41 (17, 71) years. All subjects were 
below). A spot that was comparable to or more intense than the reference spot was 
considered therapeutic. 
Technical validation of TLC method
All saliva samples were used to determine the technical sensitivity and specificity of 
the TLC method. The readings were performed by one technician. Saliva nevirapine 
concentrations by HPLC were defined as subtherapeutic if  below 1.5 mg/L, which 
is half of the cut-off value for plasma (3.0 mg/L [3]). The false positive rate was 
defined as the proportion of subtherapeutic nevirapine saliva concentrations by 
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Figure 2  Thin layer chromatography 
sheet in container with eluent.
Figure 3  Determination of spot intensity 
under ultraviolet light.
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reference was substantial between 5 technicians (Fleiss’ kappa of 0.77) and 2 
batches of TLC sheets (Cohen’s kappa of 0.80).
The stock solution for the TLC method (nevirapine in DMSO) was stable at –40 °C 
for at least 50 months (mean ± SD recovery 99.7 ± 0.3%). The reference solution 
(nevirapine in blank saliva) was stable at room temperature for at least 17 hours 
(recovery 107.6 ± 5.8%) and at –40 °C for at least 2 months (recovery 94.3 ± 3.2%). 
Freezing and thawing twice had no effect on the stability of nevirapine in blank 
saliva (recovery 95.1 ± 1.1%). The average nevirapine Rf value was 0.29; none of the 
possible co-medications that were extractable and detectable had a similar Rf value. 
Also, no interference by endogenous substances was observed in the blank saliva 
samples from subjects not taking nevirapine.
Two of the 25 subtherapeutic (<3.0 mg/L) nevirapine plasma concentrations (2.61 
and 2.91 mg/L) according to HPLC were reported as therapeutic by TLC (false 
positive rate of 0.08); the biological sensitivity of the TLC method was 92% (Table 1). 
Three of the 261 therapeutic (≥3.0 mg/L) nevirapine plasma concentrations (3.41, 
3.52 and 4.28 mg/L) according to HPLC were reported as subtherapeutic by TLC 
(false negative rate of 0.01); the biological specificity of the TLC method was 99% 
(Table 1). 
Discussion
 
Twenty-five out of 286 (9%) HIV-infected African adults had a subtherapeutic 
nevirapine plasma concentration <3.0 mg/L [3]. Saliva nevirapine concentrations 
were approximately half of the values observed in plasma. A TLC method for semi-
quantitative detection of nevirapine in saliva was found to be sensitive, specific and 
robust. This simple and economical tool is a good option for TDM of nevirapine in 
resource-limited settings.
Using saliva instead of plasma for TDM of nevirapine implies painless and 
non-invasive sampling with diminished risk of HIV-transmission to health care 
workers at a lower cost [4]. TLC is a relatively inexpensive assay technique 
compared to HPLC [9], which is commonly used in the developed world for TDM of 
treated with a nevirapine dose of 200 mg twice daily (BID) in combination with 
lamivudine and either stavudine or zidovudine.
The mean (range) plasma nevirapine concentration by HPLC was 7.35 (<0.167, 
28.59) mg/L. Twenty-five out of 286 (9%) subjects had a subtherapeutic plasma 
nevirapine concentration (i.e., below 3.0 mg/L); 18 of 25 were below the detection 
limit of the HPLC assay (0.167 mg/L). The median (interquartile range, IQR) saliva/
plasma nevirapine concentration ratio by HPLC was 0.51 (0.47, 0.54) and the 
median (IQR) time between last ingestion and sampling was 3.40 (2.52, 4.37) hours. 
There were six subjects with a saliva/plasma concentration ratio above 1.00 (range 
1.25, 15.68);  the median (IQR) time between last ingestion and sampling for these 
6 subjects was 1.19 (0.85, 1.74) hours.
None of the 23 subtherapeutic (<1.5 mg/L) nevirapine saliva concentrations 
according to HPLC were reported as therapeutic by TLC (false positive rate of 0.00); 
the technical sensitivity of the TLC method was 100% (Table 1). Three of the 263 
therapeutic (≥1.5 mg/L) nevirapine saliva concentrations (1.62, 1.74 and 1.96 mg/L) 
according to HPLC were reported as subtherapeutic by TLC (false negative rate of 
0.01); the technical specificity of the TLC method was 99% (Table 1). 
The extent of agreement in TLC result (subtherapeutic or therapeutic nevirapine 
saliva concentration) of 25 selected samples with a concentration closest to the 
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Table 1  Number of (sub)therapeutic nevirapine concentrations by  
Thin layer chromatography (TLC), compared to High-
performance liquid chromatography (HPLC), sensitivity and  
specificity of TLC assay.
 TLC - Saliva
  Subtherapeutic Therapeutic Sensitivity Specificity
HPLC - Subtherapeutic 23 0 100%
Saliva Therapeutic 3 260  99%
HPLC -  Subtherapeutic 23 2 92%
Plasma Therapeutic 3 258  99%
Subtherapeutic concentrations were defined as < 1.75 mg/L (saliva, TLC), < 1.5 mg/L (saliva, HPLC) and < 3.0 mg/L 
(plasma, HPLC). Therapeutic concentrations were defined as higher values than these cut-off values.
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subtherapeutic according to HPLC, in order to pick out those subjects at risk for 
nevirapine resistance. During the development of our TLC method, subtherapeutic 
saliva concentrations just below 1.5 mg/L were sufficiently distinguishable from a 
TLC reference of 1.75 mg/L, but not from a reference of 1.5 mg/L. For the validation 
of our TLC method we have therefore chosen a reference of 1.75 mg/L, which has 
led to an excellent technical sensitivity (100%) and specificity (99%). None of the 
subtherapeutic nevirapine saliva concentrations according to HPLC were reported as 
therapeutic by TLC and the few therapeutic saliva concentrations that were reported 
as subtherapeutic by TLC were all close to the cut-off value for saliva (1.5 mg/L). 
The biological validation comparing nevirapine saliva concentrations by TLC to 
plasma concentrations by HPLC (subtherapeutic or therapeutic) resulted in an 
acceptable sensitivity (92%) and excellent specificity (99%). False positive and 
negative results were all close to the cut-off value for plasma (3.0 mg/L). The 
somewhat lower biological sensitivity can be explained by the fact that some 
subjects with a subtherapeutic plasma concentration according to HPLC had a 
therapeutic saliva concentration according to both HPLC and TLC. Although these 
subjects had a higher saliva/plasma ratio than average, none of them had a ratio 
above 1.
As expected, it was found to be most difficult to interpret nevirapine saliva 
concentrations closest to the TLC reference. To test the worst-case scenario 
robustness of the TLC method we selected 25 samples closest to the reference. 
The fact that the extent of agreement in TLC results between 5 technicians and 2 
batches of TLC sheets was substantial provides an indication that the outcome of 
our TLC method is reliable during normal use.
At this moment we are planning to roll out the TLC method in various African 
countries as well as in Indonesia. This will make it possible to further evaluate its 
robustness and practical application to monitor adherence. Potentially, the assay 
could be further developed commercially.
In conclusion, we developed a simple and economical TLC method for semi-
quantitative detection of nevirapine saliva concentrations. The assay was found to 
be sensitive, specific and robust in the detection of subtherapeutic nevirapine 
nevirapine in plasma. An HPLC system for TDM of nevirapine costs approximately 
€40,000 and the costs for consumables per sample are estimated at €15. In contrast, 
the estimated initial set-up cost of a new TLC method for semi-quantitative 
measurement of nevirapine in saliva are €800 and the costs for consumables per 
sample are approximately €1.60. Since this simple and inexpensive method was 
developed to perform TDM of nevirapine in resource-limited settings, it was 
validated in an African target population in the current study.
The percentage of HIV-infected adults with a subtherapeutic nevirapine plasma 
concentration <3.0 mg/L [3] according to HPLC [6] in our Tanzanian population 
(9%) was low compared to the percentage in a previous report from Malawi (16%) 
[10]. This may be due to the unreliable drug supply during the time of the Malawian 
study (2003), which explained more than one-third of the total reported non-adherence 
[10]. The fact that 18 of the 25 subtherapeutic nevirapine plasma concentrations in 
our Tanzanian population were undetectable indicates non-adherence, since 
nevirapine is generally detected up to weeks after termination of drug intake due to 
its long elimination half-life [11].  
The median saliva/plasma nevirapine concentration ratio of 0.51 according to HPLC 
[6] in our population of HIV-infected Africans was comparable to the ratios observed 
in HIV-infected [4] and healthy [5] Caucasians. It has been suggested that thorough 
rinsing of the mouth is required prior to saliva sampling, because remnants of orally 
administered medicines may contaminate saliva specimens and yield spuriously 
high values [12]. Indeed, 6 of the 286 subjects in the current study had an 
unexpectedly high saliva/plasma nevirapine concentration ratio above 1 [4, 12], 
which may be due to chewing tablets without rinsing the mouth prior to sampling. 
This explanation is supported by our observation that the time between last 
ingestion and sampling was shorter for those subjects with an unexpectedly high 
nevirapine concentration in saliva compared to plasma. 
Since saliva nevirapine concentrations by HPLC were approximately half of the 
values observed in plasma, they were defined as subtherapeutic if below 1.5 mg/L 
rather than below the cut-off value for plasma of 3.0 mg/L [3]. The main requirement 
of our TLC method for semi-quantitative detection of nevirapine in saliva was 
appropriate sensitivity, meaning detection of nevirapine concentrations that were 
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concentrations in an African population. It is an attractive alternative to HPLC for 
therapeutic drug monitoring of nevirapine in resource-limited settings.
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Introduction
Without treatment, the risk to transmit HIV to the child during pregnancy or delivery is 
approximately 25 to 48%. Complexity and costs of several effective strategies to prevent 
mother-to-child transmission (MTCT) of HIV presently limit large-scale introduction in 
low-income countries. However, the administration of a single dose of the antiretroviral 
drug nevirapine (NVP) to the mother shortly before delivery and to the newborn within the 
first 24 to 72 hours after birth [1] is simple and affordable for low-income countries. 
This so-called single dose NVP (SD-NVP) strategy reduces the risk of MTCT by 50%.
Aside from the suboptimal effectiveness of the SD-NVP strategy, an important 
disadvantage is that in approximately 20 to 70% of the women the virus develops 
resistance against NVP [2, 3]. This can have a great impact. First, the effectiveness 
of SD-NVP may be diminished in a following pregnancy. Second, efficacy can be 
diminished when the mother herself has an indication for NVP-based highly active 
antiretroviral therapy (HAART) in the future [4]. Third, there is a possibility to transmit 
resistant HIV to others. NVP resistance can develop due to the long elimination 
half-life of NVP in combination with a low genetic barrier to resistance. In one study, 
women who developed the K103N mutation after intake of a single NVP dose had a 
significantly longer elimination half-life of NVP than those in whom no resistance 
was detected (74.8 vs. 51.8 hours; P = 0.01) [5]. 
A short-course of an enzyme inducer may prevent the development of resistance by 
decreasing elimination half-life of NVP. The primary elimination pathway for NVP 
appears to be the oxidative metabolism by cytochrome P-450 enzymes CYP3A4 
and CYP2B6 [6]. Several potent CYP3A inducers have been described in literature. 
Long-term treatment with anticonvulsants such as carbamazepine, phenobarbital 
and phenytoin increased the clearance of antipyrine, which is a broad marker of 
enzyme induction, on average to a similar extent [7]. St John’s Wort increased the 
clearance of NVP with 35% [8]. PXR-mediated up-regulation of CYP3A4/CYP3A7 
and CYP3A5 by retinol and ß-carotene points to a potential interference on the 
metabolism of xenobiotic and endogenous relevant compounds [9]. Finally, the fully 
active dihydroxylated metabolite of cholecalciferol, 1α,25-(OH)2D3, was shown to 
induce the expression of CYP3A4 and, to a lesser extent, CYP2B6 and CYP2C9 
genes in normal differentiated primary human hepatocytes [10]. 
Abstract
Objective: Single-dose nevirapine to prevent mother-to-child transmission of HIV is 
associated with development of nevirapine resistance, probably due to its long 
half-life in combination with a low genetic barrier to resistance. The objective of this 
study was to find enzyme inducers to reduce nevirapine half-life.
Design: The design of this phase-I pharmacokinetic study was single-center, 
open-label, two-period, nine-group.
Methods: After administration of a single 200-mg dose of nevirapine to HIV-
seronegative non-pregnant women in both period 1 and 2, blood was sampled 
twice-a-week for 21 days. In period 2 additional interventions (single dose 
carbamazepine, phenobarbital or phenytoin; phenytoin for 3 or 7 days; St John’s 
Wort, vitamin A or cholecalciferol for 14 days) were administered to all subjects 
except for the control group.
Results: Thirty-six subjects participated. In three intervention groups T-half ratio 
(nevirapine half-life in period 2 / half-life in period 1) differed significantly from the 
control group: single 400-mg dose of carbamazepine (P = 0.021), 184mg phenytoin 
once daily for 3 (P = 0.021) or 7 days (P = 0.021). The median decrease in 
nevirapine half-life was 18.8, 19.0 and 16.9 hours, respectively. 
 
Conclusion: Interventions with a single dose of 400mg carbamazepine or phenytoin 
184mg for 3 or 7 days effectively reduced nevirapine half-life. Appropriately powered 
safety and feasibility endpoint studies are warranted before these interventions can 
be tested in the setting of single-dose nevirapine for prevention of mother-to-child 
transmission of HIV to reduce the development of nevirapine resistance.
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validated immunoassay TDxFLx (Abbott, Amsterdam, the Netherlands). In addition, 
trough levels of phenytoin were determined in the blood samples of day 3 (group 5-6) 
and day 7 (group 6). Concentrations of retinol (group 8) and 25(OH)D (group 9) 
were determined in the blood sampled 8 hours after intake on day 0 by validated 
HPLC assay. Furthermore, trough levels of retinol (group 8) and 25(OH)D (group 9) 
were determined in the blood samples of day 7 and 14.  
Results
Thirty-six non-pregnant healthy women were enrolled in the protocol. The median age, 
height, and body weight (interquartile range) were 22 (20-24) years, 1.71 (1.67-1.75) m, 
and 64.5 (60.0-73.0) kg, respectively. All women were white. One woman randomized 
to group 7 dropped out of the study during period 1 for personal reasons. 
The median elimination half-life of NVP (range) in period 1 was 53.9 (34.2-104.2) 
hours. Pharmacokinetic parameters of NVP in period 1 and 2 are illustrated per 
The primary objective of this pilot study was to investigate the effect of intervention 
strategies with a number of the above described agents on the elimination half-life of 
NVP. The study was conducted in the Netherlands as a prelude to studies in Tanzania. 
Appropriately powered safety and feasibility endpoint studies need to be performed 
before these interventions can be tested in the setting of SD-NVP for prevention of 
MTCT (PMTCT) of HIV to reduce the development of nevirapine resistance. 
Methods
The present study was a single-center, open-label, two-period, nine-group, phase-I 
pharmacokinetic study. Non-pregnant healthy women aged 18 to 40 years were 
eligible for enrollment after pre-entry and laboratory evaluation. Women tested 
positive for HIV and/or hepatitis B or C were excluded. Subjects were not allowed to 
take any concomitant drug, including hormonal contraceptives and vitamin 
supplements (for two weeks preceding dosing), except for paracetamol and 
loperamid. The study protocol was reviewed and approved by the Ethics Committee 
of the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 
Informed consent was obtained from all women before enrollment. 
The study design is shown in Table 1. In both period 1 and 2, sampling of blood was 
done just before, 8 hours after and 3, 7, 10, 14, 17, and 21 days after intake of NVP. 
Plasma samples were stored at –40 °C until analysis. Plasma NVP levels were 
determined in all samples by validated high-performance liquid chromatography 
(HPLC) assay with ultraviolet (UV) detection (Thermo, Breda, the Netherlands). The 
lower and upper limits of quantification were 0.03 and 15 mg/L, respectively. The 
intra- and interday precision ranged from 0.4% to 11.4% and from 0.0% to 2.1%, 
respectively. The accuracy of the assay ranged from 100.1% to 104.8%. NVP half-life 
was calculated per group in both period 1 and 2 using all quantifiable NVP levels. 
This exploratory pilot study with 4 participants per group was not powered to 
perform statistical tests.
In period 2, several medication levels were determined for safety reasons. Plasma 
concentrations of carbamazepine (group 2), phenobarbital (group 3) and phenytoin 
(group 4-6) were determined in the blood sampled 8 hours after intake on day 0 by 
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Table 1  Study design.
Period 1*
• Group 1-9: SD NVP 200mg
Period 2*
• Group 1: SD NVP 200mg
• Group 2: SD NVP 200mg + SD carbamazepine 400mg
• Group 3: SD NVP 200mg + SD phenobarbital 200mg
• Group 4: SD NVP 200mg + SD phenytoin 184mg
• Group 5: SD NVP 200mg + phenytoin 184mg, 3 days
• Group 6: SD NVP 200mg + phenytoin 184mg, 7 days
• Group 7: SD NVP 200mg + St John’s Wort tea** bid, 14 days
• Group 8: SD NVP 200mg + SD retinyl palmitate 200000 IU + 
                   ß-carotene 30mg & retinyl palmitate 4000 IU, 13 days
• Group 9: SD NVP 200mg + cholecalciferol 2000 IU, 14 days
* Each group consisted of 4 participants. NVP was taken with water during a standardised breakfast on day 0 of  
period 1 and 2 (with an interval of 4 weeks). First doses of interventions were taken simultaneously with NVP in period 2.
** One cup (tea bag of 2g St John’s Wort & 150mL boiling water, 10 minutes). 
NVP (nevirapine)
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medication group in Table 2. Non-parametric statistical tests (Mann-Whitney) were 
performed on T-half ratio (NVP half-life in period 2 divided by NVP half-life in period 1). 
T-half ratios of three intervention groups differed significantly from group 1 (control): 
single 400-mg dose of carbamazepine (group 2; P = 0.021), 184mg phenytoin once 
daily for 3 days (group 5; P = 0.021) and 184mg phenytoin once daily for 7 days 
(group 6; P = 0.021). In these 3 intervention groups, the median [range] decrease 
in NVP half-life in period 2 was 18.8 [15.6-38.0], 19.0 [11.4-25.4] and 16.9 [10.9-37.4] 
hours, respectively. The decrease in NVP half-life has led to faster undetectable 
NVP levels in group 2, 5 and 6 with carbamazepine single dose, phenytoin 3 and 7 
days, respectively. In these 3 intervention groups, the median [range] decrease in 
time to undetectable NVP levels in period 2 was 4.0 [3.0–7.0], 7.0 [7.0-7.0] and 8.5 
[7.0-11.0] days, respectively. There are no large differences between maximum NVP 
plasma levels eight hours after intake in the two periods.
Eight hours after intake of a single dose, carbamazepine levels in group 2 ranging 
from 3.78 to 6.03 mg/L were all close to the lowest level of the therapeutic range of 
4-10 mg/L. Phenobarbital levels in group 3 eight hours after intake of a single dose 
ranged from 5.10 to 5.83 mg/L and were thus below the therapeutic range of 10-40 
mg/L. Phenytoin levels in group 4-6 ranging from 2.36 to 6.27 mg/L were all below 
the therapeutic range of 8-20 mg/L. Retinol and 25(OH)D levels were all within the 
normal range of 0.70-3.00 µmol/L and 25-100 nmol/L, respectively.  
One out of 36 women in period 1 and 2 out of 36 women in period 2 showed a mild 
elevation of the liver enzyme ALAT (84, 95 and 114 U/L, respectively). Two out of 4 
women taking carbamazepine and 5 out of 12 women taking phenytoin experienced 
mild vertigo. All 4 women in the phenobarbital group experienced mild somnolence. 
Adverse events were transient and did not influence the activities of daily living. 
Discussion
The present pilot study shows that NVP elimination half-life can be effectively 
decreased by interventions with a single 400-mg dose of carbamazepine or 184mg 
phenytoin for 3 or 7 days, most likely due to enzyme induction. 
En z y m e i n d u c e r s  r e d u c e n e v i r a p i n e  h a l f - l i f e
6
En z y m e i n d u c e r s  r e d u c e n e v i r a p i n e  h a l f - l i f e
Ta
b
le
 2
 
 P
ha
rm
ac
ok
in
et
ic
 p
ar
am
et
er
s 
of
 N
VP
 in
 p
er
io
d 
1 
&
 2
, a
nd
 v
al
ue
s 
in
 p
er
io
d 
2 
m
in
us
 v
al
ue
s 
in
 p
er
io
d 
1 
(m
ed
ia
n,
 r
an
ge
).
 
 
N
V
P
 h
al
f-
lif
e,
 
 
 Ti
m
e 
to
 fi
rs
t u
nd
et
ec
ta
b
le
 N
V
P
 le
ve
l,  
   
   
   
  N
V
P
 c
on
ce
nt
ra
tio
n 
8 
ho
ur
s 
af
te
r 
in
ta
ke
,
 
 
T
½
 (
h
o
u
rs
) 
 
 
T u
n
d
e
te
ct
 (
d
ay
s)
 
 
 
C
8
h
  (
m
g
/L
)
* 
Pe
rio
d 
1 
Pe
rio
d 
2 
Pe
rio
d 
2-
1 
Pe
rio
d 
1 
Pe
rio
d 
2 
Pe
rio
d 
2-
1 
Pe
rio
d 
1 
Pe
rio
d 
2 
Pe
rio
d 
2-
1
1 
48
.4
 
46
.3
 
+
1.
5 
15
.5
 
14
.0
 
0.
0 
2.
19
 
2.
02
 
-0
.1
6
 
[4
4.
4,
 5
8.
9]
 
[3
7.
9,
 6
2.
5]
 
[-1
3.
9,
 +
3.
8]
 
[1
4.
0,
 1
7.
0]
 
[1
4.
0,
 1
7.
0]
 
[-
3.
0,
 0
.0
] 
[1
.3
5,
 2
.2
4]
 
[1
.1
7,
 2
.7
8]
 
[-
0.
27
, +
0.
60
]
2 
52
.5
 
33
.8
 
-1
8.
8 
15
.5
 
12
.0
 
-4
.0
 
1.
81
 
2.
03
 
+
0.
17
 
[4
6.
9,
 1
04
.2
] 
[3
1.
3,
 6
6.
2]
 
[-
38
.0
, -
15
.6
] 
[1
4.
0,
 2
8.
0]
 
[1
0.
0,
 2
1.
0]
 
[-7
.0
, -
3.
0]
 
[1
.7
1,
 2
.4
6]
 
[1
.7
3,
 2
.6
5]
 
[-
0.
07
, +
0.
39
]
3 
49
.4
 
39
.7
 
-9
.8
 
14
.0
 
14
.0
 
0.
0 
1.
98
 
1.
91
 
-0
.0
5
 
[3
4.
2-
69
.4
] 
[3
0.
3-
48
.3
] 
[-
21
.1
, -
3.
9]
 
[1
0.
0,
 2
1.
0]
 
[1
0.
0,
 1
4.
0]
 
[-7
.0
, 0
.0
] 
[1
.8
8,
 2
.1
4]
 
[1
.6
7,
 2
.0
1]
 
[-
0.
47
, +
0.
09
]
4 
58
.5
 
50
.4
 
-6
.5
 
17
.0
 
15
.5
 
-1
.5
 
1.
89
 
2.
00
 
+
0.
11
 
[3
5.
3,
 6
6.
5]
 
[3
1.
7,
 7
0.
8]
 
[-1
2.
1,
 +
9.
6]
 
[1
0.
0,
 2
1.
0]
 
[1
0.
0,
 2
1.
0]
 
[-
4.
0,
 +
4.
0]
 
[1
.7
2,
 2
.1
2]
 
[1
.6
8,
 2
.3
9]
 
[-
0.
04
, +
0.
27
]
5 
46
.1
 
27
.1
 
-1
9.
0 
15
.5
 
8.
5 
-7
.0
 
2.
24
 
2.
45
 
+
0,
21
 
[3
7.
6-
59
.9
] 
[2
6.
1,
 3
4.
5]
 
[-
25
.4
, -
11
.4
] 
[1
4.
0,
 2
1.
0]
 
[7
.0
, 1
4.
0]
 
[-7
.0
, -
7.
0]
 
[2
.0
2,
 2
.7
4]
 
[1
.9
9,
 3
.3
4]
 
[-
0.
03
, +
0.
60
]
6 
55
.3
 
34
.5
 
-1
6.
9 
17
.0
 
8.
5 
-8
.5
 
1.
83
 
2.
05
 
+
0.
23
 
[3
7.
5,
 6
9.
7]
 
[2
6.
6,
 4
0.
3]
 
[-
37
.4
, -
10
.9
] 
[1
4.
0,
 2
1.
0]
 
[7
.0
, 1
0.
0]
 
[-1
1.
0,
 -7
.0
] 
[1
.4
3,
 2
.2
9]
 
[1
.7
5,
 2
.2
5]
 
[-
0.
07
, +
0.
34
]
7 
52
.0
 
54
.2
 
-2
.4
 
14
.0
 
17
.0
 
0.
0 
2.
02
 
1.
84
 
-0
.1
0
 
[4
0.
6-
79
.9
] 
[3
8.
2,
 7
4.
2]
 
[-
5.
7,
 +
2.
2]
 
[1
4.
0,
 2
1.
0]
 
[1
4.
0,
 2
1.
0]
 
[0
.0
, +
3.
0]
 
[1
.3
4,
 2
.0
2]
 
[1
.2
4,
 1
.9
2]
 
[-
0.
18
, -
0.
10
]
8 
53
.0
 
56
.1
 
+
1.
9 
15
.5
 
17
.0
 
+
1.
5 
1.
96
 
1.
94
 
-0
.1
5
 
[4
6.
2,
 6
6.
1]
 
[4
4.
4,
 6
6.
9]
 
[-7
.1
, +
8.
6]
 
[1
4.
0,
17
.0
] 
[1
4.
0,
 2
1.
0]
 
[0
.0
, +
4.
0]
 
[1
.6
0,
 2
.2
6]
 
[1
.5
3,
 2
.0
4]
 
[-
0.
23
, +
0.
18
]
9 
62
.2
 
54
.8
 
-3
.9
 
17
.0
 
17
.0
 
0.
0 
2.
01
 
1.
99
 
+
0.
22
 
[5
4.
4,
 6
2.
8]
 
[5
2.
7,
 6
0.
8]
 
[-
9.
5,
 -1
.3
] 
[1
4.
0,
 2
1.
0]
 
[1
7.
0,
 1
7.
0]
 
[-
4.
0,
 +
3.
0]
 
[1
.5
3,
 2
.5
2]
 
[1
.5
8,
 2
.7
9]
 
[-
0.
41
, +
0.
27
]
* 
G
ro
up
. 
N
VP
 (n
ev
ira
pi
ne
)
110 111
It is clear that our study population of healthy non-pregnant Dutch women of 
child-bearing age is not similar to the setting in sub-Saharan African countries, 
where HIV-infected pregnant women are black and will have different dietary habits, 
body weights, and concomitant medications. The CYP2B6 T/T genotype at position 
516 is more common in African-Americans than in European-Americans and is 
associated with greater efavirenz exposure [16] and, to a lesser extent, also to 
greater NVP exposure [17]. However, the median NVP half-life in our group of 36 
white women (53.9 hours) does not differ much from the mean NVP half-life in a 
smaller group of pregnant HIV-infected Ugandan women receiving SD-NVP (61.3 
hours) [18]. The results from this pilot study are valuable, since we were able to 
identify three potential interventions (single 400-mg dose of carbamazepine, 184mg 
phenytoin for 3 or 7 days) to be studied in the setting of PMTCT to confirm our 
finding that NVP half-life will be diminished and to test the hypothesis that hereby 
development of NVP resistance will decrease. The most rational intervention to start 
with is a single dose of carbamazepine, because of its simplicity. 
Addition of other antiretroviral agents after delivery to cover the window of 
opportunity for the virus to select for nevirapine resistance is a different approach. 
Recently, preliminary data were presented that short courses (4-7 days) of 
zidovudine plus lamivudine (Combivir®) added to SD-NVP in the prevention of 
MTCT, significantly reduced the development of NVP resistance when compared 
with no intervention [19]. However, the substantial increase in costs and complexity 
is not desirable. Recent data from a study in Zambia showed that it is already 
difficult to accurately carry out the simple SD-NVP intervention [20].
It is currently unknown at what plasma level NVP selects for resistance. NVP levels 
that are either undetectable or, in the context of HAART, greater than 3.0-3.4 mg/L 
[21, 22], do not have selective pressure. The intervention with 4-7 days Combivir® 
covers the potential zone of selective pressure below 3.0-3.4 mg/L only partially, 
which explains that NVP resistance was not fully absent in the intervention arms 
[19]. A significant decrease in NVP half-life by addition of an enzyme inducer will 
reduce the duration of the potential zone of resistance, but may also not be 
sufficient to prevent development of all NVP mutations. It might be interesting to 
study if combining these two approaches of decreasing NVP half-life and 
co-administering other antiretroviral agents will be of additional value.    
This study with small groups was not designed to perform statistical tests. However, 
because of large and very consistent decreases in NVP half-life, we decided to 
perform a non-parametric statistical test on the primary parameter T-half ratio to see 
whether the effect was actually significant. 
The interventions with St John’s Wort tea, vitamin A and D for 14 days did not show 
a decrease in NVP half-life. For St John’s Wort this may be explained by the fact that 
the product used in this study (tea) contains a relatively low amount of hyperforine 
[11], which is the constituent likely responsible for enzyme induction [12]. 
For vitamin D, one explanation might be that after intake of cholecalciferol by 
healthy women without vitamin D deficiency, in vivo conversion to the fully active 
dihydroxylated metabolite 1α,25-(OH)2D3  is not optimal. A single 200-mg dose of 
phenobarbital was not enough to substantially reduce NVP half-life. Lengthening 
treatment would not be wise, because of slow elimination by the nursing infant. It 
seemed to be necessary to take 184mg of phenytoin once daily for at least three 
days to significantly reduce NVP half-life. In the African setting of PMTCT it should 
be safe to use phenytoin during breast feeding [13], because of its poor passage 
into breast milk. Surprisingly, the simple intervention with a single 400-mg dose of 
carbamazepine appeared to effectively reduce NVP half-life. It is unknown whether 
this effect is due to enzyme activation, enzyme induction or the up-regulation of the 
efflux transporter P-glycoprotein (P-gp) [14], although data being conflicting about 
NVP being a substrate for P-gp [15]. Carbamazepine passes into breast milk, but is 
generally considered safe for use during breast feeding [13]. Rifampicin is a potent 
inducer of CYP3A, decreasing NVP AUC by 37% to 58% [6] and was also considered 
by us to be used in this pilot study. However, rifampicin was not part of the 
interventions because widespread use together with SD-NVP may promote the 
development of resistance against rifampicin in tuberculosis (co-)infected patients. 
NVP plasma levels eight hours after intake were not influenced by interventions with 
enzyme inducers. This is consistent with a delay of the effect on enzyme induction 
as increased protein synthesis is required and this takes a few days for maximum 
result. It is unlikely that these interventions will influence the protective effect of NVP 
on MTCT of HIV during labor, because there was no influence on maximum NVP 
levels. Since this finding is based on a study with small groups of healthy women, 
it needs to be confirmed in clinical practice.
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Abstract
Objective: Previous research in healthy volunteers has demonstrated that rifampicin 
and adjusted doses of lopinavir/ritonavir soft-gel capsules resulted in adequate 
exposure to lopinavir. Our objective was to study the combined use of rifampicin 
and the newly introduced lopinavir/ritonavir tablets. 
Methods: A total of 40 healthy subjects was planned to start with 600 mg rifampicin 
once daily from day 1–5. From days 6-15, subjects were randomized to receive 
lopinavir/ritonavir tablets dosed as either 600/150 mg or 800/200 mg twice daily, 
both in addition to 600 mg rifampicin once daily. A 12h pharmacokinetic curve was 
planned on day 15. Safety assessments were conducted regularly throughout the 
study period. 
Results: Eleven subjects started as the first group in this study. No major complaints 
occurred during day 1–5 (rifampicin only). After addition of lopinavir/ritonavir, eight 
subjects suffered from both nausea and vomiting, one from nausea only, and one 
from vomiting only. On day 7 increases in AST/ALT levels were reported in all 
subjects and on day 8 the study was prematurely terminated. The AST/ALT levels 
continued to rise and peaked (grade 2: n=2, grade 3: n=1, grade 4: n=8) on days 
9-10. All values returned to normal within six weeks. 
Conclusions: This study showed a high incidence of adverse events when a higher 
than standard dose of the new lopinavir/ritonavir tablets was combined with 
rifampicin. In the future, this drug combination should not be given to healthy 
volunteers. Liver function should be carefully monitored when rifampicin and 
lopinavir/ritonavir are combined in patients. 
 
Introduction
Approximately one-third of the 40 million people living with HIV/AIDS worldwide are 
co-infected with tuberculosis (TB) [1]. Rifampicin is the most powerful component 
of current TB treatment, but is also a strong inducer of cytochrome P450 enzymes, 
resulting in drug-drug interactions with antiretroviral therapy [2, 3], in particular non- 
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). 
The World Health Organization (WHO) recommends to combine rifampicin-based 
TB treatment with efavirenz-based antiretroviral therapy in TB-HIV co-infected 
patients [3]. The modest decrease in concentrations of the NNRTI efavirenz is not 
expected to be clinically relevant [4, 5]. Although rifampicin reduces concentrations 
of the NNRTI nevirapine by 20-55% [6], collected experience is sufficient to make 
nevirapine an alternative to efavirenz among non-Caucasian patients receiving 
rifampicin [7, 8]. A disadvantage of NNRTI drugs is the low genetic barrier for the 
development of resistance; only one point mutation is required to confer high-level 
cross-class resistance [9].
One alternative for patients with NNRTI-resistant HIV or those unable to take NNRTIs 
would be triple nucleoside regimens without interaction to rifampicin. However, 
these regimens are associated with less antiretroviral activity [10] and therefore not 
advisable. An equally active alternative to NNRTI-based therapy among patients 
being treated with rifampicin may be PI-based antiretroviral therapy. However, 
standard PI doses, whether boosted with ritonavir or not, cannot be given with 
rifampicin because of large decreases in PI concentrations [11-14]. 
In HIV infected adults without active tuberculosis, WHO recommends lopinavir/
ritonavir at 400/100 mg twice daily (BID) in combination with two nucleosides as 
PI-based therapy [15]. We have previously evaluated the pharmacokinetics of two 
adjusted dose regimens of lopinavir/ritonavir (800/200 mg BID and 400/400 mg 
BID) soft gel capsules when combined with rifampicin in healthy volunteers [11]. 
Because of more variable pharmacokinetics of lopinavir in the better tolerable arm 
of 800/200 mg lopinavir/ritonavir, therapeutic drug monitoring (TDM) appeared to 
be indicated. In the absence of TDM, 400/400 mg lopinavir/ritonavir could be 
combined with rifampicin, while closely monitoring for liver enzyme elevations. 
C o m b i n e d u s e  o f  r i f a m p i c i n  a n d l o p i n av i r / r i t o n av i r  t a b l e t s
7
C o m b i n e d u s e  o f  r i f a m p i c i n  a n d l o p i n av i r / r i t o n av i r  t a b l e t s
122 123
for the determination of plasma concentrations of lopinavir and ritonavir; and on day 
15 pre-dose until 12 hours post-dose for the analysis of all three drugs. Blood 
samples were stored in the refrigerator immediately and centrifuged at 2,500 g for 
10 minutes. Plasma was separated and stored below -40ºC (for the determination 
of lopinavir and ritonavir) or -80ºC (for the determination of rifampicin and 
desacetylrifampicin) within 4 hours after collection. All procedures concerning 
collection and storage of drug samples have been validated. 
Bioanalysis
Plasma lopinavir, ritonavir, rifampicin and desacetylrifampicin concentrations were 
determined by validated high-performance liquid chromatography (HPLC) 
methods [17, 18]. 
Safety and tolerability 
We planned to perform clinical chemistry and hematology tests and to ask subjects 
about the occurrence of adverse events at each study visit on day 1, 3, 5, 6, 7, 9, 11, 
13 and 15. Adverse events, clinical chemistry and hematology test results were 
graded according to the grading system of the Division of AIDS [19]. After 
termination of the study, hepatitis B and C tests were repeated. In addition, 
Epstein-Barr virus and cytomegalovirus antibody tests were performed to exclude 
acute viral infection.
Results
Subjects 
Forty healthy volunteers were enrolled in the study. The first group consisted of 
eleven subjects of whom eight were Caucasians, two were Caucasian-black and 
one was black. The median (range) age, body weight and body mass index were 24 
(19-51) years, 63 (53-92) kg and 22 (19-30) kg/m2, respectively. Five subjects (three 
females) received 600/150 mg lopinavir/ritonavir BID and six (four females) received 
800/200 mg lopinavir/ritonavir BID in addition to rifampicin 600 mg. The remaining 
29 subjects were withdrawn from the study after receiving only one dose of 
rifampicin (n=10) or no study medication at all (n=19). 
Recently, a new tablet formulation of lopinavir/ritonavir has become available. 
Compared to the soft gel capsule, the novel tablet formulation shows reduced 
pharmacokinetic variability and exhibits slightly higher (18%) bioavailability, 
irrespective of concomitant food intake [16].
The aim of this study was to evaluate the pharmacokinetics of two adjusted dose 
regimens of lopinavir/ritonavir tablets in combination with rifampicin in healthy 
volunteers. Due to an unexpectedly high incidence of adverse events, this study 
was terminated prematurely. 
Methods
Study design
The study was designed as an open-label, sequential, 2-period, phase IV multiple 
dose trial in healthy volunteers. From day 1 until day 5, subjects received 600 mg 
rifampicin once daily (QD). From day 6 until day 15, subjects were randomized to 
receive either three (600/150 mg) or four (800/200 mg) of the new lopinavir/ritonavir 
(Kaletra®) tablets BID, combined with 600 mg rifampicin QD. On days 1, 3, 5, 6, 7, 
9, 11, 13 and 15 study medication was planned to be taken under observation and 
immediately after a standardized breakfast (± 350 kcal, ± 13 g. of fat). The other 
drug doses were taken at home. All subjects gave written informed consent and the 
Ethical Review Board of Radboud University Nijmegen Medical Centre, The 
Netherlands, approved the study. 
Subjects
Healthy subjects, aged 18-55 years were eligible for enrolment after pre-entry and 
laboratory evaluation. The main exclusion criteria were: positive HIV test result; 
positive hepatitis B or C test result; positive Mantoux test result; abnormal clinical 
laboratory test results and abnormal ECG. 
Pharmacokinetic assessment
Blood samples of 5 ml were planned to be collected at the following time points; on 
day 5 just before and two hours post-dose (C2h) for the determination of rifampicin 
(and desacetylrifampicin) plasma concentrations; on day 7, 9, 11 and 13 pre-dose 
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Pharmacokinetics 
The geometric mean (range) of rifampicin and desacetylrifampicin C2h on day 5 
(rifampicin only) was 11.3 (6.8-17.4) and 1.12 (0.74-2.37) mg/L, respectively (n=11). 
In five subjects, plasma concentrations of lopinavir and ritonavir were undetectable 
in the morning of day 7 due to vomiting after the evening dose on day 6. In the 
remaining six subjects, the geometric mean (range) of the lopinavir and ritonavir 
trough concentrations on day 7 were 7.9 (6.6-10.3) mg/L and 0.71 (0.35-1.61) mg/L 
in the 600/150 mg group (n=3) and 10.9 (8.3-13.8) mg/L and 1.20 (0.64-1.85) mg/L 
in the 800/200 mg group (n=3). The median (range) of the rifampicin and 
desacetylrifampicin trough concentrations in the morning of day 7 were 0.41 
(0.0-1.13) mg/L and 0.40 (0.0-0.83) mg/L in the 600/150 mg group (n=5) and 0.47 
(0.0-1.17) mg/L and  0.21 (0.0-1.12) mg/L in the 800/200 mg group (n=6). 
Tolerability 
No major complaints or abnormal AST/ALT levels occurred during day 1–5, when 
rifampicin was given only (Table 1). After addition of lopinavir/ritonavir, eight 
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Table 1  Distribution of adverse events (n, %) in eleven healthy volunteers. 
Medication was stopped on day 7 or 8. 
Adverse event Day 1-11 Day 1-5 Day 6- 11
  (overall)  (rifampicin) (day 6-7/8: rifampicin
    and lopinavir/ritonavir)
Flatulence 1 (9%) 0 1 (9%)
Headache 1 (9%) 1 (9%) 0
Rash    
 Grade 1 1 (9%) 1 (9%) 0
Fever   
 Grade 1 1 (9%) 0 1 (9%)
Myalgia    
 Grade 2 1 (9%) 0 1 (9%)
Joint pain   
 Grade 1 2 (18%) 2 (18%) 0
Fatigue   
 Grade 1 1 (9%) 0 1 (9%)
 Grade 2 1 (9%) 0 1 (9%) 
Trismus* 1 (9%) 0 1 (9%)
Diarrhoea    
 Grade 1 2 (18%) 1 (9%) 2 (18%)
 Grade 2 1 (9%) 0 1 (9%)
Nausea   
 Grade 1 3 (18%) 1 (9%) 2 (18%)
 Grade 2 8 (73%) 2 (18%) 7 (64%)
Vomiting    
 Grade 2 3 (27%) 0  3 (27%)
 Grade 3 6 (55%) 0 6 (55%)
Pruritis    
 Grade 1 3 (27%) 3 (27%) 3 (27%)
 Grade 2 1 (9%) 1 (9%) 0
Headache 1 (9%) 1 (9%) 0
ALT   
 Grade 2 2 (18%) 0 2 (18%) 
 Grade 3 1 (9%)  0 1 (9%)
 Grade 4 8 (73%) 0 8 (73%)
AST   
 Grade 2 2 (18%) 0 2 (18%)
 Grade 3 1 (9%) 0 1 (9%)
 Grade 4 8 (73%) 0 8 (73%)
GGT   
 Grade 1 4 (36%) 0 4 (36%)
 Grade 2 2 (18%) 0 2 (18%)
 Grade 3 1 (9%) 0 1 (9%)
Bilirubin   
 Grade 2 3 (27%) 0 3 (27%)
 Grade 3 5 (45%) 0 5 (45%)
* Probably related to excessive metoclopramide usage.
ALT (alanine aminotransferase), AST (aspartate aminotransferase), GGT (gamma glutamyl transferase).
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Figure 1  Mean clinical parameters versus time in eleven healthy volunteers 
until study day 47 (day 1-5: rifampicin only; day 6-7/8: rifampicin 
and lopinavir/ritonavir; day 7/8-47: no medication). 
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arm in which rifampicin usage was followed by the combination of rifampicin and 
the PI [20], analogous to the current study. However, this sequence is a reflection of 
the clinical situation of TB-HIV co-infected patients as TB is preferably treated first. 
Besides, TB-HIV co-infected patients seem to tolerate the combination of rifampicin 
and saquinavir/ritonavir well in both sequences [14, 21], suggesting a yet unidentified 
difference between patients and healthy volunteers. It has not been investigated so 
far, whether TB-HIV co-infected patients tolerate the combination of rifampicin and 
lopinavir/ritonavir better than healthy volunteers.
With respect to the second difference, the absence of a dose escalation scheme for 
the adjusted dose of lopinavir/ritonavir may have contributed to the high incidence 
of adverse events in the current study. We decided to omit dose escalation because 
the liver enzymes had been induced by rifampicin already. The efflux transporter 
P-glycoprotein (P-gp) can mediate the transport of lopinavir and ritonavir [22, 23] as 
well as rifampicin [24]. A time-dependent effect by lopinavir/ritonavir on P-gp was 
previously suggested; inhibition after single-dose and induction after repeated 
administration [25]. The immediate administration of the high dose of lopinavir/
ritonavir in the current study may have resulted in inhibition of the efflux transporter 
P-gp and therefore to the relatively high trough concentrations of the study 
medication observed. This may explain part of the adverse events. 
Finally, unidentified toxic excipients of the new tablet formulation and its slightly 
higher bioavailability may have played a role. Studies show that this slight increase 
in bioavailability of lopinavir/ritonavir tablets may compensate for the inductive 
effect of efavirenz [26]. This same compensation may occur when combined with 
rifampicin, as in the current study in which we found relatively high non steady-state 
lopinavir trough levels compared to the steady-state levels in the previous study 
[11]. In short, data from interaction studies with one formulation cannot be 
extrapolated to another formulation.
In conclusion, this study demonstrates the challenging character of the compatibility 
of rifampicin and PIs in TB-HIV therapy. We advise that further studies investigating 
the interaction between rifampicin and lopinavir/ritonavir tablets be performed in the 
actual target population of TB-HIV co-infected patients rather than in healthy 
volunteers. Awaiting these results, simultaneous treatment with rifampicin and 
subjects suffered from both nausea and vomiting, one had nausea only, and one 
vomited only. Eight subjects were given the antiemetic drug metoclopramide. All six 
subjects in the 800/200 mg lopinavir/ritonavir group vomited, compared to three out 
of five in the 600/150 mg group. On day 7, increases in AST and ALT levels were 
reported in all subjects and increases in GGT in all but one subject. Study 
medication was stopped on day 7 for 8 subjects and on day 8 for the remaining 
three subjects. The AST/ALT levels continued to rise and peaked (range 125-1400 
and 201-1657 U/L, respectively) on days 9-10 (Figure 1). The GGT levels increased 
more gradually and peaked (range 21-177 U/L) on days 10-12 (Figure 1). Four out of 
six subjects in the 800/200 mg lopinavir/ritonavir group experienced grade 4 AST or 
ALT toxicity versus four out of five in the 600/150 mg group. All clinical parameters 
returned to normal within six weeks after study termination (Figure 1). Test results 
for hepatitis B and C, Epstein-Barr virus and cytomegalovirus were all negative after 
study termination.
Discussion
This study showed an unexpected high incidence of nausea, vomiting and liver 
enzyme elevations when a higher than standard dose of the recently introduced 
lopinavir/ritonavir tablets was combined with rifampicin in healthy volunteers. 
Therefore, the study was terminated prematurely. 
In our previous study in which rifampicin and adjusted doses of lopinavir/ritonavir 
capsules were combined [11], toxicity of this magnitude was not observed. However, 
the current study differed from our previous study [11] in several aspects, and this 
may explain the higher incidence of adverse events. Firstly, rifampicin was 
introduced prior to lopinavir/ritonavir; secondly, the adjusted dose of lopinavir/
ritonavir tablets was not escalated; and thirdly, the new lopinavir/ritonavir tablet 
formulation was used instead of the capsule formulation. 
Firstly, the sequence of introduction of rifampicin and lopinavir/ritonavir may have 
played a role. Termination of a study because of unexpected hepatotoxicity in 
healthy volunteers using the combination of rifampicin and saquinavir/ritonavir, was 
reported before [20]. The majority of the adverse events was observed in the study 
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Abstract
Objective: A retrospective study was conducted to describe the clinical experience 
in the Netherlands with the combined use of lopinavir/ritonavir and rifampicin.   
Methods: Adult HIV-infected patients treated concomitantly with lopinavir/ritonavir 
and rifampicin were selected from the Dutch ATHENA cohort and evaluated with 
regard to 6 items: lopinavir/ritonavir dose and formulation, sequence of drug 
administration, lopinavir trough plasma concentration, plasma viral load and 
tolerability. 
Results: Thirty-four patients with a median age of 36 years were included. Overall, 
only 15% used the recommended increased dose of lopinavir/ritonavir. Of the 23 
patients on a non-adjusted dose of lopinavir/ritonavir, 4 out of 6 (67%) had a 
subtherapeutic lopinavir trough plasma concentration and 3 out of 8 (38%) had a 
detectable viral load after at least 4 months of concomitant treatment. Two out of 5 
(40%) patients on a recommended increased dose of lopinavir/ritonavir prematurely 
stopped the drug combination because of adverse events vs. 4 out of 23 (17%) on 
a non-adjusted dose and 1 out of 6 (17%) on a slightly increased dose. 
Conclusions: Combined use of lopinavir/ritonavir and rifampicin is challenging as 
it implies balancing between suboptimal efficacy and toxicity. An adequately 
powered prospective study in HIV-infected patients is needed to investigate the 
consequences of inferior exposure to lopinavir due to non-adjusted doses of 
lopinavir/ritonavir versus the tolerability of recommended increased doses. 
 
Introduction
Tuberculosis (TB) is the most prevalent opportunistic infection among HIV-infected 
patients worldwide [1]. Rifampicin is an important drug in the treatment of TB and 
has strong liver enzyme inducing capacity, resulting in drug-drug interactions with 
antiretroviral therapy [2].
Rifampicin-based TB treatment can be combined with antiretroviral therapy based on 
the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz [1], since the 
decrease in exposure to efavirenz due to co-administration of rifampicin is not expected 
to be clinically relevant [3, 4]. However, efavirenz cannot be used in case of pregnancy, 
intolerance or resistance to the drug [5]. The NNRTI nevirapine is considered to be an 
alternative to efavirenz among non-Caucasian patients receiving rifampicin [6, 7], 
despite the fact that rifampicin reduces the exposure to nevirapine by 20-55% [8].
An alternative for patients with NNRTI-resistant HIV who are treated with rifampicin 
would be protease inhibitor (PI)-based antiretroviral therapy [1]. However, rifampicin 
has been shown to cause large decreases in exposure to PIs [9-12]. We have 
previously performed two studies in healthy volunteers to evaluate whether 
adjustment of the standard lopinavir/ritonavir dose of 400/100 mg twice daily (BID) 
could compensate for the drug interaction with rifampicin [9, 13]. 
Our first study demonstrated that, on average, rifampicin and increased doses of 
lopinavir/ritonavir soft gel capsules (SGCs; 800/200 mg BID and 400/400 mg BID) 
resulted in adequate exposure to lopinavir in healthy volunteers [9]. However, 
therapeutic drug monitoring (TDM) was advised when combining rifampicin with 
800/200 mg lopinavir/ritonavir BID and close monitoring for liver enzyme elevations 
was advocated when combined with 400/400 mg BID. 
A new tablet formulation of lopinavir/ritonavir became available in 2006 to replace 
the former SGC formulation. In our second study, we aimed to evaluate the 
pharmacokinetics of two adjusted dose regimens of lopinavir/ritonavir tablets 
(600/150 mg BID and 800/200 mg BID) in combination with rifampicin in healthy 
volunteers [13]. However, the study was terminated prematurely due to an 
unexpectedly high incidence of nausea, vomiting and liver enzyme elevations. 
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For patients who used the drug combination of lopinavir/ritonavir and rifampicin for 
at least 4 months, plasma viral load data were collected until the end of concomitant 
treatment. Viral loads were classified as undetectable (HIV-RNA <50 copies/ml) or 
detectable (≥50 copies/ml). The proportion of patients with an undetectable plasma 
viral load at baseline and at the end of concomitant treatment was determined in 
those on a non-adjusted, slightly adjusted or recommended dose of lopinavir/
ritonavir. 
Acute, premature termination of lopinavir/ritonavir and rifampicin was defined as 
stopping concomitant treatment within 4 weeks from the start. Reported adverse 
events and grade of liver toxicity expressed by elevation of aspartate and alanine 
aminotransferase (AST/ALT) were collected for patients who prematurely stopped 
and for those who continued the drug combination [18]. The clinicians of patients 
who prematurely terminated the drug combination were asked to review the patient 
file and report the reason for stopping. We calculated the proportion of patients 
with premature stops because of adverse events overall and according to the 3 
dose groups. In addition, we identified the formulations and lead-in drugs that were 
used by the patients who prematurely stopped the drug combination because of 
adverse events.
Results
The 34 patients (8 women, 26 men) who were included in the study originated from 
Sub-Saharan Africa (n=12), The Netherlands (n=8), Latin America (n=7), 
The Netherlands Antilles (n=3), South East Asia (n=2) or Middle East / North Africa 
(n=2). Combined treatment with lopinavir/ritonavir and rifampicin was initiated 
between October 2000 and February 2007. 32 Patients (94%) were treated for TB. 
Antiretroviral co-medication consisted of zidovudine and lamivudine (n=12), 
stavudine and lamivudine (n=4), lamivudine and tenofovir (n=4), zidovudine, 
lamivudine and abacavir (n=4) or alternative combinations (n=10). Median 
(interquartile range) age, weight, CD4 cell count and plasma viral load at baseline 
were 36 (32, 43) years, 62 (55, 70) kg, 105 (27, 248) cells/µl and 75,750 (<50, 
204,085) copies HIV-RNA/ml. 
In the absence of similar interaction studies in patients, we performed a retrospective 
analysis of observational data from the ATHENA cohort [14] to describe the clinical 
experience in the Netherlands of combining lopinavir/ritonavir and rifampicin. 
 
Methods
Adult (≥ 18 years) HIV-infected patients treated concomitantly with lopinavir/ritonavir 
and rifampicin were selected from the Dutch ATHENA cohort [14]. Baseline was 
defined as the 6 months period before the start of concomitant treatment. Patient 
demographic and clinical characteristics were collected at baseline. During the 
period of concomitant use, the patients were evaluated with regard to six items: 
lopinavir/ritonavir dose and formulation, sequence of drug administration, lopinavir 
trough plasma concentration (i.e. the concentration just prior to the next dose), 
plasma viral load, and tolerability.
Recommendations of lopinavir/ritonavir dose increment to 400/400 or 800/200 mg 
BID when combined with rifampicin [1, 15] are based on a pharmacokinetic 
interaction study in healthy volunteers presented at the end of September 2002 [16]. 
In the current analysis, prescribed doses of lopinavir/ritonavir in combination with 
rifampicin were classified as non-adjusted (400/100 mg BID or 800/200 mg once 
daily (QD)), slightly adjusted (500/125 mg as liquid or 533/133 mg as SGC, both 
BID) or adjusted according to recommendation (400/400 or 800/200 mg BID). The 
overall proportions of prescribed lopinavir/ritonavir formulations (SGC, tablet, liquid) 
and sequences of drug administration (rifampicin lead-in, lopinavir/ritonavir lead-in, 
simultaneous initiation) were determined. We determined the overall proportion of 
lopinavir/ritonavir dose adjustments when combined with rifampicin and the 
proportion before and after the recommendation of dose adjustment was first 
presented (October 1, 2002) [16]. 
Lopinavir trough plasma concentrations were classified as subtherapeutic (<1.0 
mg/L) or therapeutic (≥1.0 mg/L) [17]. The proportion of patients with a subtherapeutic 
lopinavir trough plasma concentration was determined in those on a non-adjusted, 
slightly adjusted or recommended dose of lopinavir/ritonavir. 
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slightly adjusted dose and 2 of 5 (40%) patients on a recommended dose. Four of 6 
(67%) patients on a non-adjusted dose of lopinavir/ritonavir had a subtherapeutic 
lopinavir trough plasma concentration, whereas the 2 patients on a recommended 
dose had a therapeutic concentration.
Viral load data were available for all 11 patients who used lopinavir/ritonavir and 
rifampicin concomitantly for at least 4 months. In Figure 1, the proportion of patients 
with an undetectable plasma viral load at baseline and at the end of concomitant 
treatment is shown according to lopinavir/ritonavir dose group. 
In Table 1, the reported adverse events and toxicity grade of AST/ALT elevations are 
shown for the 12 (35%) patients who prematurely stopped concomitant lopinavir/
ritonavir and rifampicin treatment within 4 weeks and for the 22 (65%) who continued 
the drug combination. Nausea and malaise were the most experienced adverse events, 
but were only reported in the group that prematurely discontinued the drug combination. 
Grade 2 AST/ALT elevations were more often reported in the group that continued the 
drug combination. Overall, 7 of 34 (21%) patients prematurely stopped the combination 
within 4 weeks because of acute adverse events; this was 4 of 23 (17%) on a 
non-adjusted dose, 1 of 6 (17%) on a slightly adjusted dose and 2 of 5 (40%) on a 
recommended dose of lopinavir/ritonavir (Table 2). 
Twenty-eight of 34 (82%) patients were on the SGC formulation, 4 (12%) on the tablet 
formulation and 2 (6%) on the liquid formulation of lopinavir/ritonavir. Twenty-three 
(68%) patients had a rifampicin lead-in, 10 (29%) had a lopinavir/ritonavir lead-in and 1 
(3%) initiated both drugs simultaneously. The formulations and lead-in drugs that were 
used by the 7 patients who prematurely stopped the drug combination because of 
adverse events are shown in Table 2; none of them was using tablets and the proportion 
of lead-in drugs was comparable to the overall proportion.
Discussion
This retrospective study demonstrates that the dose of lopinavir/ritonavir was 
usually not increased when combined with rifampicin in Dutch HIV-infected patients. 
This may have led to the relatively high proportion of subtherapeutic lopinavir trough 
Overall, 23 of 34 (68%) patients were on a non-adjusted dose of lopinavir/ritonavir 
(400/100 mg BID or 800/200 mg QD), 6 (18%) on a slightly adjusted dose (500/125 or 
533/133 mg BID) and 5 (15%) on a recommended dose (400/400 or 800/200 mg BID). 
8 Patients started concomitant treatment before the recommendation of lopinavir/
ritonavir dose adjustment was first presented; 26 patients started concomitant 
treatment after the recommendation of lopinavir/ritonavir dose adjustment became 
available in the public domain [16]. Of the 8 patients who started concomitant treatment 
before the recommendation of lopinavir/ritonavir dose adjustment was first presented, 
7 (88%) were on a non-adjusted dose, 1 (13%) on a slightly adjusted dose and none on 
a recommended dose. Of the 26 patients who started concomitant treatment after the 
recommendation of lopinavir/ritonavir dose adjustment was in the public domain, 16 
(62%) were on a non-adjusted dose, 5 (19%) on a slightly adjusted dose and 5 (19%) 
on a recommended dose.
Lopinavir trough plasma concentrations during combined use were available for 6 of 23 
(26%) patients on a non-adjusted dose of lopinavir/ritonavir, none of 6 patients on a 
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Figure 1  Proportion of patients with an undetectable viral load according  
to lopinavir/ritonavir dose group at baseline and after at least  
4 months of co-administration with rifampicin. 
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plasma concentrations and detectable viral loads. The low adherence to this 
particular dose recommendation is in line with a recent study demonstrating that a 
minority of patients received dose adjustments to compensate for interactions 
between antiretroviral therapy and rifabutin [19].
Recommendations of lopinavir/ritonavir dose increment when combined with 
rifampicin [1, 15] have been based on one of our previous pharmacokinetic 
interaction studies [16]. Although the uptake of this dose recommendation was 
noticed to some extent after presentation of the particular study [16], general 
adherence to the recommendation was low. This may be due to clinicians not being 
aware of the recommendation at the time of prescription, because of slow integration 
into guidelines [1, 15] and medication monitoring systems. Another reason may be 
that clinicians did not follow this recommendation as it was only based on a 
pharmacokinetic interaction study in healthy volunteers [9] without evidence based 
confirmation of clinical relevance and tolerability of dose increments in HIV-infected 
patients. 
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Table 1  Distribution of adverse events and grade of ASTa/ALTb in those  
who prematurely terminated (<4 weeks) and those who continued 
(≥ 4 weeks) co-administration of lopinavir/ritonavir and rifampicin. 
Category Adverse event <4 weeks ≥4 weeks
 and grade of ASTa/ALTb n=12 n=22
Cardiovascular Sinus tachycardia  1 (5%)
Chemistries Slightly elevated LDHc/ALPd 1 (8%) 
Dermatological Rash  2 (9%)
 Nausea 4 (33%) 
Gastrointestinal Diarrhoea 2 (17%) 1 (5%)
 Bad taste mouth 1 (8%) 
 Vomiting 1 (8%) 
Genitourinary Renal disorder  1 (5%)
 Candidiasis genital  1 (5%)
Infection Cerebral toxoplasmosis  1 (5%)
 Conjunctivitis  1 (5%)
 Herpes zoster  1 (5%)
Metabolic Diabetes Mellitus  1 (5%)
 Paraesthesia 1 (8%) 1 (5%)
Neurologic Peripheral neuropathy  1 (5%)
 Bad dreams  1 (5%)
 Malaise 3 (25%) 
 Fatigue 1 (8%) 1 (5%)
Systemic Fever 1 (8%) 1 (5%)
 Cachexia 1 (8%) 
 Liver toxicity 1 (8%) 
 Pain upper abdomen 1 (8%) 
 ASTa/ ALTb  
      Grade 0 2 (17%) 1 (5%)
      Grade 1  1 (5%)
      Grade 2  5 (23%)
      Grade 3 1 (8%) 2 (9%)
Values given are n (%)
a  aspartate aminotransferase
b  alanine aminotransferase
c  lactate dehydrogenase
d  alkaline phosphatase
Table 2  Adverse events responsible for premature termination of  
concomitant treatment with lopinavir/ritonavir and rifampicin in 7  
out of 34 patients. 
 
LPV/rtva dose
 
Adverse event
 LPV/rtva Lead-in
   Formulation drug
1  Liver toxicity, malaise, nausea, vomiting  
Rifampicin
2 
Non-adjustedb
 Nausea
3  Diarrhoea  LPV/rtva
4  Immune reconstitution syndrome 
SGCh
 
5 Slightly adjustedc Pain upper abdomen  
Rifampicin
6  Bad taste mouth, diarrhoea, nausea, paraesthesia  LPV/rtva
7 
Recommendedd
 Nausea, slightly elevated LDHe, ALPf and ALTg liquid None
a lopinavir/ritonavir
b 400/100 mg twice daily
c 533/133 mg twice daily
d 400/400 mg (n=1) or 800/200 mg (n=1) twice daily
e lactate dehydrogenase
f alkaline phosphatase
g alanine aminotransferase
h soft gel capsule
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Secondly, the fact that the current study was performed in HIV-infected patients 
rather than healthy volunteers may have led to the better tolerability of the 
combination lopinavir/ritonavir and rifampicin. This explanation is supported by 
other studies demonstrating that HIV patients tolerate another PI-combination, 
saquinavir/ritonavir, and rifampicin better than healthy volunteers [12, 20, 21].
Although the magnitude of toxicity in our previous studies in healthy volunteers was 
more severe when using tablets [13] rather than SGCs [9], in the present study we 
did not find any support that this may be caused by the formulation itself. In another 
study, without rifampicin, it is even claimed that the new tablet formulation of 
lopinavir/ritonavir is better tolerated than the SGC [22]. 
Previous studies in healthy volunteers suggest that the rifampicin lead-in before the 
introduction of protease inhibitors may have contributed to the high incidence of 
toxicity observed [13, 20, 23]. However, we could not confirm that the sequence of 
drug administration may have led to the overall better tolerability in HIV-infected 
patients.
Several limitations of our study need to be mentioned. This was a retrospective 
analysis of an observational cohort. Data were not collected on prespecified time 
points and were not always available. However, the quality of the data in the 
ATHENA cohort is independently monitored [14]. In case of missing or possible 
inaccuracy of data, we contacted the treating physician for clarification. As the 
design of the study was observational and not a randomized study, observed 
findings may have been confounded. Also, the number of patients involved in this 
evaluation was limited. Therefore, statistical analyses were not performed.
In conclusion, a small minority of HIV-infected patients in the Netherlands has been 
treated with the recommended increased dose of lopinavir/ritonavir in combination 
with rifampicin. This resulted in inferior exposure to lopinavir and possibly related 
virological failure. The overall tolerability of the drug combination was better than 
previously reported in healthy volunteers, whereas a higher proportion of those on 
a recommended increased dose prematurely stopped the combination because of 
adverse events. Concomitant use of lopinavir/ritonavir and rifampicin remains 
challenging. An adequately powered prospective study in HIV-infected patients is 
One would expect that lopinavir plasma concentrations are monitored when 
rifampicin is combined with a non-adjusted dose of lopinavir/ritonavir, but in our 
study plasma concentrations were monitored in a quarter of such cases only. This 
is a concern, as two-thirds of the patients on a non-adjusted lopinavir/ritonavir dose 
appeared to have subtherapeutic lopinavir trough plasma concentrations [17] in 
accordance with one of our previous studies in healthy volunteers [9]. Moreover, 
none of the doses that resulted in subtherapeutic lopinavir trough plasma 
concentrations were adjusted.  
Viral loads have been monitored in all patients in our cohort who were concomitantly 
treated with rifampicin and lopinavir/ritonavir for at least 4 months. Unfortunately, 
the number of participants with this duration of concurrent treatment was too small 
to draw firm conclusions. Whereas the available data suggest that inappropriate 
virological response may be explained by low lopinavir exposure due to non-adjusted 
doses, alternative factors, such as non-adherence to antiretroviral therapy or 
insensitivity of the virus, may also have contributed. Also, a difference between 
these groups in the proportion of patients with an undetectable viral load at baseline 
(1/8 vs. 1/3) cannot be ruled out.
The occurrence of nausea, vomiting and liver enzyme elevations when combining 
lopinavir/ritonavir and rifampicin in our cohort of HIV-infected patients was far less 
than previously reported in healthy volunteers on recommended increased doses of 
the SGC formulation [9] and in particular the tablet formulation [13] of lopinavir/
ritonavir. The observed difference in hepatotoxicity is striking considering the fact 
that 94% of the HIV-infected patients were treated with other tuberculostatic agents 
in addition to rifampicin, compared to none of the healthy volunteers. The overall 
better tolerability of the drug combination in the current study compared to our 
previous studies [9, 13] may be explained by differences in drug dose, study 
population, drug formulation and sequence of drug administration. 
Firstly, the fact that the lopinavir/ritonavir dose was increased as recommended in 
only the minority of patients on rifampicin may have contributed to the lower incidence 
of adverse events in the current study. This explanation is supported by our 
observation that a higher proportion of those on a recommended lopinavir/ritonavir 
dose prematurely stopped the drug combination because of adverse events. 
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Introduction
This thesis presents the first output of a North-South collaboration in clinical 
pharmacological research of HIV treatment in which the Department of Clinical 
Pharmacy of the Radboud University Nijmegen Medical Centre was involved. 
Sub-Saharan Africa continues to be the region most affected by HIV. Although the 
access to adult HIV treatment in resource-poor countries is being improved and an 
increasing amount of data is generated on treatment efficacy, limited data are 
available on clinical pharmacology. In this thesis, a collaboration between partners 
from The Netherlands, United Kingdom, Zambia and Tanzania has led to clinical 
pharmacological research of HIV treatment that is specifically relevant for resource-
limited countries. Part I deals with the optimization of paediatric regimens for the 
scale-up of HIV treatment in resource-limited countries. Part II focuses on 
therapeutic drug monitoring in HIV-infected adults and the optimization of a 
cost-effective strategy for the reduction of mother-to-child transmission in low-income 
countries. Part III describes the challenges of combined treatment with lopinavir/
ritonavir and rifampicin for HIV-TB co-infection. Overviewing the presented studies, 
five topics that are relevant for developing countries were selected for discussion: 
(1) access to HIV treatment; (2) monitoring of HIV treatment; (3) prevention of 
mother-to-child transmission of HIV; (4) treatment of HIV-TB co-infection; and (5) 
North-South collaboration in clinical pharmacological research. This general 
discussion is concluded with future perspectives.
1. Access to HIV treatment
The recent improvement in the access to HIV treatment in developing countries has 
largely depended on the introduction of cheap generic fixed dose combination 
(FDC) tablets with standard doses of antiretroviral drugs for adults. The lack of 
affordable and appropriate paediatric antiretroviral drug formulations has led to 
prescription of generic adult FDC tablets to children. Several reasons may have 
contributed to the delay in development of generic paediatric formulations for 
HIV-infected children in developing countries. 
Firstly, the incorrect assumption that there is no need of a generic paediatric 
formulation may have hindered its development. HIV-infected children cannot 
simply be regarded as small adults, pharmacologically speaking (Chapter 1). 
For example, children metabolize the antiretroviral drug nevirapine more rapidly 
than adults. Chapter 2 demonstrates that it is impossible to achieve adequate 
nevirapine concentrations without risking overdosing with stavudine in HIV-infected 
children receiving divided adult FDC tablets (Triomune; Cipla Ltd., India; 200mg 
nevirapine, 30 or 40 mg stavudine, 150 mg lamivudine). This is of concern, as 
children with subtherapeutic nevirapine concentrations are at risk of virological 
failure and development of resistance [1, 2].
Secondly, the incorrect assumption that a generic paediatric FDC formulation 
should be liquid may have tempered the enthusiasm for its development by generic 
manufacturers. The development of liquid formulations can be complex due to 
problems with stability, solubility and taste. For example, no liquid formulations 
have been marketed for the insoluble drugs indinavir and saquinavir, and the liquid 
formulations of efavirenz, ritonavir and lopinavir/ritonavir all have an unpleasant 
taste. The current development of a lopinavir/ritonavir tablet with half the strength of 
the adult formulation will offer an attractive alternative to older children in the near 
future. The time and energy spent trying to develop liquid paediatric FDC 
formulations is better used in the manufacture of small, dispersible, crushable and 
scored FDC tablets, which are easier to develop, dispense, transport, store and 
administer [3]. The development of separate tablet formulations for young and older 
children would minimize the number of tablets to be taken per dosing interval. On 
the other hand, management of stocks would be facilitated by the introduction of 
only one paediatric formulation. 
Thirdly, the fact that generic paediatric FDC formulations may be less lucrative for 
commercial institutions could also explain the delay in development. Only 2.5 
million children out of 33.5 million people were estimated to be living with HIV at the 
end of 2007 [4], indicating a relatively small market for generic paediatric FDC 
formulations. In addition, developed countries that can afford to pay a higher price 
for paediatric formulations may not be as interested in generic paediatric FDC 
tablets as resource-poor countries.  
Finally, the fact that global efforts such as the “3 by 5” initiative of the World Health 
Organization (WHO) have mainly focussed on the access to HIV treatment for adults 
[5] may have contributed to the delay in development of generic paediatric formulations. 
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present our data for Triomune Baby and Junior (Chapter 4) at one of the PAWG 
meetings in Geneva. Following successful review, WHO now recommend the 
antiretroviral drug ratios and the weight-band based dosing table that we used. 
Triomune Baby and Junior were the first paediatric FDC tablets to be approved by 
the United States Food and Drug Administration (FDA) and to become available for 
distribution under the Presidents Emergency Plan For AIDS Relief (PEPFAR) and 
Clinton Foundation programmes. The accessibility of Triomune Baby and Junior will 
drastically improve the necessary scale-up of appropriate HIV treatment for children 
in resource-limited countries. 
It is hoped that future efforts will be made to expand the development of generic 
paediatric formulations with the guidance of PAWG recommendations [6]. The use 
of the nucleoside reverse transcriptase inhibitor (NRTI) stavudine may lead to 
toxicities such as lipodystrophy and peripheral neuropathy, which can be difficult to 
identify in children and may be irreversible. Therefore, paediatric FDCs that do not 
contain stavudine should be developed. Most of the generic regimens that are 
being developed contain the non-nucleoside reverse transcriptase inhibitor (NNRTI) 
nevirapine, while NNRTIs have a low genetic barrier for the development of 
resistance [7]. For those children who fail first-line NNRTI-based regimens, 
second-line protease inhibitor-based regimens should become available. Because 
it can be challenging to develop an FDC with two NRTIs and one protease inhibitor, 
co-packaging may be indicated. 
2. Monitoring of HIV treatment 
Provision of adequate HIV care in developing countries can be hindered by a 
shortage of trained personnel, complexity and costs of laboratory equipments and 
unreliable drug supply, especially in remote settings [8]. Staff training is required to 
improve the general quality of care. Patients who are not identified in time to be 
eligible for antiretroviral treatment remain at risk of dying from AIDS. Facilities to 
perform CD4 counts are needed to indentify the patients eligible for treatment and 
to monitor the response to treatment [9]. At a large tertiary referral hospital in the 
northern zone of Tanzania, the Kilimanjaro Christian Medical Centre (KCMC), 
facilities to perform CD4 counts have recently been introduced through the National 
AIDS programme. Furthermore, patients on antiretroviral treatment are at risk of 
It was only recently that a WHO paediatric antiretroviral working group (PAWG) started 
to encourage the development of paediatric-friendly FDC tablets and the universal 
access to safe treatment for HIV-infected children [6]. PAWG identified a prioritized list 
of paediatric products and used a generic dosing tool, assessing the intended dose 
delivered, to arrive at recommended doses. Weight-band based dosing tables were 
developed to simplify dosing of antiretroviral drugs in resource-limited settings. For 
drugs that should be dosed by body surface area, such as nevirapine, doses were 
converted into weight bands. PAWG advised a higher nevirapine to stavudine and 
lamivudine dose ratio for the paediatric version of the adult FDC Triomune investigated 
in Chapter 2. In addition to the initiatives of WHO [6], the new European paediatric 
regulation has led to an obligation for paediatric research for every new drug developed 
for adults and having a potential use for children, in exchange for a six month extension 
of the supplementary protection certificate. 
In response to the urgent need for generic paediatric FDC tablets, Cipla Ltd. has 
developed Triomune Baby and Junior with higher nevirapine to stavudine and 
lamivudine ratios than adult Triomune tablets, in accordance with paediatric 
recommendations. Bioequivalence studies are of importance as products of poor 
quality should not reach the market. Formal bioequivalence of Triomune Baby and 
Junior was demonstrated by Cipla Ltd. at the end of 2006 (data on file). Our 
independent pilot bioequivalence study demonstrated similar pharmacokinetics to 
the branded products in 2005 already (Chapter 3). This has led to an earlier start 
of our subsequent study in HIV-infected Zambian children (Chapter 4), which was 
of benefit for those children in urgent need of Triomune Baby and Junior. The fact 
that we received funding from the European and Developing Countries Clinical 
Trials Partnership (EDCTP) for our research in the actual target population of 
HIV-infected African children (Chapter 4) underlines the high relevancy of the issue. 
Although the Triomune Baby and Junior antiretroviral drug ratios were shown to be 
appropriate for children weighing over 6 kg (Chapter 4) and even for those under 6 
kg (unpublished data), it is of importance that the children in our trial remain to be 
followed for investigation of long-term safety and efficacy of the FDCs. 
The correctness of WHO PAWG recommendations for drug ratios of prioritized 
paediatric FDCs [6] can only be confirmed by pharmacokinetic research in the 
actual target population of HIV-infected children. Therefore, we were invited to 
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14]. As alternative to HPLC, a relatively inexpensive thin layer chromatography (TLC) 
technique has been investigated for the detection of nevirapine in plasma [15]. We 
developed a cheap and simple TLC method for semi-quantitative detection of 
nevirapine in saliva. The assay was validated in HIV-infected Tanzanian adults on 
nevirapine treatment at KCMC and was found to be sensitive, specific and robust in 
the detection of subtherapeutic nevirapine concentrations (Chapter 5). 
Enough capacity has been built to implement this TLC method as a tool for TDM at 
the HIV clinic of KCMC. In the light of cost-efficiency, it would be wise to focus on 
those patients suspected of inappropriate response or non-adherence to nevirapine-
based treatment. Counselling of patients with a subtherapeutic nevirapine 
concentration should include the importance of improved adherence or an increased 
dose to prevent virological failure and resistance development. The effect of such 
interventions could be checked by repetition of TDM. Global provision of HIV care 
would benefit from the transfer of this TLC technique to other developing countries.
3. Prevention of mother-to-child transmission of HIV
Without antiretroviral treatment, the risk to transmit HIV to a baby during pregnancy 
or delivery is 25-48%. The introduction of highly active antiretroviral therapy 
(HAART) has reduced the rate of mother-to-child transmission (MTCT) to 1-2% in 
the developed world [16]. The mainstay of prevention of MTCT (PMTCT) programmes 
in low-resource settings have focussed on a single dose nevirapine to the mother 
shortly before delivery and to the baby after birth [17]. This simple and inexpensive 
intervention, reducing the risk of MTCT by 50%, is less effective than combination 
antiretroviral therapy [18], but was found to be cost-effective. A major disadvantage 
is the development of resistance in up to 70% of women [19], which may diminish 
the response to nevirapine in the future [20].
It is sad that combination antiretroviral therapy in pregnancy is not yet feasible in 
many resource-limited settings. Even the coverage of a simple PMTCT intervention 
such as single dose nevirapine remains low [21]. Only 30% of seropositive 
mother-infant pairs in a city-wide PMTCT programme in Lusaka, Zambia, received 
both a maternal and infant dose of nevirapine [22]. For as long as PMTCT 
programmes in the developing world will have to depend on the single dose 
side effects and laboratory abnormalities [10], but at KCMC clinical chemistry and 
haematology testing is only being performed for those patients who can afford to 
pay a small fee. 
Many key anti-HIV drugs are not yet marketed in cheap generic versions. Most of 
the generic antiretroviral regimens that have become available in developing 
countries combine the NNRTI nevirapine with two NRTIs. A disadvantage of 
nevirapine is the low genetic barrier for the development of resistance [7]. Resistant 
strains against nevirapine-based regimens provided in national programmes of 
developing countries could be spread through the population. This is of concern, 
as there are few second-line options for antiretroviral therapy in resource-limited 
countries, where the national expenditure to health-care is restricted. Patients at risk 
for virological failure and resistance are those with subtherapeutic plasma 
concentrations of nevirapine [1, 2], which can be caused by intersubject variability 
in pharmacokinetics, missed doses due to inadequate drug supply, or 
non-adherence. 
The risk of resistance development could be reduced in several ways. First of all, drug 
supply should be improved to prevent treatment interruptions [8]. Viral load testing 
would certainly help to identify those patients with an inappropriate response to 
treatment and thus at risk for resistance development [11], but is often unaffordable. 
At KCMC, viral load testing is mainly reserved for determination of the HIV status of 
babies that were born to HIV-positive mothers. From a pharmacological point of view, 
therapeutic drug monitoring (TDM) would be an important tool to identify those 
patients with an inappropriate exposure to drugs such as nevirapine and thus at risk 
for virological failure and resistance development. However, the assay technique 
high-performance liquid chromatography (HPLC) which is commonly used for TDM 
of nevirapine in the developed world [12] is too expensive for resource-poor settings. 
Furthermore, the required sampling technique to obtain plasma may be too 
complicated. To facilitate the implementation of TDM in developing countries, 
alternative options for sampling and assay technique are needed. 
Previous studies suggest that saliva may be used as an alternative body fluid to 
plasma for TDM of nevirapine, implying painless and non-invasive sampling with 
diminished risk of HIV-transmission to health care workers, and at a lower cost [13, 
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significant decrease in nevirapine half-life by addition of an enzyme inducer will 
reduce the duration of the potential zone of resistance development, but may also 
not be sufficient to prevent development of all nevirapine mutations. We are 
planning for a subsequent VITA-2 study to investigate if combining these two 
approaches of decreasing nevirapine half-life and co-administering other 
antiretroviral agents will be of added value. Our study proposal should comply with 
new national and WHO [26] PMTCT guidelines advising to combine the single dose 
of nevirapine at delivery with zidovudine from 28th week of gestation and zidovudine/
lamivudine intrapartum until 1 week after delivery, if feasible.
The PMTCT field is dynamic as preferred interventions with higher activity, such as 
HAART, are likely to be more complex and thus less feasible for resource-limited 
settings. The design of future VITA studies will depend on further adjustments to 
PMTCT guidelines and the capacity that has been built in the mean time to 
implement guidelines and to perform clinical trials.
 
4. Treatment of HIV-TB co-infection
The poverty-related communicable disease tuberculosis (TB) is the most common 
opportunistic infection among HIV-infected subjects worldwide, but particularly in 
developing countries [27]. Although co-administration of HIV and TB treatment is 
frequently indicated, there is a lack of knowledge about drug-drug interactions and 
overlap in toxicity profiles, particularly for the combination of rifampicin and 
protease inhibitors. When designing pharmacological trials for the optimization of 
HIV-TB treatment, several issues should be considered.
An international code of ethics for clinical research, the Declaration of Helsinki, has 
been established to assure that trials are performed in an ethical manner [28]. The 
declaration of Helsinki states that medical research involving human subjects 
should only be conducted if the importance of the objective outweighs the inherent 
risks and burdens to the subject. As healthy volunteers do not benefit from a drug 
trial, the risks to which they are exposed can be justified only by the value of the 
knowledge gained by their participation [29, 30]. However, despite adequate risk 
estimation, it cannot be excluded that the magnitude of drug toxicity during the 
actual trial may be higher than expected. Outside the scope of HIV-TB research, a 
nevirapine intervention, it is useful to try and reduce the related risk for resistance 
development. One approach is the addition of other antiretroviral agents after 
delivery to inhibit viral replication. Short-courses (4-7 days) of zidovudine/lamivudine 
added to a single dose nevirapine significantly reduced the development of 
nevirapine resistance [23]. Recently, a simple adjuvant of single dose tenofovir and 
emtricitabine to intrapartum nevirapine was found to reduce resistance by half [24]. 
Because the long half-life of nevirapine is expected to contribute to the development 
of resistance [25], we hypothesised that a short-course of an enzyme inducer may 
reduce resistance development by increasing metabolism and decreasing half-life 
of nevirapine. Interventions of 3-7 days of phenytoin (184 mg) and even a single 
dose of carbamazepine (400 mg) were found to significantly reduce nevirapine 
half-life in healthy non-pregnant women (Chapter 6). 
Single dose nevirapine has been recommended for use in the PMTCT programme 
of Tanzania from the year 2000, but was only implemented in May 2004 at the 
antenatal clinics in the northern zone of Tanzania. We selected the single dose 
carbamazepine intervention, which does not increase complexity, to be tested in 
Tanzanian HIV-infected pregnant women for its ability to reduce the development of 
nevirapine resistance (VITA-1 study). As expected, preliminary interim-results show 
a lower half-life in those that received an additional single dose of 400 mg 
carbamazepine compared to those that only received nevirapine (unpublished 
data). Whether this will lead to a reduction in the development of resistance has not 
been analysed so far. Execution of VITA-1 has been challenging with the lack of 
clinical trial capacity at the antenatal clinics in the Moshi area. Many women are lost 
to follow-up after delivery and laboratory facilities are poor. We have been missing 
a project car to chase those mothers not showing-up at their study visits and to 
transport samples from the antenatal clinics to the well-equipped biotechnology 
laboratory of KCMC. Another limitation is the lack of daily supervision and support 
of the Tanzanian PhD candidate, particularly during this author’s absence. 
Nevertheless, as clinical trial experience and infrastructure improves, capacity is 
being built for future research. 
One of the alternative interventions of 4-7 days zidovudine/lamivudine covers the 
period with subtherapeutic nevirapine concentrations below 3.0 mg/L [2] only 
partially, which explains that nevirapine resistance was not fully eradicated [23]. A 
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combination of rifampicin-containing tuberculostatic treatment and first-line 
antiretroviral treatment (tenofovir, emtricitabine and efavirenz) will be started at a 
large referral hospital for HIV-TB co-infected patients, Kibon’goto National 
Tuberculosis Hospital (KNTH), in the northern zone of Tanzania. It is hoped that 
hereby capacity is being built for future studies investigating the combination of 
rifampicin and second-line antiretroviral treatment, which is often based on protease 
inhibitors. As a follow-up of Chapters 7 and 8 it would be interesting to study a 
rifampicin lead-in followed by addition of standard lopinavir/ritonavir doses in 
HIV-TB co-infected patients. This should happen under online TDM of lopinavir/
ritonavir concentrations to be able to increase the dose if necessary. 
5. North-South collaboration in clinical pharmacological research
Clinical pharmacological research questions that are specifically relevant to 
developing countries are not always addressed in countries with a high-standard of 
health care. A North-South collaboration between partners from the developed and 
developing world can facilitate pharmacological research in resource-poor countries. 
Research institutes from the developed world can contribute their experience and 
institutes from the developing world are needed for the provision of ethics approval, 
study personnel and patients. The collaboration between two European and two 
African institutes in this thesis was achieved by networking. One of the preceding 
pharmacology PhD students at the Radboud University Nijmegen Medical Centre 
(RUNMC) in the Netherlands, Alina Bergshoeff, was involved in the paediatric 
European network for treatment of AIDS (PENTA). Within this PENTA network, 
RUNMC has collaborated with the Medical Research Council (MRC), Clinical Trials 
Unit (CTU) in London, United Kingdom. MRC CTU was also collaborating with the 
University Teaching Hospital (UTH) in Lusaka, Zambia and asked the RUNMC to 
join the network. Nijmegen University has a history of 37 years of collaboration with 
the Tanzanian Health system. A decade ago, RUNMC was very closely involved in 
the development of the Medical College at KCMC in Moshi, Tanzania. This has been 
the basis for a research collaboration between the two institutes. 
When looking at the output of this thesis, it can be said that the collaboration between 
European and African institutes has been successful. The large pharmacokinetic trial 
in Zambian HIV-infected children (Chapter 4) has benefitted from the pharmacological 
Phase I trial with a new anti-CD28 monoclonal antibody (TGN1412) resulted in 
serious adverse events and even hospital admittance for all 6 healthy male subjects 
in March 2006 [31]. Within the scope of HIV-TB research, several studies in healthy 
volunteers were carried out to evaluate if adjusted doses of protease inhibitors 
would compensate for the interaction with rifampicin. Among healthy volunteers 
receiving once-daily rifampicin, addition of saquinavir/ritonavir [32], increased 
lopinavir/ritonavir doses (Chapter 7) and twice-daily atazanavir/ritonavir [33] 
resulted in an unexpectedly high incidence of adverse events. All studies were 
terminated prematurely. The rifampicin lead-in may have contributed to the toxicity 
observed. However, the studied sequence is a reflection of the clinical situation of 
HIV-TB co-infected patients as TB is preferably treated first. 
A disadvantage of drug-drug interaction studies in HIV-infected patients is the risk 
for the development of subtherapeutic plasma concentrations of antiretroviral 
drugs. For patients who develop resistance as a result of subtherapeutic antiretroviral 
drug  concentrations during a trial, there will be less treatment options in the future. 
Particularly in resource-limited settings, it will be difficult to select those patients at 
risk for resistance development, because of the lack of TDM facilities to monitor for 
subtherapeutic drug concentrations. The fact that there is no network to perform 
clinical drug trials in HIV-TB co-infected patients in Europe has limited the outcome 
of our study evaluating the clinical experience with the combined use of lopinavir/
ritonavir and rifampicin (Chapter 8). As only a minority of physicians appeared to 
follow recommendations and treatment was not standardised across the institutions 
involved, it was difficult to draw conclusions. We would have learned more from 
Chapter 8 if expertise had been gathered.
Taking into account these experiences, it would be best to investigate the 
combination of rifampicin and antiretroviral drugs in HIV-TB co-infected patients in 
the developing world. A requirement would be that patients with an inappropriate 
exposure to antiretroviral drugs and thus at risk for resistance development will be 
identified in time. In case there is not enough funding or capacity to implement 
current methods for TDM in developing countries, efforts should be made to develop 
alternative methods that are feasible. A simple and inexpensive TLC method has 
already been developed for the determination of nevirapine (Chapter 5), but not yet 
for the determination of protease inhibitors. In 2008, a study investigating the 
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success of a North-South collaboration in clinical pharmacological research of HIV 
treatment is the complementary contribution of different partners. Adequate funding 
is required to build the capacity to perform clinical trials in the developing world and 
experienced scientists are needed to train and supervise the local study staff. 
experience of our department at RUNMC and from the clinical trial experience of 
MRC CTU. When this so-called CHAPAS1 study was started in Zambia, the 
infrastructure to perform clinical trials was already in place. The same study clinic 
and nurses were involved in the previous so-called CHAP trial (Chapter 2, [34]). In 
contrast, execution of the VITA-1 study, as a follow-up to Chapter 6, trying to 
optimize PMTCT in Tanzania, appears to be much more complicated. There was a 
general lack of clinical trial capacity when VITA-1 was started. In addition, MRC CTU 
with a lot of clinical trial experience in resource-limited settings has not been 
involved so far.  
Pharmaceutical industries that are traditional sponsors of drug trials in the 
developed world are often not interested to sponsor research for developing 
countries. Sponsorships should come from international governmental organisations 
such as the European Union, The Bill Gates Foundation, G8, WHO and the Joint 
United Nations Programme on HIV/AIDS (UNAIDS). Most of the research in this 
thesis was funded by EDCTP and by the Poverty Related Infection Oriented 
Research (PRIOR) network that was established by a grant from the Netherlands 
Foundation for the Advancement of Tropical Research (NWO-WOTRO) and the 
Netherlands Foundation for Health Research and Development (ZonMw).
Conclusions and future perspectives
In conclusion, our North-South collaboration between research partners from the 
developed and developing world has improved the knowledge about clinical 
pharmacology of HIV treatment that is specifically relevant for resource-limited 
countries. Although the first affordable and appropriate paediatric FDC tablets 
recently became available for HIV-infected children in developing counties, future 
efforts should be made to expand the development of generic paediatric formulations. 
It is hoped that the cheap and simple TLC method that was developed for the 
detection of nevirapine in saliva is implemented as a tool for TDM in resource-
limited countries. For as long as PMTCT programmes in the developing world will 
have to depend on the single dose nevirapine intervention, the search for 
interventions to reduce the risk of resistance development should be continued. 
Moreover, future research is needed in HIV-TB co-infected patients in the developing 
world to investigate the co-administration of HIV and TB treatment. The key to 
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Introduction
This thesis presents the first output of a North-South (Europe-Africa) collaboration 
in clinical pharmacological research of HIV treatment. Part I deals with the 
optimization of paediatric regimens for the scale-up of HIV treatment in resource-
limited countries. Part II focuses on therapeutic drug monitoring (TDM) in 
HIV-infected adults and the optimization of a cost-effective strategy for the reduction 
of mother-to-child transmission (MTCT) of HIV in low-income countries. Part III 
describes the challenges of combined treatment with lopinavir/ritonavir and 
rifampicin for HIV-tuberculosis (TB) co-infection.
I. Clinical pharmacology in HIV-infected children
The brief review in Chapter 1 focuses on general characteristics relating to 
pharmacokinetic processes (absorption, distribution, metabolism, excretion) in the 
paediatric population, followed by recent examples of antiretroviral drug 
pharmacokinetics in HIV-infected children. Pharmacokinetics of antiretroviral drugs 
are highly variable in the paediatric population as children mature and grow rapidly 
and individually until they are adults. It was unexpectedly found that exposure to 
lopinavir is decreased in the first 6 months of life. In addition, recommended dosing 
of lamivudine leads to lower exposure in children younger than 6 years of age. 
Recent findings of subtherapeutic efavirenz concentrations in children suggest that 
paediatric dose recommendations should be re-evaluated. There is a general 
shortage of pharmacokinetic data in HIV-infected children. Selected pharmacology 
studies should be undertaken to improve paediatric dose guidance of existing 
antiretroviral drugs. TDM is a useful tool to optimize treatment in HIV-infected 
children. However, more data are needed to establish child-specific reference values.
Chapter 2 describes the exposure to nevirapine in HIV-infected African children 
treated with divided adult fixed dose combination (FDC) tablets (Triomune) in 
routine outpatient settings. Of the 127 children, 23 (18%) had a subtherapeutic 
random nevirapine plasma concentration (<3.0 mg/L). Only 1 (3%) of those 
prescribed ≥ 300 mg/m2/day nevirapine had subtherapeutic concentrations 
compared with 22 (23%) of those prescribed <300 mg/m2/day. Lower nevirapine 
concentrations were independently associated with lower prescribed dose/m2, 
lower height-for-age, and higher body mass index-for-age. Most children with 
subtherapeutic nevirapine concentrations were taking half or quarter FDC tablets. It 
was concluded that currently available adult FDC tablets are not well suited for 
children, particularly at younger ages. Development of appropriate paediatric FDC 
tablets is essential if antiretroviral therapy is to be made widely available to children 
in resource-limited settings.
Two generic paediatric FDC tablets (Triomune Baby & Junior) were developed with higher 
nevirapine to stavudine and lamivudine ratios than the adult FDC tablet (Triomune) in 
accordance with paediatric dose recommendations. In Chapter 3, the pharmacokinetics 
of Triomune Baby & Junior were compared to the branded products. This pilot study in 
six healthy males shows that the pharmacokinetic profiles of stavudine, lamivudine and 
nevirapine in the generic paediatric FDC tablets are similar to the branded products. 
Based on these results, it is acceptable to test the pharmacokinetics and dosing 
requirements of Triomune Baby & Junior in HIV-infected children. 
Chapter 4 describes the pharmacokinetics of the two generic paediatric FDC 
tablets Tiomune Baby & Junior in a target population of 71 African HIV-infected 
children. After treatment of the children according to weight-bands for at least 4 
weeks, a 12-hour pharmacokinetic curve was recorded. Nevirapine plasma 
concentrations were higher but more variable than those in adults. The nevirapine 
trough concentration was subtherapeutic (<3.0 mg/L) in four (6%) children. 
Pharmacokinetic parameters of stavudine and lamivudine were comparable to 
those in adults. There was no evidence of a difference in nevirapine exposure 
across weight-bands, while the difference in stavudine and lamivudine exposure 
was driven by the single weight-band with an unequal morning and evening dose 
(15-<20kg). As nevirapine underdosing is of greater concern than overdosing, 
it was concluded that the Triomune Baby & Junior ratio is appropriate for children 
weighing 6kg and over. Further research is required for children under 6kg.
II. Clinical pharmacology in HIV-infected adults
In Chapter 5, the option to perform TDM of nevirapine in resource-limited settings 
was explored. A simple and inexpensive thin layer chromatography (TLC) assay was 
developed for semi-quantitative detection of nevirapine saliva concentrations. 
The method was validated in a target population of 300 African HIV-infected adults. 
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from nausea only, and one from vomiting only. Moreover, increases in AST/ALT 
levels were reported in all subjects. All levels returned to normal within six weeks. 
The observed toxicity may be explained by three facts. Firstly, rifampicin was 
introduced prior to lopinavir/ritonavir; secondly, the adjusted dose of lopinavir/
ritonavir tablets was not escalated; and thirdly, the new lopinavir/ritonavir tablet 
formulation was used instead of the capsule formulation. It was advised that further 
studies investigating the interaction between rifampicin and lopinavir/ritonavir 
tablets be performed in the actual target population of HIV-TB co-infected patients 
rather than in healthy volunteers.
Chapter 8 describes the clinical experience with the combined use of lopinavir/
ritonavir and rifampicin in the Netherlands. Thirty-four adult HIV-infected patients on 
combined treatment were selected from the Dutch ATHENA cohort for retrospective 
analysis. Overall, 15% used a recommended increased dose of lopinavir/ritonavir, 
82% were on the soft gel capsule formulation of lopinavir/ritonavir and 68% had a 
lead-in with rifampicin. Of the 23 patients on a non-adjusted dose of lopinavir/
ritonavir, 4 out of 6 (67%) had a subtherapeutic lopinavir trough plasma concentration 
(<1.0 mg/L) and 3 out of 8 (38%) had a detectable viral load (≥50 copies/ml) after 
at least 4 months of concomitant treatment. Two out of 5 (40%) patients on a 
recommended increased dose of lopinavir/ritonavir prematurely stopped the drug 
combination because of adverse events vs. 4 out of 23 (17%) on a non-adjusted 
dose and 1 out of 6 (17%) on a slightly increased dose. An adequately powered 
prospective study in HIV-TB co-infected patients is needed to investigate the 
consequences of inferior lopinavir exposure due to non-adjusted doses of lopinavir/
ritonavir and to determine the tolerability of recommended increased doses.
General discussion
In the general discussion the following issues that are relevant for developing 
countries are discussed: access to HIV treatment, monitoring of HIV treatment, 
PMTCT of HIV, treatment of HIV-TB co-infection, and North-South collaboration in 
clinical pharmacological research.
Although the first affordable and appropriate paediatric FDC tablets recently 
became available for HIV-infected children in developing counties, future efforts 
Paired plasma and saliva nevirapine concentrations were assayed by high-
performance liquid chromatography (HPLC). Saliva concentrations were also 
assayed by TLC. Nine percent of the subjects had a subtherapeutic plasma 
nevirapine concentration. The median saliva/plasma nevirapine concentration ratio 
was 0.51. The TLC assay was found to be sensitive, specific and robust in detection 
of subtherapeutic nevirapine concentrations in saliva of African HIV-infected adults. 
It is an attractive alternative to HPLC for TDM of nevirapine in resource-limited settings.
Single-dose nevirapine to prevent MTCT of HIV is associated with the development 
of nevirapine resistance, probably due to its long elimination half-life in combination 
with a low genetic barrier to resistance. The pilot study in Chapter 6 aimed to 
identify enzyme inducers to reduce the half-life of nevirapine. After administration of 
a single 200-mg dose of nevirapine to 36 healthy non-pregnant women in both 
period 1 and 2, blood was sampled twice-a-week for 21 days to determine 
concentrations of nevirapine. In period 2 additional interventions (single dose 
carbamazepine, phenobarbital or phenytoin; phenytoin for 3 or 7 days; St John’s 
Wort, vitamin A or cholecalciferol for 14 days) were administered to all subjects 
except for the control group. In three intervention groups T-half ratio (nevirapine 
half-life in period 2 / half-life in period 1) differed significantly from the control group: 
single 400-mg dose of carbamazepine, 184mg phenytoin once daily for 3 or 7 days. 
The mean decrease in nevirapine half-life in period 2 was 35.3, 38.2 and 35.9%, in 
these groups respectively. It was concluded that these interventions should be 
tested in the setting of single-dose nevirapine for the prevention of MTCT (PMTCT) 
of HIV to reduce the development of nevirapine resistance.
III. Clinical pharmacology in HIV-TB co-infection
Previous research in healthy volunteers has demonstrated that increased doses of 
lopinavir/ritonavir soft gel capsules compensate for the interaction with rifampicin. 
The pharmacokinetic interaction study in Chapter 7 shows a high incidence of 
adverse events in 11 healthy volunteers treated with a higher than standard dose of 
the new lopinavir/ritonavir tablets in combination with rifampicin. No major 
complaints occurred when 600 mg rifampicin was given only. However, the study 
had to be terminated prematurely after addition of 600/150 or 800/200 mg lopinavir/
ritonavir twice daily. Eight subjects suffered from both nausea and vomiting, one 
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should be made to expand the development of generic paediatric formulations. It is 
hoped that the cheap and simple TLC method that was developed for the detection 
of nevirapine in saliva will soon be implemented in resource-limited countries. For 
as long as PMTCT programmes in the developing world will have to depend on the 
single dose nevirapine intervention, the search for interventions to reduce the risk 
of resistance development should be continued. Moreover, future research is 
needed in HIV-TB co-infected patients in the developing world to investigate the 
co-administration of HIV and TB treatment. The key to success of a North-South 
collaboration in clinical pharmacological research of HIV treatment is the 
complementary contribution of different partners.
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Introductie
Dit proefschrift laat de eerste resultaten zien van een Noord-Zuid samenwerking 
tussen Europa en Afrika met betrekking tot klinisch farmacologisch onderzoek van 
HIV behandeling. Deel I gaat over de optimalisering van preparaten om kinderen 
met HIV in ontwikkelingslanden te kunnen behandelen. De focus van Deel II ligt bij 
het monitoren van geneesmiddelconcentraties (therapeutic drug monitoring, TDM) 
in volwassenen met HIV. Daarnaast is er aandacht voor de optimalisering van een 
kosteneffectieve strategie voor de vermindering van HIV overdracht van moeder op 
kind (mother-to-child transmission, MTCT) in ontwikkelingslanden. Deel III beschrijft 
de uitdagingen van gecombineerde behandeling met lopinavir/ritonavir en 
rifampicine in geval van HIV-tuberculose (TB) dubbelinfectie.
I. Klinische farmacologie in HIV geïnfecteerde kinderen
Hoofdstuk 1 geeft een beknopt overzicht van de algemene kenmerken van 
farmacokinetische processen (opname, verdeling, afbraak, uitscheiding) in kinderen, 
gevolgd door recente voorbeelden van de farmacokinetiek van antiretrovirale 
geneesmiddelen in HIV geïnfecteerde kinderen. De farmacokinetiek van antiretrovirale 
geneesmiddelen in kinderen is sterk variabel aangezien kinderen zich individueel 
ontwikkelen en groeien totdat ze volwassen zijn. Er is onverwacht aangetoond dat 
de blootstelling aan lopinavir is verminderd in kinderen jonger dan 6 maanden. 
Daarnaast leidt de aanbevolen dosering van lamivudine tot een lagere blootstelling in 
kinderen jonger dan 6 jaar. Recente bevindingen van te lage, oftewel subtherapeutische, 
efavirenz concentraties in kinderen laten zien dat de aanbevolen kinderdosering 
van efavirenz opnieuw geëvalueerd zou moeten worden. Er is een algemeen tekort 
aan farmacokinetische data in kinderen met HIV. Zorgvuldig gekozen farmacologische 
onderzoeken zouden uitgevoerd moeten worden om de aanbeveling van kinder-
doseringen van bestaande antiretrovirale geneesmiddelen te verbeteren. Het monitoren 
van geneesmiddelconcentraties zou de behandeling van kinderen met HIV kunnen 
verbeteren. Desondanks zijn er meer gegevens nodig om specifieke referentiewaarden 
voor kinderen te bepalen.
Hoofdstuk 2 beschrijft de blootstelling aan nevirapine in HIV geïnfecteerde 
Afrikaanse kinderen die in de thuissituatie behandeld worden met gedeelde vaste 
dosis combinatietabletten (fixed dose combination, FDC) voor volwassenen 
(Triomune). Van de 127 kinderen hadden er 23 (18%) een subtherapeutische 
willekeurige nevirapine bloedconcentratie (<3.0 mg/L). Slechts 1 (3%) van de 
kinderen die ≥ 300 mg/m2 nevirapine per dag kregen had een subtherapeutische 
concentratie in vergelijking met 22 (23%) van de kinderen die <300 mg/m2 
nevirapine per dag gebruikten. Lagere nevirapine concentraties waren onafhankelijk 
geassocieerd met een lagere voorgeschreven dosering per m2, een lagere lengte 
voor de leeftijd en een hogere body mass index voor de leeftijd. De meeste kinderen 
met subtherapeutische nevirapine concentraties werden behandeld met halve of 
kwart FDC tabletten. Er werd geconcludeerd dat de huidig beschikbare FDC 
tabletten voor volwassenen niet geschikt zijn voor (met name jonge) kinderen. De 
ontwikkeling van FDC kindertabletten is essentieel voor het algemeen beschikbaar 
maken van antiretrovirale therapie voor kinderen in ontwikkelingslanden.
Er zijn twee generieke FDC kindertabletten (Triomune Baby & Junior) ontwikkeld die 
voldoen aan de aanbevolen kinderdoseringen. Deze kindertabletten bevatten 
relatief meer nevirapine en relatief minder stavudine en lamivudine in vergelijking tot 
de FDC tablet voor volwassenen (Triomune). In Hoofdstuk 3 werd de farmacokinetiek 
van Triomune Baby & Junior vergeleken met de merkpreparaten. Dit proefonderzoek 
in zes gezonde mannen laat zien dat de farmacokinetische profielen van stavudine, 
lamivudine en nevirapine in de generieke kindertabletten vergelijkbaar zijn met de 
merkpreparaten. Gebaseerd op deze resultaten kan gesteld worden dat het 
acceptabel is om de farmacokinetiek en de vereiste dosering van Triomune Baby & 
Junior in HIV geïnfecteerde kinderen te onderzoeken. 
Hoofdstuk 4 beschrijft de farmacokinetiek van de twee generieke FDC 
kindertabletten Triomune Baby & Junior in een doelpopulatie van 71 Afrikaanse HIV 
geïnfecteerde kinderen. Na behandeling van de kinderen aan de hand van 
gewichtsgroepen voor tenminste 4 weken werden er diverse bloedmonsters 
afgenomen gedurende 12 uur. Nevirapine concentraties waren hoger en meer 
wisselend dan die in volwassenen. De nevirapine dalconcentratie was sub-
therapeutisch (<3.0 mg/L) in vier (6%) kinderen. De farmacokinetische parameters 
van stavudine en lamivudine waren vergelijkbaar met die in volwassenen. Er was 
geen bewijs voor een verschil in nevirapine blootstelling tussen de gewichtsgroepen, 
terwijl het verschil in blootstelling aan stavudine en lamivudine werd veroorzaakt 
door de enige gewichtsgroep met ongelijke ochtend- en avonddosering (15-<20kg). 
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(nevirapine halfwaardetijd in periode 2 / halfwaardetijd in periode 1) significant van 
de controlegroep: éénmalige 400-mg dosis van carbamazepine, 184mg fenytoïne 
één maal daags gedurende 3 dagen of 7 dagen. De gemiddelde daling in nevirapine 
halfwaardetijd in periode 2 was respectievelijk 35.3, 38.2 and 35.9% in deze 
groepen. Deze interventies zouden in Afrika getest moeten worden in de setting van 
een éénmalige dosis nevirapine ter preventie van moeder-op-kind transmissie met 
het doel de ontwikkeling van nevirapine resistentie te verminderen.
III. Klinische farmacologie bij HIV-TB dubbelinfectie
Voorafgaand onderzoek in gezonde vrijwilligers heeft aangetoond dat verhoogde 
doseringen van lopinavir/ritonavir zachte gel capsules compenseren voor de interactie 
met rifampicine. Het farmacokinetische interactieonderzoek in Hoofdstuk 7 laat een 
hoge incidentie van bijwerkingen zien in 11 gezonde vrijwilligers bij gecombineerd 
gebruik van rifampicine en een hogere dan standaard dosering van de nieuwe lopinavir/
ritonavir tabletten. Rifampicine in een dosering van 600 mg werd goed verdragen. Maar 
het onderzoek moest vroegtijdig worden stopgezet na toevoeging van 600/150 of 
800/200 mg lopinavir/ritonavir twee maal daags. Acht vrijwilligers waren misselijk en 
moesten braken, één vrijwilliger was alleen misselijk en één moest alleen braken. 
Daarnaast werden verhoogde ASAT/ALAT waarden gerapporteerd in alle vrijwilligers. 
Alle waarden keerden binnen 6 weken terug naar normaal. Er zijn drie mogelijke 
oorzaken te noemen voor de geobserveerde toxiciteit. Allereerst werd rifampicine 
eerder geïntroduceerd dan lopinavir/ritonavir. Ten tweede werd de aangepaste dosering 
van de lopinavir/ritonavir tabletten niet geleidelijk verhoogd. Ten derde werd de nieuwe 
tabletformulering van lopinavir/ritonavir gebruikt in plaats van de capsuleformulering. 
Het advies was om vervolgonderzoek naar de interactie tussen rifampicine en lopinavir/
ritonavir tabletten uit te voeren in de werkelijke doelpopulatie van HIV-TB geïnfecteerde 
patiënten in de plaats van in gezonde vrijwilligers.
Hoofdstuk 8 beschrijft de klinische ervaring met het gecombineerd gebruik van 
lopinavir/ritonavir en rifampicine in Nederland. Vierendertig volwassen HIV 
geïnfecteerde patiënten behandeld met bovenstaande combinatie werden voor 
retrospectieve analyse geselecteerd uit het Nederlandse ATHENA cohort. Van de 
34 patiënten, gebruikte 15% een aanbevolen verhoogde dosering van lopinavir/
ritonavir en 82% de capsuleformulering van lopinavir/ritonavir. In 68% van de 
Omdat nevirapine onderdosering van grotere zorg is dan overdosering, werd 
geconcludeerd dat de geneesmiddelenratio in Triomune Baby & Junior geschikt is 
voor kinderen van tenminste 6kg. Meer onderzoek is nodig voor kinderen met een 
gewicht van minder dan 6kg.
II. Klinische farmacologie in HIV geïnfecteerde volwassenen
In Hoofdstuk 5 werd bekeken of er een mogelijkheid bestaat om concentraties van 
nevirapine te monitoren (therapeutic drug monitoring, TDM) in een omgeving met 
beperkte middelen. Een eenvoudige en goedkope dunne laag chromatografie 
(DLC) methode werd ontwikkeld voor semikwantitatieve detectie van nevirapine 
speekselconcentraties. De methode werd gevalideerd in een doelpopulatie van 300 
Afrikaanse volwassenen met HIV. Gepaarde bloed- en speekselconcentraties van 
nevirapine werden gemeten met HPLC (high-performance liquid chromatography). 
Speekselconcentraties werden tevens bepaald met DLC. Negen procent van de 
patiënten had een subtherapeutische bloedconcentratie van nevirapine. 
De mediane speeksel/bloed concentratieratio van nevirapine was 0.51. 
De ontwikkelde DLC is een gevoelige, specifieke en robuuste methode voor de 
detectie van subtherapeutische nevirapine concentraties in speeksel van Afrikaanse 
HIV geïnfecteerde volwassenen. Het is een aantrekkelijk alternatief voor HPLC om 
TDM van nevirapine in ontwikkelingslanden mogelijk te maken.
Een éénmalige dosis nevirapine, zoals gebruikt in Afrika ter voorkoming van 
moeder-op-kind transmissie van HIV, is geassocieerd met de ontwikkeling van 
resistentie tegen nevirapine. Dit is waarschijnlijk het gevolg van de lange 
eliminatiehalfwaardetijd van nevirapine in combinatie met een lage barrière tegen 
resistentie. Het proefonderzoek in Hoofdstuk 6 was gericht op de zoektocht naar 
enzyminductoren om de eliminatiehalfwaardetijd van nevirapine te bekorten. 
Na toediening van een éénmalige 200-mg dosis van nevirapine aan 36 gezonde, 
niet-zwangere vrouwen in zowel periode 1 als 2, werd twee maal per week 
gedurende 21 dagen bloed afgenomen ter bepaling van nevirapine concentraties. 
In periode 2 werden additionele interventies (éénmalige dosis van carbamazepine, 
fenobarbital of fenytoïne; fenytoïne gedurende 3 of 7 dagen; St Janskruid thee, 
vitamine A of vitamine D gedurende 14 dagen) toegediend aan alle personen 
behalve de controlegroep. In drie interventiegroepen verschilde T-half ratio 
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patiënten werd rifampicine eerder geïntroduceerd dan lopinavir/ritonavir. Van de 23 
patiënten op een niet-aangepaste dosering van lopinavir/ritonavir, hadden 4 van de 
6 (67%) een subtherapeutische lopinavir dalconcentratie (<1.0 mg/L) en 3 van de 8 
(38%) een detecteerbare virale load (≥50 kopieën/ml) na gecombineerde behandeling 
voor tenminste 4 maanden. Twee van de 5 (40%) patiënten op een aanbevolen 
verhoogde dosering van lopinavir/ritonavir stopten vroegtijdig met de geneesmiddel-
combinatie in verband met bijwerkingen vs. 4 van de 23 (17%) op een niet-aangepaste 
dosering en 1 van de 6 (17%) op een licht verhoogde dosering. Een groot prospectief 
onderzoek in HIV-TB geïnfecteerde patiënten is nodig naar de consequenties van te 
lage lopinavir blootstelling door niet-aangepaste doseringen van lopinavir/ritonavir 
en naar de verdraagbaarheid van aanbevolen verhoogde doseringen.
Algemene discussie
Het proefschrift wordt afgesloten met een discussie over punten die relevant zijn 
voor ontwikkelingslanden: toegang tot HIV behandeling, monitoren van HIV 
behandeling, preventie van moeder-op-kind transmissie van HIV (PMTCT), 
behandeling van HIV-TB dubbelinfectie, en Noord-Zuid samenwerking met 
betrekking tot klinisch farmacologisch onderzoek.
Ondanks het feit dat sinds kort de eerste goedkope en adequate FDC kindertabletten 
beschikbaar zijn voor HIV geïnfecteerde kinderen in ontwikkelingslanden, is het van 
groot belang dat de ontwikkeling van generieke kinderformuleringen in de toekomst 
wordt voortgezet. Het is te hopen dat de eenvoudige en goedkope DLC methode 
die werd ontwikkeld voor de detectie van nevirapine in speeksel binnenkort zal 
worden geïmplementeerd in ontwikkelingslanden. Voor zolang PMTCT programma’s 
in ontwikkelingslanden afhankelijk zijn van een éénmalige dosis nevirapine, zou de 
zoektocht naar interventies voor het verkleinen van het risico op resistentieontwikkeling 
moeten voortduren. Daarnaast zou er een plek moeten zijn voor verder onderzoek 
in HIV-TB geïnfecteerde patiënten in ontwikkelingslanden naar de gecombineerde 
behandeling van HIV en TB. De sleutel tot succes van een Noord-Zuid samenwerking 
met betrekking tot klinisch farmacologisch onderzoek van HIV behandeling is de 
complementaire bijdrage van verschillende onderzoekspartners.
S
am
en
va
tt
in
g
Dankwoord 
184 185
Al weer vier jaar geleden begon ik met mijn promotieonderzoek bij de afdeling 
Apotheek/Klinische Farmacie van het UMC St Radboud. Hoewel ik het grootste 
deel van de tijd in Nijmegen was, ben ik regelmatig voor 4-8 weken in Tanzania en 
Zambia geweest. Daarnaast bestond er een intensieve samenwerking met een 
onderzoeksgroep in Engeland. Het reizen en samenwerken met andere culturen 
binnen mijn promotietraject heb ik ervaren als een zeer geslaagd experiment! 
Het is me een genoegen om een woord van dank te richten tot allen die een 
bijdrage hebben geleverd aan het onderzoek in dit proefschrift.
Prof. dr. Hekster, promotor, beste Chiel, ik ben onder de indruk van je kennis, 
creativiteit en toegankelijkheid! Je was altijd op de achtergrond aanwezig om de 
onderzoeken in goede banen te leiden, wat ik als zeer prettig heb ervaren.
Dr. Burger, co-promotor, beste David, ik had me geen betere begeleider kunnen 
wensen! Doordat je deur ten alle tijden voor me openstond, werden mijn 
vragenlijstjes steeds binnen no-time weggewerkt. Dit heeft mij geholpen om 
efficiënt te kunnen werken. Ondanks je overvolle agenda, ben je een man op wie je 
kunt bouwen en dat siert je. Je passie voor NEC heb ik helaas niet met je kunnen 
delen, maar wel je hart voor Afrika. Fantastisch dat je onderzoekslijn een bijdrage 
levert  aan de HIV behandeling waar het zó hard nodig is!
De analisten van het Laboratorium Klinische Farmacie wil ik hartelijk bedanken voor 
het uitvoeren van de vele metingen en voor de interesse in het onderzoek achter de 
getallen. Zonder jullie was ik nooit zo ver gekomen in de afgelopen vier jaar. 
Peter Diebels, (destijds) hoofdanalist, ik vond het erg plezierig om met je samen te 
werken. Knap hoe je, ondanks de drukte op het Laboratorium, het meten van de 
onderzoeksmonsters telkens weer snel ingepland kreeg. Rob Aarnoutse, hoofd van 
het Laboratorium, als begeleider van Hanneke heb ik zeker ook veel van jouw 
kennis mogen opsteken. Bedankt hiervoor!   
Oud-collega HIV onderzoekers: Jackie, ik wil je danken voor alles wat ik van je heb 
geleerd! Geweldig dat je een eenvoudige en goedkope methode hebt ontwikkeld 
voor de bepaling van nevirapine in speeksel. Samen met Liselotte was je van 
onschatbare waarde bij het tot stand komen van hoofdstuk 5. Manon, je ging me 
nog geen jaar geleden voor in het promotietraject, bedankt voor de tips! Ik wens je 
veel succes met je opleiding tot klinisch farmacoloog en je verdere onderzoeks-
carrière. 
Collega-promovendi: Hanneke, ik vond het erg gezellig om een kamer met je te 
delen. Bedankt voor je enorme bijdrage aan hoofdstuk 7 en 8 naar de gecombineerde 
behandeling van HIV en tuberculose. Ik vind het knap dat je als eerste tuberculose 
onderzoeker binnen de afdeling zo’n mooie studies hebt uitgevoerd in Nederland 
en Indonesië. Veel succes met de verdediging van je proefschrift en met je nieuwe 
baan. En dan de mannen, Roger & Matthijs, dank voor jullie gezelligheid en succes 
met het afronden van jullie onderzoek. 
Anita Huisman en Angela Colbers, hartelijk dank voor jullie gezelschap en jullie hulp 
bij het oplossen van vele praktische problemen met betrekking tot de onderzoeken 
in Nederland en Afrika. 
Graag wil ik alle collega’s uit de apotheek bedanken voor de interesse in mijn 
onderzoek en de gezelligheid tijdens de pauzes.
I would like to thank Prof. Chifumbe Chintu for giving me the opportunity to work at 
UTH in Lusaka, Zambia.
Prof. Diana Gibb, it has been a pleasure to work with you and learn about 
paediatrics. I am impressed by your agenda and the way you keep many relevant 
projects running in resource-poor countries.    
I want to thank Veronica Mulenga for making me feel at home at UTH.
Desiré Kabamba, thank you for your help with the CHAPAS1 PK study (Chapter 4). 
I very much enjoyed the joint presentation of our study results in Los Angeles.
Fiona Ewings & Sarah Walker, thanks so much for your help with statistics and writing.
Margaret Thomason & Fiona Ewings, I very much enjoyed our trip to the Victoria 
falls! I still have to laugh when I think about all the funny experiences we had. 
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De medewerkers van het Clinical Research Centre Nijmegen dank ik voor hun 
bijdrage aan de uitvoering van de onderzoeken in gezonde vrijwilligers (Hoofdstuk 
3, 6 & 7).
Luuk Gras, ik dank je voor het verzamelen van de database gegevens voor 
Hoofdstuk 8. Reinout van Crevel, Martin Boeree, Kees Brinkman, Jan Prins en Job 
Juttmann, jullie klinische blik was onmisbaar bij het tot stand komen van hoofdstuk 8. 
De leden van de manuscriptcommissie, Prof. dr. de Groot, Prof. dr. Brouwers en 
Prof. dr. Lange, wil ik bedanken voor het bestuderen en beoordelen van dit 
proefschrift.
Lotte en Elke, ik vind het geweldig dat jullie als paranimfen achter mij willen staan. 
Lotte, ontmoet tijdens pianoles en vriendin vanaf de brugklas. Het feit dat je zelf in 
Afrika stage hebt gelopen, heeft waarschijnlijk bijgedragen aan je enthousiasme 
voor het onderzoek in dit proefschrift. Bedankt hiervoor! Elke, we zijn vriendinnen 
vanaf de introductie van de studie Farmacie. Ik heb enorm genoten van onze 
studententijd en vooral van de onderzoeksstage in Finland. Super dat ik als 
paranimf achter jou mocht staan afgelopen jaar!   
Vrienden en familie, dank voor jullie interesse in mijn promotietraject. Het was altijd 
weer heerlijk om thuis te komen en van jullie te genieten! 
Lieve Koen, mijn grote steun en toeverlaat, bedankt dat je me zo vaak naar het 
buitenland hebt laten gaan. Ik heb je gemist! Gelukkig ben je af en toe achter me 
aan gevlogen om samen op ontdekkingsreis te gaan. Ik vind je oprechte interesse 
voor de onderwerpen van mijn proefschrift heel bijzonder.   
En als laatste natuurlijk, lieve Lenthe, bedankt voor het gezellige getrappel in mijn 
buik tijdens het afronden van dit proefschrift. Je maakt ons heel gelukkig! 
Further thanks to all the colleagues from the CHAPAS team at UTH (Lusaka, 
Zambia) and MRC CTU (London, UK). It has been absolutely great to work with you 
in the CHAPAS clinic.
André van der Ven dank ik voor de mogelijkheid die me geboden werd om 
promotieonderzoek te doen binnen PRIOR.
I would like to thank Prof. Shao for giving me the opportunity to work at KCMC in 
Moshi, Tanzania.
Special thanks to my counterpart Eva Muro for the pleasant cooperation and for the 
hard work collecting our study samples. I hope you enjoyed your stay in the 
Netherlands just as much as I enjoyed working in Tanzania. Good luck with the 
(VITA) studies and the rest of your PhD! 
Werner Schimana, thank you for your time to be our local supervisor at KCMC.  
I thank dr. Frank Mosha for his warm hospitality and local support of our research 
projects at KCMC. 
Liselotte Wolters, je doet je bijnaam “the flower of PRIOR” eer aan! Zonder jouw 
hulp op het Laboratorium in Tanzania waren onze projecten niet mogelijk geweest. 
Ook wil ik je bedanken voor de gezelligheid tijdens mijn verblijf in Tanzania. 
Mirjam Oudijk & Minke Huibers, hartelijk dank voor jullie hulp als stagiaires bij de 
VITA1 studie. Leuk om te horen dat Afrika jullie blijvende interesse heeft.
Clara Blaauw, Mieke Daalderop en Carla Ysenbrandt dank ik voor de goede 
organisatie van mijn reizen naar Afrika. 
And to all the PRIOR colleagues: Asante sana (-Thank you very much-  in Swahili)!
De infectiologen (i.o.), HIV consulenten en virologen van het UMC St Radboud wil ik 
bedanken voor de gezellige, en vooral, leerzame HIV patiëntenbesprekingen. 
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Rafaëlla Francisca Anna L’homme werd geboren op 1 juli 1978 te Heerlen. Ze groeide 
op in Wijlre en behaalde in 1996 het V.W.O. diploma aan het Katholiek Gymnasium 
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